




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> :  C07K 3/08, C12N 9/64		A2	(11) International Publication Number: WO 94/18227  (43) International Publication Date: 18 August 1994 (18.08.94)
(21) International Application Number: PCT/DK94/00054  (22) International Filing Date: 4 February 1994 (04.02.94)		(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data:  130/93 4 February 1993 (04.02.93) DK 139/93 5 February 1993 (05.02.93) DK PCT/GB93/02492 3 December 1993 (03.12.93) WO  (34) Countries for which the regional or international application was filed: US et al.			
(71) Applicant (for all designated States except US): DENZYME APS [DK/DK]; Gustav Wieds Vej 10, DK-8000 Århus C (DK).			
(72) Inventors; and (75) Inventors/Applicants (for US only): THØGERSEN, Hans, Christian [DK/DK]; Ristrupvej 41, DK-8381 Mundelstrup (DK). HOLTET, Thor, Las [DK/DK]; Østerlarsvej 41, DK-8210 Århus V (DK). ETZERODT, Michael [DK/DK]; Mosevænget 5, DK-8382 Hinnerup (DK).			
(74) Agent: PLOUGMANN & VINGTOFT A/S; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021 Copenhagen K (DK).			

(54) Title: IMPROVED METHOD FOR THE REFOLDING OF PROTEINS



## (57) Abstract

A novel, generally applicable method for producing correctly folded proteins from a mixture of misfolded proteins, e.g. bacterial inclusion-body aggregates. A major new aspect of the method is that over-all efficiency is achieved by subjecting proteins to a time-sequence of multiple denaturation-renaturation cycles, resulting in gradual accumulation of the correctly folded protein. The method has proven efficient for a variety of recombinant proteins. Also provided are novel encrypted recognition sites for bovine coagulation factor X<sub>a</sub>. The encrypted recognition sites described may be activated in vitro by controlled oxidation or by reversible derivatization of cysteine residues and thereby generate new cleavage sites for factor X<sub>a</sub>. Two new recombinant serine protease exhibiting narrow substrate specificity for factor X<sub>a</sub> recognition sites are also provided. They may replace natural coagulation factor X<sub>a</sub> for cleavage of chimeric proteins.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## IMPROVED METHOD FOR THE REFOLDING OF PROTEINS

## FIELD OF THE INVENTION

This invention relates to recombinant DNA technology and, in particular to protein engineering technologies for the production of correctly folded proteins by expression of genes or gene fragments in a host organism, heterologous or homologous, as recombinant protein products, by describing novel general principles and methodology for efficient *in vitro* refolding of misfolded and/or insoluble proteins, including proteins containing disulphide bonds. This invention further relates to the refolding of unfolded or misfolded polypeptides of any other origin. The invention also relates to novel designs of encrypted recognition sites for factor  $X_a$  cleavage of chimeric proteins, sites that only become recognized after *in vitro* derivatization. Two analogues of bovine coagulation factor  $X_a$ , suitable for small-, medium-, or large-scale technological applications involving specific cleavage of chimeric proteins at sites designed for cleavage by factor  $X_a$  are provided, too. Finally the invention relates to designs of reversible disulphide-blocking reagents, useful as auxiliary compounds for refolding of cysteine-containing proteins, including a general assay procedure by which such disulphide exchange reagents can be evaluated for suitability for this specific purpose.

## 25 GENERAL BACKGROUND OF THE INVENTION

Technologies for the production of virtually any polypeptide by introduction, by recombinant DNA methods, of a natural or synthetic DNA fragment coding for this particular polypeptide into a suitable host have been under intense development over the past fifteen years, and are at present essential tools for biochemical research and for a number of industrial processes for production of high-grade protein products for biomedical or other industrial use.

Four fundamental properties of biological systems render heterologous production of proteins possible:

- (i) The functional properties of a protein are entirely specified by its three-dimensional structure, and, due to the 5 molecular environment in the structure, manifested by chemical properties exhibited by specific parts of this structure.
- (ii) The three-dimensional structure of a protein is, in turn, specified by the sequence information represented by the specific sequential arrangement of amino acid residues in 10 the linear polypeptide chain(s). The structure information embedded in the amino acid sequence of a polypeptide is by itself sufficient, under proper conditions, to direct the folding process, of which the end product is the completely and correctly folded protein.
- (iii) The linear sequence of amino acid residues in the polypeptide chain is specified by the nucleotide sequence in the coding region of the genetic material directing the assembly of the polypeptide chain by the cellular machinery. The translation table governing translation of nucleic acid 20 sequence information into amino acid sequence is known and is almost universal among known organisms and hence allows nucleic acid segments coding for any polypeptide segment to direct assembly of polypeptide product across virtually any cross-species barrier.
- (iv) Each type of organism relies on its own characteristic array of genetic elements present within its own genes to interact with the molecular machinery of the cell, which in response to specific intracellular and extracellular factors regulates the expression of a given gene in terms of transcription and translation. 30

In order to exploit the protein synthesis machinery of a host cell or organism to achieve substantial production of a desired recombinant protein product, is it therefore neces-

sary to present the DNA-segment coding for the desired product to the cell fused to control sequences recognized by the genetic control system of the cell.

The immediate fate of a polypeptide expressed in a host is  
5 influenced by the nature of the polypeptide, the nature of  
the host, and possible host organism stress states invoked  
during production of a given polypeptide. A gene product  
expressed in a moderate level and similar or identical to a  
protein normally present in the host cell, will often undergo  
10 normal processing and accumulation in the appropriate cellu-  
lar compartment or secretion, whichever is the natural fate  
of this endogenous gene product. In contrast, a recombinant  
gene product which is foreign to the cell or is produced at  
high levels often activate cellular defence mechanisms simi-  
15 lar to those activated by heat shock or exposure to toxic  
amino acid analogues, pathways that have been designed by  
nature to help the cell to get rid of "wrong" polypeptide  
material by controlled intracellular proteolysis or by segre-  
gation of unwanted polypeptide material into storage par-  
20 ticles ("inclusion bodies"). The recombinant protein in these  
storage particles is often deposited in a misfolded and  
aggregated state, in which case it becomes necessary to  
dissolve the product under denaturing and reducing conditions  
and then fold the recombinant polypeptide by *in vitro* methods  
25 to obtain a useful protein product.

Expression of eukaryotic genes in eukaryotic cells often  
allows the direct isolation of the correctly folded and  
processed gene product from cell culture fluids or from  
cellular material. This approach is often used to obtain  
30 relatively small amounts of a protein for biochemical studies  
and is presently also exploited industrially for production  
of a number of biomedical products. However, eukaryotic  
expression technology is expensive in terms of technological  
complexity, labour- and material costs. Moreover, the time  
35 scale of the development phase required to establish an  
expression system is at least several months, even for la-

boratory scale production. The nature and extent of post-translational modification of the recombinant product often differs from that of the natural product because such modifications are under indirect genetic control in the host cell.

5 Sequence signals invoking a post-synthetic modification are often mutually recognized among eukaryotes, but availability of the appropriate suit of modification enzymes is given by the nature and state of the host cell.

A variety of strategies have been developed for expression of  
10 gene products in prokaryotic hosts, advantageous over eukaryotic hosts in terms of capital, labour and material requirements. Strains of the eubacteria *Escherichia coli* are often preferred as host cells because *E. coli* is far better characterized genetically than any other organism, also at  
15 the molecular level.

Prokaryotic host cells do not possess the enzymatic machinery required to carry out post-translational modification, and an eukaryotic gene product will therefore necessarily be produced in its unmodified form. Moreover, the product must be  
20 synthesized with an N-terminal extension, at least one additional methionine residue arising from the required translation initiation codon, more often also including an N-terminal segment corresponding to that of a highly expressed host protein. General methods to remove such N-terminal  
25 extensions by sequence specific proteolysis at linker segments inserted at the junction between the N-terminal extension and the desired polypeptide product have been described (Enterokinase-cleavable linker sequence: EP 035384, The Regents of the University of California; Factor X<sub>a</sub>-cleavable  
30 linker sequence: EP 161937, Nagai & Thøgersen, Assignee: Celltech Ltd.).

Over the years a considerable effort has been directed at the development of strategies for heterologous expression in prokaryotes to generate recombinant protein products in a  
35 soluble form or fusion protein constructs that allow secre-

tion from the cell in an active, possibly N-terminally processed form, an effort resulting in limited success only, despite recent developments in the chaperone field. Typically, much time and effort is required to develop and modify an expression system before even a small amount of soluble and correctly folded fusion protein product can be isolated. More often all of the polypeptide product is deposited within the host cell in an improperly folded state in "inclusion bodies". This is in particular true when expressing eukaryotic proteins containing disulphide bridges.

Available methods for *in vitro* refolding of proteins all describe processes in which the protein in solution or non-specifically adsorbed to ion exchange resins etc. is exposed to solvent, the composition of which is gradually changed over time from strongly denaturing (and possibly reducing) to non-denaturing in a single pass. This is often carried out by diluting a concentrated solution of protein containing 6-8 M guanidine hydrochloride or urea into a substantial volume of non-denaturing buffer, or by dialysis of a dilute solution of the protein in the denaturing buffer against the non-denaturing buffer. Numerous variants of this basic procedure have been described, including addition of specific ligands or cofactors of the active protein and incorporation of polymer substances like polyethylene oxide (polyethylene glycol), thought to stabilize the folded structure.

Although efficient variants of the standard *in vitro* refolding procedure have been found for a number of specific protein products, including proteins containing one or more disulphide bonds, refolding yields are more often poor, and scale-up is impractical and expensive due to the low solubility of most incompletely folded proteins which implies the use of excessive volumes of solvent.

The common characteristic of all traditional *in vitro* refolding protocols is that refolding induced by sudden or gradual reduction of denaturant is carried out as a single-

pass operation, the yield of which is then regarded as the best obtainable for the protein in question.

The general field of protein folding has been summarized in a recent text book edited by Thomas W. Creighton ("Protein folding", ed. Creighton T.E., Freeman 1992) and a more specific review of practical methods for protein refolding was published in 1989 by Rainer Jaenicke & Rainer Rudolph (p. 191-223 in, "Protein Structure, a practical approach", ed. T. E. Creighton, IRL Press 1989). Among the numerous more detailed publications, state-of-the-art reviews like those by Schein (Schein C. H., 1990, Bio/Technology 8, 308-317) or Buchner and Rudolph (Buchner J. and Rudolph R, 1991 Bio/Technology 9, 157-162) may be consulted.

In conclusion, there is a definite need for generally applicable high-yield methods for the refolding of un- or misfolded proteins derived from various sources, such as prokaryotic expression systems or peptide synthesis.

#### SUMMARY OF THE INVENTION

It has been found by the inventors that refolding yields can be greatly increased by taking into account that the protein folding process is a kinetically controlled process and that interconversion between folded, unfolded and misfolded conformers of the protein are subject to hysteresis and time-dependent phenomena that can be exploited to design a cyclic denaturation-renaturation process, in which refolded protein product accumulates incrementally in each cycle at the expense of unfolded and misfolded conformers, to generate a new refolding process of much greater potential than the basic traditional approach.

30 By the term "folded protein" is meant a polypeptide in (a) conformational state(s) corresponding to that or those occurring in the protein in its biologically active form or unique stable intermediates that in subsequent steps may be con-

verted to generate the biologically active species. The covalent structure of the folded protein in terms of crosslinking between pairs of cysteine residues in the polypeptide is identical to that of the protein in its biologically active form.

Accordingly, the term "unfolded protein" refers to a polypeptide in conformational states less compact and well-defined than that or those corresponding to the protein in its biologically active, hence folded, form. The covalent structure of the unfolded protein in terms of crosslinking between pairs of cysteine residues in the polypeptide may or may not be identical to that of the protein in its biologically active form. Closely related to an unfolded protein is a "misfolded protein" which is a polypeptide in a conformational state which is virtually thermodynamically stable, sometimes even more so than that or those states corresponding to the protein in its folded form, but which does not exhibit the same degree, if any, of the biological activity of the folded protein. As is the case for the unfolded protein, the covalent structure in terms of crosslinking between pairs of cysteine residues in the polypeptide may or may not be the same as that of the folded protein.

By the term "refolded protein" is meant a polypeptide which has been converted from an unfolded state to attain its biologically active conformation and covalent structure in terms of crosslinking between correct pairs of cysteine residues in the polypeptide.

The new generally applicable protein refolding strategy has been designed on the basis of the following general properties of protein structure.

(a) The low solubility of unfolded proteins exposed to non-denaturing solvents reflects a major driving force inducing the polypeptide either to form the compact correctly refolded structure or to misfold and generate dead-end aggregates or

precipitates, which are unable to refold and generate the correctly refolded structure under non-denaturing conditions within a reasonable amount of time.

(b) A newly formed dead-end aggregate is more easily "denatured" i.e. converted into an unfolded form than the correctly refolded protein because the structure of the dead-end aggregate is more disordered. Probably misfolding is also in general a kinetically controlled process.

(c) An unfolded protein is often not (or only very slowly) able to refold into the correctly refolded form at denaturant levels required to denature dead-end aggregates within a reasonable amount of time.

(d) The body of evidence available to support (b) includes detailed studies of folding and unfolding pathways and intermediates for several model proteins. Also illustrative is the observation made for many disulphide bonded proteins that the stability of disulphide bonds against reduction at limiting concentrations of reducing and denaturing agents is often significantly different for each disulphide bridge of a given protein, and that the disulphide bridges in the folded protein are in general much less prone to reduction or disulphide exchange than "non-native" disulphide bonds in a denatured protein or protein aggregate.

The new strategy for a refolding procedure is most easily illustrated by way of the following theoretical example:

Consider a hypothetical protein - stably folded in a non-denaturing buffer "A" and stably unfolded in the strongly denaturing buffer "B" (being e.g. a buffer containing 6 M guanidine-HCl) - exposed to buffer A or to buffer B and then subjected to incubation at intermediate levels of denaturation in mixtures of buffers A and B.

Levels between e.g. 100-75% B lead to conversion of both folded protein and dead-end aggregated protein to the unfolded form within a short period of time.

5 Levels between e.g. 75-50% B lead to conversion of newly formed dead-end aggregate to the unfolded form, whereas almost all refolded protein remains in a native-like structure, stable at least within a period of time of hours, from which it may snap back into the refolded form upon removal of the denaturant.

10 Levels in excess of 10% B prevent rapid formation of refolded form from unfolded form.

A solvent composition step from 100% B to 0% B converts unfolded protein to dead-end aggregate (75% yield) and refolded protein (25% yield).

15 Let us now subject a sample of this protein, initially in its unfolded form in 100% B, to a time-series of programmed denaturation-renaturation cycles as illustrated in Fig. 1, each consisting of a renaturation phase ( $F_n$ ) (<10% B) and a denaturation phase ( $D_n$ ). At the end of the renaturation phase 20 of cycle(i) the denaturant content is changed to a level,  $k_i$  % less than the denaturant level of the previous cycle. Following a brief incubation the denaturant is again removed, and the next renaturation phase  $F_{i+1}$  entered. Assuming the denaturation level starts out at 100% B and  $k_i$  for each cycle 25 is fixed at 4%, this recipe will generate a damped series of "denaturation steps" dying out after 25 cycles.

Through 25 cycles, as outlined above, the accumulation of refolded protein would progress as follows:

30 In cycles 1 to 5 all of the protein, folded as well as misfolded will become unfolded in each of the denaturation phases  $D_n$ .

Cycles 7 through 12: Dead-end aggregates will be converted to unfolded protein in each step whereas protein recoverable as refolded product will accumulate in the following amounts, cycle by cycle: 25%, 44%, 58%, 68%, 5 76% and 82%.

No further conversions take place through cycles 13 to 25.

The cyclic refolding process would therefore produce a total refolding yield of over 80%, whereas traditional one-pass 10 renaturation at best would produce a yield of 25%.

It will be appreciated that a great number of simplifying approximations in terms of all-or-none graduation of each characteristic of the various conformational states of the hypothetical protein have been made. The basic working principle, nevertheless, remains similar if a more complicated 15 set of presumptions are incorporated in the model.

Arranging a practical setup for establishing a cyclic denaturation/renaturation protein refolding process can be envisaged in many ways.

20 The protein in solution could e.g. be held in an ultrafiltration device, held in a dialysis device or be confined to one of the phases of a suitable aqueous two-phase system, all of which might allow the concentration of low-molecular weight chemical solutes in the protein solution to be controlled 25 by suitable devices.

Alternatively, the protein could be adsorbed to a suitable surface in contact with a liquid phase, the chemical composition of which could be controlled as required. A suitable surface could e.g. be a filtration device, a hollow-fibre 30 device or a beaded chromatographic medium. Adsorption of the protein to the surface could be mediated by non-specific interactions, e.g. as described in WO 86/05809 (Thomas Edwin

Creighton), by folding-compatible covalent bonds between surface and protein or via specific designs of affinity handles in a recombinant derivative of the protein exhibiting a specific and denaturation-resistant affinity for a suitably 5 derivatized surface.

The specific implementation of the cyclic denaturation/re-naturation protein refolding process established to investigate the potential of the general method was based on a design of cleavable hybrid proteins (EP 161937, Nagai & 10 Thøgersen, Assignee: Celltech Ltd.) containing a metal affinity handle module (EP 0282042 (Heinz Döbeli, Bernhard Eggi-mann, Reiner Gentz, Erich Hochuli; Hoffmann-La Roche)) inserted N-terminally to the designed factor  $X_a$  cleavage site. Recombinant proteins of this general design, adsorbed 15 on Nickel-chelating agarose beads could then be subjected to the present cyclic refolding process in a chromatographic column "refolding reactor" perfused with a mixture of suitable denaturing and non-denaturing buffers, delivered by an array of calibrated pumps, the flow rates of which was time- 20 programmed through computer control.

A general scheme of solid-state refolding entails cycling the immobilized protein as outlined above or by any other means and implementations between denaturing and non-denaturing conditions in a progressive manner, in which the concentration 25 of the denaturing agent is gradually reduced from high starting values towards zero over a train of many renaturation-denaturation cycles. Using this approach it is not necessary to determine precisely which limiting denaturant concentration is required to obtain folding yield enrichment 30 in the course of cycling of the specific protein at hand, because the progressive train of cycles will go through (up to) three phases, an early phase in which folded product present at the end of cycle (i) is completely denatured at the denaturation step of cycle (i+1), an intermediate productive 35 phase during which refolded protein accumulates in increasing quantity, and a late phase during which the con-

centration of denaturant is too low to perturb the refolded protein or any remaining misfolded structures. Subjecting the protein to a progressing series of denaturation-renaturation cycles as outlined will therefore include several productive 5 cycles.

For disulphide-containing proteins progressive denaturation-renaturation cycling may be enhanced by using equipment similar to advanced chromatography equipment with on-line facilities to monitor buffer compositions of folding reactor 10 effluent. Information on effluent composition with regard to reductant and disulphide reshuffling reagent concentration profile would reveal productive cycling, and could therefore be used as input to an intelligent processor unit, in turn regulating the progression of denaturant concentration in a 15 feed-back loop to ensure that most of the cycling effort is spent within the productive phase of the denaturation-renaturation cycle train. Such auto-optimization of cycling conditions would be possible because the analytical system may be used to measure extent and direction of changes in redox 20 equilibrium in the buffer stream, measurements that directly reflect titration of thiol-groups /disulphide equivalents in the immobilized protein sample, and is therefore directly translatable into average number of disulphide bonds being disrupted or formed during the various phases of a cycle.

25 Other possible inputs for the intelligent processor controlling the progression of cycling include measurements of ligand-binding, substrate conversion, antibody binding ability and, indeed, any other interacting soluble agent interacting in distinct ways with misfolded and folded protein, 30 which in the assessing stage of folding measurement might be percolated through the refolding reactor and then in-line monitored in the effluent by suitable analytical devices.

An intelligent monitoring and control system could furthermore use the available information to direct usable portions

of reactor effluent to salvage/recycling subsystems thereby minimizing expenses for large scale operations.

After execution of the folding procedure the final product may be eluted from the affinity matrix in a concentrated 5 form, processed to liberate the mature authentic protein by cleavage at the designed protease cleavage site and then subjected to final work-up using standard protein purification and handling techniques, well-known within the field of protein chemistry.

#### 10 DETAILED DISCLOSURE OF THE INVENTION

Thus, the present invention relates to a method for generating a processed ensemble of polypeptide molecules, in which processed ensemble the conformational states represented contain a substantial fraction of polypeptide molecules in 15 one particular uniform conformation, from an initial ensemble of polypeptide molecules which have the same amino acid sequence as the processed ensemble of polypeptide molecules, comprising subjecting the initial ensemble of polypeptide molecules to a series of at least two successive cycles each 20 of which comprises a sequence of

- 1) at least one denaturing step involving conditions exerting a denaturing influence on the polypeptide molecules of the ensemble followed by
- 2) at least one renaturing step involving conditions having a renaturing influence on the polypeptide molecules having conformations resulting from the preceding step.

In the present specification and claims, the term "ensemble" is used in the meaning it has acquired in the art, that is, 30 it designates a collection of molecules having essential common features. Initially ("an initial ensemble"), they have at least their amino acid sequence in common (and of course retain this common feature). When the ensemble of polypeptide

molecules has been treated in the method of the invention (to result in "a processed ensemble"), the conformational states represented in the ensemble will contain a substantial fraction of polypeptide molecules with one particular conformation. As will be understood from the discussion which follows, the substantial fraction of polypeptide molecules with one particular conformation in the processed ensemble may vary

dependent on the parameters of the treatment by the method of the invention, the size of the protein in the particular conformation, the length and identity of the amino acid sequence of the molecules, etc. In the examples reported herein, in which the process parameters have not yet been optimized, the fraction of polypeptide molecules with one particular conformation varied between 15% and 100% of the ensemble, which in all cases is above what could be obtained prior to the present invention. In example 13 it is further demonstrated that purification of the polypeptide molecules prior to their subjection to the method of the invention increases the fraction of polypeptide molecules with one particular conformation.

"Denaturing step" refers to exposure of an ensemble of polypeptide molecules during a time interval to physical and/or chemical circumstances which subject the ensemble of polypeptide molecules to conditions characterized by more severe denaturing power than those characterizing conditions immediately prior to the denaturing step.

Accordingly, the term "renaturing step" refers to exposure of an ensemble of polypeptide molecules during a time interval to physical and/or chemical circumstances which subject the ensemble of polypeptide molecules to conditions characterized by less severe denaturing power than those characterizing conditions immediately prior to the denaturing step.

It will be understood, that the "substantial fraction" mentioned above will depend in magnitude on the ensemble of

polypeptide molecules which are subjected to the method of the invention. If the processed ensemble of polypeptides consists of monomeric proteins of relatively short lengths and without intramolecular disulphide bridges the method will

5 in general result in very high yields, whereas complicated molecules (such as polymeric proteins with a complicated disulphide bridging topology) may result in lower yields, even if the conditions of the method of the invention are fully optimized.

10 An interesting aspect of the invention relates to a method described above wherein the processed ensemble comprises a substantial fraction of polypeptide molecules in one conformational state the substantial fraction constituting at least 1% (w/w) of the initial ensemble of polypeptide molecules.

15 Higher yields are preferred, such as at least 5%, at least 10%, at least 20%, and at least 25% of the initial ensemble of polypeptide molecules. More preferred are yields of at least 30%, such as at least 40%, 50%, 60%, 70%, and at least 80%. Especially preferred are yields of at least 85%,

20 such as 90%, 95%, 97%, and even at 99%. Sometimes yields close to 100% are observed.

When the polypeptide molecules of the ensemble contain cysteine, the processed ensemble will comprise a substantial fraction of polypeptide molecules in one particular uniform conformation which in addition have substantially identical disulphide bridging topology.

In most cases, the polypeptide molecules subjected to the method of the invention will be molecules which have an amino acid sequence identical to that of an authentic polypeptide, or molecules which comprise an amino acid sequence corresponding to that of an authentic polypeptide joined to one or two additional polypeptide segments.

By the term "authentic protein or polypeptide" is meant a polypeptide with primary structure, including N- and C-ter-

minal structures, identical to that of the corresponding natural protein. The term also denotes a polypeptide which has a known primary structure which is not necessarily identical to that of a natural protein, which polypeptide is the 5 intentional end-product of a protein synthesis.

By the term "natural protein" is meant a protein as isolated in biologically active form from an organism, in which it is present not as a consequence of genetic manipulation.

In contrast, the term "artificial protein or polypeptide" as 10 used in the present specification and claims is intended to relate to a protein/polypeptide which is not available from any natural sources, i.e. it cannot be isolated and purified from any natural source. An artificial protein/polypeptide is thus the result of human intervention, and may for instance 15 be a product of recombinant DNA manipulation or a form of *in vitro* peptide synthesis. According to the above definitions such an artificial protein may be an authentic protein, but not a natural protein.

Thus, the invention also relates to a method wherein natural 20 proteins as well as artificial proteins are subjected to the refolding processes described herein.

As will be explained in greater detail below, it may be advantageous for various reasons that the authentic polypeptide is joined to polypeptide segments having auxiliary 25 functions during the cycling and other previous or subsequent processing, e.g. as "handles" for binding the polypeptide to a carrier, as solubility modifiers, as expression boosters which have exerted their beneficial function during translation of messenger RNA, etc. Such an auxiliary 30 polypeptide segment will preferably be linked to the authentic polypeptide via a cleavable junction, and where two such auxiliary polypeptide segments are linked to the authentic polypeptide, this may be via similar cleavable junctions which will normally be cleaved simultaneously, or through

dissimilar cleavable junctions which may be cleaved in any time sequence.

In accordance with what is explained above, it is believed to be a major novel characteristic feature of the present invention that the cycling (which, as explained above, comprises at least two successive cycles) will give rise to at least one event where a renaturing step is succeeded by a denaturing step where at least a substantial fraction of the refolded polypeptides will be denatured again.

10 In most cases, the processing will comprise at least 3 cycles, often at least 5 cycles and more often at least 8 cycles, such as at least 10 cycles and, in some cases at least 25 cycles. On the other hand, the series of cycles will normally not exceed 2000 cycles and will often comprise at 15 most 1000 cycles and more often at most 500 cycles. The number of cycles used will depend partly on the possibilities made available by the equipment in which the cycling is performed.

Thus, if the cycling treatment is performed with the peptide molecules immobilized to a carrier column, such as will be explained in greater detail below, the rate with which the liquid phase in contact with the column can be exchanged will constitute one limit to what can realistically be achieved. On the other hand, high performance liquid 25 chromatography (HPLC) equipment will permit very fast exchange of the liquid environment and thus make cycle numbers in the range of hundreds or thousands realistic.

Other considerations determining the desirable number of cycles are, e.g., inherent kinetic parameters such as inter- 30 conversion between cis and trans isomers at proline residues which will tend to complicate redistribution over the partially folded states and will thus normally require due consideration of timing. Another time-critical characteristic

resides in the kinetics of disulphide reshuffling (cf. the discussion below of disulphide-reshuffling systems).

With due consideration of the above, the cycling series will often comprise at most 200 cycles, more often at most 100

5 cycles and yet more often at most 50 cycles.

In accordance with what is stated above, the duration of each denaturing step may be a duration which, under the particular conditions in question, is at least one millisecond and at most one hour, and the duration of each renaturing step may

10 be a duration which, under the particular conditions in question, is at least 1 second and at most 12 hours.

In most embodiments of the method, the denaturing conditions of each individual denaturing step are kept substantially constant for a period of time, and the renaturing conditions

15 of each individual renaturing step are kept substantially constant for a period of time, the periods of time during which conditions are kept substantially constant being separated by transition periods during which the conditions are changed. The transition period between steps for which conditions are kept substantially constant may have a duration varying over a broad range, such as between 0.1 second and 12 hours and will normally be closely adapted to the durations of the denaturing and renaturing steps proper.

Bearing this in mind, the period of time for which the denaturing conditions of a denaturing step are kept substantially constant may, e.g. have a duration of at least one millisecond and at most one hour, often at most 30 minutes, and the period of time for which the renaturing conditions of a renaturing step are kept substantially constant has a duration of at least 1 second and at most 12 hours, and often at most 2 hours.

In practice, the period of time for which the denaturing conditions of a denaturing step are kept substantially con-

stant will often have a duration of between 1 and 10 minutes, and the period of time for which the renaturing conditions of a renaturing step are kept substantially constant will often have a duration of between 1 and 45 minutes.

5 It will be understood from the above, that adjustments should be made to the intervals stated above, taking into consideration the change of kinetics resulting from the change in physical conditions to which the polypeptides are subjected. For instance, the pressure may be very high (up to 5000 Bar)  
10 when using an HPLC system when performing the method of the invention, and under such circumstances very rapid steps may be accomplished and/or necessary. Further, as can be seen from the examples, the temperature parameter is of importance, as some proteins only will refold properly at temperatures far from the physiological range. Both temperature and pressure will of course have an effect on the kinetics of the refolding procedure of the invention, and therefore the above-indicated time intervals of renaturing and denaturing steps are realistic boundaries for the many possible embodiments of the invention.  
20

For a given utilization of the method of the invention, the skilled person will be able to determine suitable conditions based, e.g., on preliminary experiments.

As indicated above, the polypeptide molecules are normally in contact with a liquid phase during the denaturing and renaturing steps, the liquid phase normally being an aqueous phase.  
25 This means that any reagents or auxiliary substances used in the method will normally be dissolved in the liquid phase, normally in an aqueous phase. However, if convenient, the liquid phase may also be constituted by one or more organic solvents.  
30

In connection with renaturing of proteins, it is well known to use a so-called "chaperone" or "chaperone complex". Chaperones are a group of recently described proteins that show a

common feature in their capability of enhancing refolding of unfolded or partly unfolded proteins. Often, the chaperones are multimolecular complexes. Many of these chaperones are heat-shock proteins, which means that *in vivo*, they are 5 serving as factors doing post-traumatic "repair" on proteins that have been destabilized by the trauma. To be able to fulfil this function, chaperones tend to be more stable to traumatic events than many other proteins and protein complexes. While the method of the invention does not depend on 10 the use of a molecular chaperone or a molecular chaperone complex, it is, of course, possible to have a suitable molecular chaperone or molecular chaperone complex present during at least one renaturing step, and it may be preferred to have a molecular chaperone or a molecular chaperone complex 15 present during substantially all cycles.

As mentioned above, the polypeptide molecules are preferably substantially confined to an environment which allows changing or exchanging the liquid phase substantially without entraining the polypeptide molecules. 20 This can be achieved in a number of ways. For instance, the polypeptide molecules may be contained in a dialysis device, or they may be confined to one of the phases of a suitable liquid two-phase system. Such a suitable aqueous two phase system may, e.g., contain a polymer selected from the group 25 consisting of polyethylene oxide (polyethylene glycol), polyvinyl acetate, dextran and dextran sulphate. In one interesting setup, one phase contains polyethylene oxide (polyethylene glycol) and the other phase contain dextran, whereby the polypeptide molecules will be confined to the 30 dextran-containing phase.

Another way of avoiding entraining the polypeptide by having the polypeptide molecules bound to a solid or semisolid carrier, such as a filter surface, a hollow fibre or a beaded chromatographic medium, e.g. an agarose or polyacrylamide 35 gel, a fibrous cellulose matrix or an HPLC or FPLC (Fast Performance Liquid Chromatography) matrix. As another

measure, the carrier may be a substance having molecules of such a size that the molecules with the polypeptide molecules bound thereto, when dissolved or dispersed in a liquid phase, can be retained by means of a filter, or the carrier may be a 5 substance capable of forming micelles or participating in the formation of micelles allowing the liquid phase to be changed or exchanged substantially without entraining the micelles. In cases where the micelle-forming components would tend to escape from the system as monomers, e.g. where they would be 10 able to some extent to pass an ultrafilter used in confining the system, this could be compensated for by replenishment will additional micelle-forming monomer.

The carrier may also be a water-soluble polymer having molecules of a size which will substantially not be able to 15 pass through the pores a filter or other means used in confining the system.

The polypeptide molecules are suitably non-covalently adsorbed to the carrier through a moiety having affinity to a component of the carrier. Such a moiety may, e.g., be a 20 biotin group or an analogue thereof bound to an amino acid moiety of the polypeptide, the carrier having avidin, streptavidin or analogues thereof attached thereto so as to establish a system with a strong affinity between the thus modified polypeptide molecules and the thus modified carrier. 25 It will be understood that the affinity between the modified polypeptide and the modified carrier should be sufficiently stable so that the adsorption will be substantially unaffected by the denaturing conditions; the removal of the polypeptide molecules from the carrier after the cycling 30 should be performed using specific cleaving, such as is explained in the following.

An example of a suitable amino acid residue to which a biotinyl group may be bound is lysine.

One interesting way of introducing an amino acid carrying a moiety having affinity to the carrier is CPY synthesis. CPY (carboxy peptidase Y) is known to be capable of adding amino acid amide irrespective of the nature of the side chain of 5 that amino acid amide.

In an interesting embodiment, the moiety having affinity to the carrier is the polypeptide segment SEQ ID NO: 47, in which case the carrier suitably comprises a Nitrilotriacetic Acid derivative (NTA) charged with  $\text{Ni}^{++}$  ions, for instance an 10 NTA-agarose matrix which has been bathed in a solution comprising  $\text{Ni}^{++}$ .

An important aspect of the invention relates to the presence of suitable means in the polypeptide molecule preparing the molecule for later cleavage into two or more segments, where- 15 in one segment is an authentic polypeptide as defined above. Such combined polypeptide molecules (fusion polypeptide molecules) may for this purpose comprise a polypeptide seg- ment which is capable of directing preferential cleavage by a cleaving agent at a specific peptide bond. The polypeptide 20 segment in question may be one which directs the cleavage as a result of the conformation of the segment which serves as a recognition site for the cleaving agent.

The cleavage-directing polypeptide segment may for instance be capable of directing preferential cleavage at a specific 25 peptide bond by a cleaving agent selected from the group consisting of cyanogen bromide, hydroxylamine, iodosobenzoic acid and N-bromosuccinimide.

The cleavage-directing polypeptide segment may be one which is capable of directing preferential cleavage at a specific 30 peptide bond by a cleaving agent which is an enzyme and one such possible enzyme is bovine enterokinase or an analogue and/or homologue thereof.

In an important aspect of the invention, the cleaving agent is the enzyme bovine coagulation factor  $X_a$  or an analogue and/or homologue thereof (such analogues will be discussed in greater detail further below), and the polypeptide segment 5 which directs preferential cleavage is a sequence which is substantially selectively recognized by the bovine coagulation factor  $X_a$  or an analogue and/or homologue thereof. Important such segments are polypeptide segments that have a sequence selected from the group consisting of SEQ ID NO: 38, 10 SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42.

An interesting feature of the invention is the possibility of masking and unmasking polypeptide segments with respect to their ability to direct cleavage at a specific peptide bond, whereby it is obtained that different segments of the 15 polypeptide can be cleaved at different stages in the cycles.

Thus, when the polypeptide molecules comprise a polypeptide segment which is *in vitro*-convertible into a derivatized polypeptide segment capable of directing preferential cleavage by a cleaving agent at a specific peptide bond, a masking/unmasking effect as mentioned becomes available. An 20 especially interesting version of this strategy is where the *in vitro*-convertible polypeptide segment is convertible into a derivatized polypeptide segment which is substantially selectively recognized by the bovine coagulation factor  $X_a$  or 25 an analogue and/or homologue thereof.

It is contemplated that both cysteine and methionine residues can be converted into modified residues, which modified residues make the segments having amino acid sequences selected from the group consisting of SEQ ID NO: 43, SEQ ID 30 NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46 *in vitro*-convertible into segments recognized by bovine coagulation factor  $X_a$  or an analogue and/or homologue thereof.

According to the invention, one possible solution involving the cysteine residue is that a polypeptide segment with the amino acid sequence SEQ ID NO: 43 or SEQ ID NO: 44, is converted into a derivatized polypeptide which is substantially selectively recognized by bovine coagulation factor  $X_a$ , by reacting the cysteine residue with N-(2-mercaptopethyl)morpholyl-2-thiopyridyl disulphide or mercaptothioacetate-2-thiopyridyl disulphide.

A possible strategy according to the invention involving methionine is that a polypeptide segment with the amino acid sequence SEQ ID NO: 45 or SEQ ID NO: 46, is converted into a derivatized polypeptide, which is substantially selectively recognized by bovine coagulation factor  $X_a$ , by oxidation of the thioether moiety in the methionine side group to a sulphoxide or sulphone derivative.

Preferred embodiments of the method according to the invention are those wherein the cleavage-directing segments with the amino acid sequences SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 42, or the masked cleavage-directing segments with the amino acid sequences SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46 are linked N-terminally to the authentic polypeptide, because then no further processing other than the selective cleaving is necessary in order to obtain the authentic polypeptide in solution. On the other hand, one possible reason for linking the cleavage directing sequences at the C-terminal end of the authentic polypeptide would be that the correct folding of the polypeptide molecules is dependent on a free N-terminal of the polypeptide molecules. In such a case, the part of the cleaving-directing sequence remaining after cleaving can be removed by suitable use of carboxypeptidases A and B.

The change of conditions during the transition period between the steps may according to the invention be accomplished by changing the chemical composition of the liquid phase with which the polypeptide molecules are in contact. Thus, dena-

turing of the polypeptide molecules may be accomplished by contacting the polypeptide molecules with a liquid phase in which at least one denaturing compound is dissolved, and renaturing of the polypeptide molecules is accomplished by

5 contacting the polypeptide molecules with a liquid phase which either contains at least one dissolved denaturing compound in such a concentration that the contact with the liquid phase will tend to renature rather than denature the ensemble of polypeptide molecules in their respective confor-

10 mation states resulting from the preceding step, or contains substantially no denaturing compound.

The expression "denaturing compound" refers to a compound which when present as one of the solutes in a liquid phase comprising polypeptide molecules may destabilize folded

15 states of the polypeptide molecules leading to partial or complete unfolding of the polypeptide chains. The denaturing effect exerted by a denaturing compound increases with increasing concentration of the denaturing compound in the solution, but may furthermore be enhanced or moderated due to

20 the presence of other solutes in the solution, or by changes in physical parameters, e.g. temperature or pressure.

As examples of suitable denaturing compounds to be used in the method according to the invention may be mentioned urea, guanidine-HCl, di-C<sub>1-6</sub>-alkylformamides such as dimethylform-

25 amide and di-C<sub>1-6</sub>-alkylsulphones.

The liquid phase used in at least one of the denaturing steps and/or in at least one of the renaturing steps may according to the invention contain a least one disulphide-reshuffling system.

30 "Disulphide reshuffling systems" are redox systems which contain mixtures of reducing and oxidizing agents, the presence of which facilitate the breaking and making of disulphide bonds in a polypeptide or between polypeptides. Accordingly, "disulphide reshuffling agents" or "disulphide

reshuffling compounds" are such reducing and oxidizing agents which facilitate the breaking and making of disulphide bonds in a polypeptide or between polypeptides. In an important aspect of the invention, the disulphide-reshuffling system 5 contained in the aqueous phase which is in contact with the proteins comprises as a disulphide reshuffling system a mixture of a mercaptan and its corresponding disulphide compound.

As an example, all cysteine residues in the polypeptide 10 molecules may have been converted to mixed disulphide products of either glutathione, thiocholine, mercaptoethanol or mercaptoacetic acid, during at least one of the denaturing/renaturing cycles. Such a converted polypeptide is termed a "fully disulphide-blocked polypeptide or protein" and this 15 term thus refers to a polypeptide or a protein in which cysteine residues have been converted to a mixed-disulphide in which each cysteine residue is disulphide-linked to a mercaptan, e.g. glutathione. The conversion of the cysteine residues to mixed disulphide products may be accomplished by 20 reacting a fully denatured and fully reduced ensemble of polypeptide molecules with an excess of a reagent which is a high-energy mixed disulphide compounds, such as aliphatic-aromatic disulphide compounds, e.g. 2-thiopyridyl glutathionyl disulphide, or by any other suitable method.

25 As examples of high-energy mixed disulphides, that is, mixed disulphides having a relatively unstable S-S bond) may be mentioned mixed disulphides having the general formula:



wherein  $R_1$  is 2-pyridyl, and each of  $R_2$ ,  $R_3$  and  $R_4$  is hydrogen or an optionally substituted lower aromatic or aliphatic

hydrocarbon group. Examples of such mixed disulphides are glutathionyl-2-thiopyridyl disulphide, 2-thiocholyl-2-thiopyridyl disulphide, 2-mercaptopropanol-2-thiopyridyl disulphide and mercaptoacetate-2-thiopyridyl disulphide.

5 In interesting embodiments, the disulphide-reshuffling system contains glutathione, 2-mercaptopropanol or thiocholine, each of which in admixture with its corresponding symmetrical disulphide.

The suitability of a given mixture of thiols for use as 10 selective reducing and/or disulphide-reshuffling system in a cyclic refolding/reoxidation procedure for a specific protein product can be directly assayed by incubating ensembles of samples of a mixture of folded and misfolded protein with an array of thiol mixtures at several different concentrations 15 of denaturant exerting weakly, intermediate or strongly denaturing effects on the protein. Following incubation, the disulphide topology in each sample is then locked by reaction with an excess of thiol-blocking reagent (e.g. Iodoacetamide) before subjecting each set of samples to SDS-PAGE under non-reducing conditions. Correctly disulphide-bridged material 20 and material in undesired covalent topological states will appear in separate bands and will therefore allow quantitative assessment of folding state of the protein at the time of thiol-blocking, because only correctly unique disulphide- 25 bonded topoisomer may correspond to correctly folded protein present at the end of incubation with thiol/disulphide and denaturant agents. This set of experiments allows identification of the range of denaturant levels at which a given thiol/disulphide reagent may be advantageously used as 30 disulphide reshuffling agent, as revealed by preferential reduction and reshuffling of wrong disulphide bonds and low tendency to reduce bonds in the fully folded protein. This reagent testing procedure may be used as a general procedure for selecting advantageous reducing and/or thiol/disulphide 35 reshuffling reagents. Example 12 demonstrates application of this analytical procedure to assess the suitability for

selective reduction of misfolded forms of a model protein for 5 thiol reagents and thereby demonstrates the operability of the above procedure.

It will be understood that the above-indicated procedure for 5 selecting suitable disulphide reshuffling systems may also be employed for selecting other compositions than mixtures of thiols. Any mixture containing suitable reducing/oxidating agents may be evaluated according to the above indicated procedure, and the composition of choice in the method of the 10 invention will be the one which shows the highest ability of preferentially reduce incorrectly formed disulphide bridges.

Thus, a very important aspect of the invention is a method for protein refolding as described herein, wherein at least one disulphide-reshuffling system contained in liquid phase 15 in at least one renaturing and/or denaturing step is one which is capable of reducing and/or reshuffling incorrectly formed disulphide bridges under conditions with respect to concentration of the denaturing agent at which unfolded and/or misfolded proteins are denatured and at which there is 20 substantially no reduction and/or reshuffling of correctly formed disulphide bridges.

An interesting embodiment of the invention is a method as described above, wherein a disulphide reshuffling system is used in at least one denaturing/renaturing step and resulting 25 in a ratio between the relative amount of reduced/reshuffled initially incorrectly formed disulphide bridges and the relative amount of reduced/reshuffled initially correctly formed disulphide bridges of at least 1.05. The ratio will preferably be higher, such as 1.1, 1.5, 2.0, 3.0, 5.0, 10, 30 100, 1000, but even higher ratios are realistic and are thus especially preferred according to the invention.

By the terms "initially incorrectly/correctly" with respect to the form of disulphide bridges is meant the disulphide

bridging topology just before the disulphide reshuffling system exerts its effects.

It will be understood that the ratio has to be greater than 1 in order to allow the net formation of correctly formed 5 disulphide bridges in a protein sample. Normally the ratio should be as high as possible, but even ratios which are marginally above 1 will allow the net formation of correctly formed disulphide bridges in the method of the invention, the important parameter in ensuring a high yield being the number 10 of denaturing/renaturing cycles. Ratios just above one require that many cycles are completed before a substantive yield of correctly formed disulphide bridges is achieved, whereas high ratios only require a limited number of cycles.

In cases where only one disulphide reshuffling system is 15 going to be employed such a disulphide reshuffling system may according to the invention be selected by

- 1) incubating samples of folded and misfolded protein of the same amino acid sequence as the protein to be processed in the method of the invention with an array of 20 disulphide reshuffling systems at several different concentrations of a chosen denaturing agent,
- 2) assessing at each of the different concentrations of denaturing agent the ability of each of the disulphide reshuffling systems to reduce and/or reshuffle initially 25 incorrectly formed disulphide bridges without substantially reducing and/or reshuffling initially correctly formed disulphide bridges as assessed by calculating the ratio between the relative amount of reduced/reshuffled initially incorrectly formed disulphide bridges and the relative amount of reduced/reshuffled initially correctly 30 formed disulphide bridges, and
- 3) selecting as the disulphide reshuffling system X, the disulphide reshuffling system which exhibit the capa-

bility of reducing initially incorrectly formed disulphide bridges without substantially reducing and/or reshuffling initially correctly formed disulphide bridges in the widest range of concentrations of the chosen 5 denaturing agent.

Alternatively more than one disulphide reshuffling system may be employed, for instance in different cycles in the cyclic refolding method of the invention, but also simultaneously in the same cycles. This will e.g. be the case when it is likely 10 or has been established by e.g. the method outlined above that the overall yield of correctly folded protein with correct disulphide bridging topology will be higher if using different disulphide reshuffling systems in the method of the invention.

15 In order to calculate the above-indicated the ratio between the relative amount of reduced/reshuffled initially incorrectly formed disulphide bridges and the relative amount of reduced/reshuffled initially correctly formed disulphide bridges, the following method may be employed: to the initial 20 mixture of reactants in step 1) is added a known amount of radioactively labelled correctly folded protein. When the amounts of correctly and incorrectly folded protein are assessed in step 2) (for instance by non-reducing SDS-PAGE) the content of radioactivity in the correctly folded protein 25 fraction is determined as well. Thereby an assessment of the now incorrectly folded (but initially correctly folded) protein can be determined in parallel with the determination of the total distribution of correctly/incorrectly folded protein. The above-mentioned ratio can thus be calculated as

$$R = \frac{C_2 - \frac{A_2}{A_1} \cdot C_1}{U_1 \cdot \frac{A_2}{A_1}}$$

wherein  $C_1$  and  $C_2$  are the initial and the final amounts of correctly folded proteins, respectively,  $U_1$  is the amount of initially incorrectly folded protein, and  $A_1$  and  $A_2$  are the radioactivity in the initial correctly folded protein fraction and in the final correctly folded protein, respectively.

In addition to the denaturing means mentioned above, denaturing may also be achieved or enhanced by decreasing pH of the liquid phase, or by increasing pH of the liquid phase.

The polarity of the liquid phase used in the renaturing may 10 according to the invention have been modified by the addition of a salt, a polymer and/or a hydrofluoro compound such as trifluoroethanol.

According to the invention, the denaturing and renaturing of the polypeptide molecules may also be accomplished by direct 15 changes in physical parameters to which the polypeptide molecules are exposed, such as temperature or pressure, or these measures may be utilized to enhance or moderate the denaturing or renaturing resulting from the other measures mentioned above.

20 However, it will be understood that a most important practical embodiment of the method is performed by accomplishing chemical changes in the liquid phase by changing between a denaturing solution B and a renaturing solution A. In this case, the concentration of one or more denaturing compounds 25 in B will often be adjusted after each cycle, and as one important example, the concentration of one or more denaturing compounds in B will be decremented after each cycle, but in another important embodiment, the concentration of one or more denaturing compounds in medium B is kept constant in 30 each cycle.

This embodiment of the invention, wherein the concentration of denaturing compound(s) medium B is kept constant, is

especially interesting when the most productive phase of the cycling process (with respect to correctly folded protein) has been identified, and large scale production of correctly folded protein is desired. As will be understood, the preferred concentration(s) of denaturing compound(s) of medium B in this embodiment is the concentration(s) which has been established to ensure maximum productivity in the cyclic process according to the invention.

The polypeptide molecules of the ensemble which is subjected to the method of the invention normally have a length of at least 25 amino acid residues, such as at least 30 amino acid residues or at least 50 amino acid residues.

On the other hand, the polypeptide molecules of the ensemble normally have a length of at most 5000 amino acid residues, such as at most 2000 amino acid residues or at most 1000 or 800 amino acid residues.

As can be seen from example 10, the method of the invention has made possible the production of correctly folded diabody molecules (diabodies are described in Holliger et al., 1993).

An important aspect of the invention therefore relates to a method for producing correctly folded diabody molecules, wherein an initial ensemble of polypeptide molecules comprising unfolded and/or misfolded polypeptides having amino acid sequences identical to the amino acid sequences of monomer fragments of diabody molecules is subjected to a series of at least two successive cycles, each of which comprises a sequence of

- 1) at least one denaturing step involving conditions exerting a denaturing influence on the polypeptide molecules of the ensemble followed by
- 2) at least one renaturing step involving conditions having a renaturing influence on the polypeptide mole-

cules having conformations resulting from the preceding step,

the series of cycles being so adapted that a substantial fraction of the initial ensemble of polypeptide molecules is 5 converted to a fraction of correctly folded diabody molecules.

Such a method for the correct folding of diabodies can be envisaged in any of the above-mentioned scenarios and aspects of the refolding method of the invention, that is, with 10 respect to the choice of physical/chemical conditions as well as cycling schedules. However, an important aspect of the method for correct folding of diabodies is a method as the above-identified, wherein the polypeptide molecules are in contact with a liquid phase containing at least one 15 disulphide reshuffling system in at least one denaturing or renaturing step. The preferred denaturing agent to be used in such a liquid phase is urea, and the preferred disulphide reshuffling system comprises glutathione as the main reducing agent.

20 A particular aspect of the invention relates to a polypeptide which is a proenzyme of a serine protease, but is different from any naturally occurring serine protease and, in particular, has an amino acid sequence different from that of bovine coagulation factor X (Protein Identification Resource (PIR), 25 National Biomedical Research Foundation, Georgetown University, Medical Center, U.S.A., entry: P1;EXBO) and which can be proteolytically activated to generate the active serine protease by incubation of a solution of the polypeptide in a non-denaturing buffer with a substance that cleaves the 30 polypeptide to liberate a new N-terminal residue,

the substrate specificity of the serine protease being identical to or better than that of bovine blood coagulation factor  $X_a$ , as assessed by each of the ratios

( $k(I)/k(V)$  and  $k(III)/k(V)$  between cleavage rate against each of the substrates I and III:

I:       Benzoyl-Val-Gly-Arg-paranitroanilide,  
III:      Tosyl-Gly-Pro-Arg-paranitroanilide,

5       versus that against the substrate

V:       Benzoyl-Ile-Glu-Gly-Arg-paranitroanilide

at 20°C, pH=8 in a buffer consisting of 50 mM Tris, 100 mM NaCl, 1 mM CaCl<sub>2</sub>, being identical to or lower than the corresponding ratio determined for bovine coagulation 10 factor X<sub>a</sub> which is substantially free from contaminating proteases.

The characterization of the above-identified new polypeptides as serine proteases is in accordance with the normal nomenclatural use of the term serine proteases. As is well known 15 in the art, serine proteases are enzymes which are believed to have a catalytic system consisting of an active site serine which is aligned with a histidine residue, and it is believed that the activation of the enzymes from the corresponding proenzymes is based on the liberation of a new N- 20 terminal residue, the  $\alpha$ -amino group of which is capable of repositioning within the polypeptide structure to form a salt bridge to an aspartic acid residue preceding an active-site serine residue, thereby forming the catalytic site characteristic of serine proteases.

25 The "artificial" serine proteases defined above are extremely valuable polypeptide cleaving tools for use in the method of the invention and in other methods where it is decisive to have a cleaving tool which will selectively cleave proteins, even large folded proteins. Analogously to bovine coagulation 30 factor X<sub>a</sub>, the above-defined artificial serine proteases in activated form are capable of selectively recognizing the cleaving-directing polypeptide segment SEQ ID NO: 38, but in

contrast to bovine coagulation factor  $X_a$ , they can be established with such amino acid sequences that they can be readily produced using recombinant DNA techniques. Thus, the preferred artificial serine proteases of the invention are 5 ones which have amino acid sequences allowing their synthesis by recombinant DNA techniques, in particular in a prokaryote cells such as *E. coli*. As will appear from the following discussion and the examples, the artificial serine proteases of the invention, when produced in a prokaryote, may be given 10 an enzymatically active conformation, in which the catalytically active domains are suitably exposed, by cycling according to the method of the present invention.

The quantitative test for selectivity of the artificial serine proteases involves determination of the cleavage rate, 15  $k$ , determined as the initial slope of a curve of absorption of light at 405 nm (absorption maximum of free paranitroaniline) versus time at 20°C.

Expressed quantitatively, the selectivity of the artificial serine proteases should be characterized by the value of 20  $(k(I)/k(V))$  being at most 0.06, and the value  $k(III)/k(V)$  being at most 0.5. It is preferred that  $(k(I)/k(V))$  is at most 0.05 and  $k(III)/k(V)$  is at most 0.4, and more preferred that  $(k(I)/k(V))$  is at most 0.04 and  $k(III)/k(V)$  is at most 0.15.

A more comprehensive specificity characterization involves 25 further model substrates: thus, the substrate specificity could be assessed to be identical to or better than that of bovine blood coagulation factor  $X_a$  by each of the ratios  $(k(I)/k(V))$ ,  $k(II)/k(V)$ ,  $k(III)/k(V)$  and  $k(IV)/k(V)$ ) between cleavage rate against each of the substrates I-IV:

30        I:        Benzoyl-Val-Gly-Arg-paranitroanilide,  
              II:      Tosyl-Gly-Pro-Lys-paranitroanilide,  
              III:     Tosyl-Gly-Pro-Arg-paranitroanilide,  
              IV:     (d,1)Val-Leu-Arg-paranitroanilide

versus that against the substrate

V:       Benzoyl-Ile-Glu-Gly-Arg-paranitroanilide

5       at 20°C, pH=8 in a buffer consisting of 50 mM Tris, 100 mM NaCl, 1 mM CaCl<sub>2</sub>, being identical to or lower than the corresponding ratio determined for bovine coagulation factor X<sub>a</sub> which is substantially free from contaminating proteases.

10      Within this characterization, (k(I)/k(V) should be at most 0.06, k(II)/k(V) should be at most 0.03, k(III)/k(V) should be at most 0.5, and k(IV)/k(V) should be at most 0.01, and it is preferred that (k(I)/k(V) is at most 0.05, k(II)/k(V) is at most 0.025, k(III)/k(V) is at most 0.4, and k(IV)/k(V) is at most 0.008, and more preferred that (k(I)/k(V) is at most 0.04, k(II)/k(V) is at most 0.015, k(III)/k(V) is at most 0.15, and k(IV)/k(V) is at most 0.005.

The serine protease type polypeptide as defined above will normally have a molecular weight, M<sub>r</sub>, of at most 70,000 and at least 15,000.

20      One such novel polypeptide according to the invention has the amino acid sequence SEQ ID NO: 2 or is an analogue and/or homologue thereof. Other important embodiments of the polypeptide of the invention have an amino acid sequence which is a subsequence of SEQ ID NO: 2 or an analogue and/or homologue of such a subsequence.

25      By the use of the term "an analogue of a polypeptide encoded by the DNA sequence" or "an analogue of a polypeptide having the amino acid sequence" is meant any polypeptide which is capable of performing as bovine coagulation factor X<sub>a</sub> in the tests mentioned above. Thus, included are also polypeptides 30     from different sources, such as different mammals or vertebrates, which vary e.g. to a certain extent in the amino acid composition, or the post-translational modifications

e.g. glycosylation or phosphorylation, as compared to the artificial serine protease described in the examples.

The term "analogue" is thus used in the present context to indicate a protein or polypeptide of a similar amino acid 5 composition or sequence as the characteristic amino acid sequence SEQ ID NO: 2 derived from a artificial serine protease as described in Example 5, allowing for minor variations that alter the amino acid sequence e.g. deletions, site directed mutations, insertions of extra amino acids, or 10 combinations thereof, to generate artificial serine protease analogues.

Therefore, in the present description and claims, an analogue (of a polypeptide) designates a variation of the polypeptide in which one or several amino acids may have been deleted or 15 exchanged, and/or amino acids may have been introduced, provided the enzymatic activity with the above-defined specificity is retained, as can be assessed as described above.

With respect to homology, an analogue of a polypeptide according to the invention may have a sequence homology at the 20 polypeptide level of at least 60% identity compared to the sequence of a fragment of SEQ ID NO: 2, allowing for deletions and/or insertions of at most 50 amino acid residues.

Such polypeptide sequences or analogues thereof which has a homology of at least 60% with the polypeptide shown in SEQ ID 25 NO: 2 encoded for by the DNA sequence of the invention SEQ ID NO: 1 or analogues and/or homologues thereof, constitute an important embodiment of this invention.

By the term "sequence homology" is meant the identity in sequence of either the amino acids in segments of two or more 30 amino acids in a amino acid sequence, or the nucleotides in segments of two or more nucleotides in a nucleotide sequence. With respect to polypeptides, the terms are thus intended to mean a homology between the amino acids in question between

which the homology is to be established, in the match with respect to identity and position of the amino acids of the polypeptides.

The term "homologous" is thus used here to illustrate the 5 degree of identity between the amino acid sequence of a given polypeptide and the amino acid sequence shown in SEQ ID NO: 2. The amino acid sequence to be compared with the amino acid sequence shown in SEQ ID NO: 2 may be deduced from a nucleotide sequence such as a DNA or RNA sequence, e.g. 10 obtained by hybridization as defined in the following, or may be obtained by conventional amino acid sequencing methods.

Another embodiment relates to a polypeptide having an amino acid sequence from which a consecutive string of 20 amino acids is homologous to a degree of at least 40% with a string 15 of amino acids of the same length selected from the amino acid sequence shown in SEQ ID NO: 2.

One serine protease polypeptide according to the invention has the amino acid sequence of SEQ ID NO: 2, residues 82-484, or is an analogue and/or homologue thereof. Another serine 20 protease polypeptide according to the invention has the amino acid sequence of SEQ ID NO: 2, residues 166-484, or is an analogue and/or homologue thereof.

A number of modifications of the sequences shown herein are particularly interesting: The insertion of the cleaving 25 directing sequences SEQ ID NO: 38 or 40-42 instead of residues 230-233 in SEQ ID NO: 2, combined with exchange of cysteine residue 245 by preferably Gly, Ser or Arg in SEQ ID NO: 2. Another interesting possibility is insertion of SEQ ID NO: 38 or 40-42 instead of residues 179-182 in SEQ ID NO: 2. 30 Quite generally, in any of the artificial serine proteases defined above, replacement of the cleaving sequence corresponding to residues 230-233 in SEQ ID NO: 2 with one of the cleavage-directing sequences defined above will give rise to extremely useful cleaving enzymes for use in the method

according to the invention, in that these can be selectively and very efficiently cleaved by enzymes having the specific enzymatic activity of bovine coagulation factor  $X_a$ , and thus by artificial serine proteases as defined above, including by 5 molecules identical to themselves. The latter fact means that artificial serine proteases modified by such insertion of the specific cleaving-directing sequences can be extremely effectively activated, as the first molecules cleaved and activated will be able to cleave other molecules, thus starting a 10 chain reaction.

As mentioned above, it is a most important feature that the artificial serine proteases can be produced by recombinant DNA techniques, and hence, another important embodiment of the invention relates to a nucleic acid fragment capable of 15 encoding a polypeptide according as defined above, in particular a DNA fragment which is capable of encoding an artificial serine protease polypeptide as defined above.

In one of its aspects, the invention relates to a nucleotide sequence encoding a polypeptide of the invention as defined 20 above. In particular, the invention relates to a nucleotide sequence having the nucleotide sequence shown in the DNA sequence SEQ ID NO: 1 or an analogue thereof which has a homology with the any of the DNA sequences shown in SEQ ID NO: 1 of at least 60%, and/or encodes a polypeptide, the 25 amino acid sequence of which is at least 60% homologous with the amino acid sequences shown in SEQ ID NO: 2.

Generally, only coding regions are used when comparing nucleotide sequences in order to determine their internal homology.

30 The term "analogue" with regard to the DNA fragments of the invention is intended to indicate a nucleotide sequence which encodes a polypeptide identical or substantially identical to the polypeptide encoded by a DNA fragment of the invention. It is well known that the same amino acid may be encoded by

various codons, the codon usage being related, inter alia, to the preference of the organisms in question expressing the nucleotide sequence. Thus, one or more nucleotides or codons of the DNA fragment of the invention may be exchanged by 5 others which, when expressed, result in a polypeptide identical or substantially identical to the polypeptide encoded by the DNA fragment in question.

Furthermore, the term "analogue" is intended to allow for variations in the sequence such as substitution, insertion 10 (including introns), addition and rearrangement of one or more nucleotides, which variations do not have any substantially effect on the polypeptide encoded by the DNA fragment.

Thus, within the scope of the present invention is a modified nucleotide sequence which differs from the DNA sequence shown 15 in SEQ ID NO: 1 in that at least one nucleotide has been substituted, added, inserted, deleted and/or rearranged.

The term "substitution" is intended to mean the replacement of one or more nucleotides in the full nucleotide sequence with one or more different nucleotides, "addition" is understood 20 to mean the addition of one or more nucleotides at either end of the full nucleotide sequence, "insertion" is intended to mean the introduction of one or more nucleotides within the full nucleotide sequence, "deletion" is intended to indicate that one or more nucleotides have been deleted 25 from the full nucleotide sequence whether at either end of the sequence or at any suitable point within it, and "rearrangement" is intended to mean that two or more nucleotide residues have been exchanged within the DNA or polypeptide sequence, respectively. The DNA fragment may, however, also 30 be modified by mutagenesis either before or after inserting it in the organism. The DNA or protein sequence of the invention may be modified in such a way that it does not lose any of its biophysical, biochemical or biological properties, or part of such properties (one and/or all) or all of such 35 properties (one and/or all).

An example of a specific analogue of the DNA sequence of the invention is a DNA sequence which comprises the DNA sequence shown in SEQ ID NO: 1 and particularly adapted for expression in *E. coli*. This DNA sequence is one which, when inserted in 5 *E. coli* together with suitable regulatory sequences, results in the expression of a polypeptide having substantially the amino acid sequence shown in SEQ ID NO: 2. Thus, this DNA sequence comprises specific codons recognized by *E. coli*.

The terms "fragment", "sequence", "homologue" and "analogue", 10 as used in the present specification and claims with respect to fragments, sequences, homologues and analogues according to the invention should of course be understood as not comprising these phenomena in their natural environment, but rather, e.g., in isolated, purified, *in vitro* or recombinant 15 form.

One embodiment of the nucleic acid fragment according to the invention is a nucleic acid fragment as defined above in which at least 60% of the coding triplets encode the same amino acids as a nucleic acid fragment of the nucleic acid 20 which encodes bovine coagulation factor X, allowing for insertions and/or deletions of at most 150 nucleotides. An example of such a nucleic acid fragment is SEQ ID NO: 1, nucleotides 76-1527, and analogues and/or homologues thereof. Another example is SEQ ID NO: 1, nucleotides 319-1527, and 25 analogues and/or homologues thereof. Still another example is SEQ ID NO: 1, nucleotides 571-1527, and analogues and/or homologues thereof.

The DNA fragment described above and constituting an important aspect of the invention may be obtained directly from 30 the genomic DNA or by isolating mRNA and converting it into the corresponding DNA sequence by using reverse transcriptase, thereby producing a cDNA. When obtaining the DNA fragment from genomic DNA, it is derived directly by screening for genomic sequences as is well known for the person skilled 35 in the art. It can be accomplished by hybridization to a DNA

probe designed on the basis of knowledge of the sequences of the invention, or the sequence information obtained by amino acid sequencing of a purified serine protease. When the DNA is of complementary DNA (cDNA) origin, it may be obtained by

5 preparing a cDNA library with mRNA from cells containing an artificial serine protease. Hybridization can be accomplished by a DNA probe designed on the basis of knowledge of the cDNA sequence, or the sequence information obtained by amino acid sequencing of a purified artificial serine protease.

10 The DNA fragment of the invention or an analogue and/or homologue thereof of the invention can be replicated by fusing it with a vector and inserting the complex into a suitable microorganism or a mammalian cell line. Alternatively, the DNA fragment can be manufactured using chemical

15 synthesis. Also, polymerase chain reaction (PCR) primers can be synthesized based on the nucleotide sequence shown in SEQ ID NO: 1. These primers can then be used to amplify the whole or a part of a sequence encoding an artificial serine protease polypeptide.

20 Suitable polypeptides of the invention can be produced using recombinant DNA technology. More specifically, the polypeptides may be produced by a method which comprises culturing or breeding an organism carrying the DNA sequence shown in SEQ ID NO: 1 or an analogue and/or homologue thereof of the

25 invention under conditions leading to expression of said DNA fragment, and subsequently recovering the expressed polypeptide from the said organism.

The organism which is used for the production of the polypeptide may be a higher organism, e.g. an animal, or a lower

30 organism, e.g. a microorganism. Irrespective of the type of organism used, the DNA fragment of the invention (described above) should be introduced in the organism either directly or with the help of a suitable vector. Alternatively, the polypeptides may be produced in the mammalian cell lines by

35 introducing the DNA fragment or an analogue and/or homologue

thereof of the invention either directly or with the help of an expression vector.

The DNA fragment of the invention can also be cloned in a suitable stable expression vector and then put into a suitable cell line. The cells expressing the desired polypeptides are then selected using the conditions suitable for the vector and the cell line used. The selected cells are then grown further and form a very important and continuous source of the desired polypeptides.

10 Thus, another aspect of the invention relates to an expression system comprising a nucleic acid fragment as defined above and encoding an artificial serine protease polypeptide as defined above, the system comprising a 5'-flanking sequence capable of mediating expression of said nucleic acid

15 fragment. The expression system may be a replicable expression vector carrying the nucleic acid fragment, which vector is capable of replicating in a host organism or a cell line; the vector may, e.g., be a plasmid, phage, cosmid, minichromosome or virus; the vector may be one which, when introduced in a host cell, is integrated in the host cell genome.

20

Another aspect of the invention relates to an organism which carries and is capable of replicating the nucleic acid fragment as defined above. The organism may be a microorganism such as a bacterium, a yeast, a protozoan, or a cell derived from a multicellular organism such as a fungus, an insect cell, a plant cell, a mammalian cell or a cell line. Particularly interesting host organisms are microorganisms such as a bacterium of the genus *Escherichia*, *Bacillus* or *Salmonella*.

25 A further aspect of the invention relates to a method of producing an artificial serine protease polypeptide as defined above, comprising the following steps of:

1. inserting a nucleic acid fragment as defined above in an expression vector,

2. transforming a host organism as defined above with the vector produced in step a,
3. culturing the host organism produced in step b to express the polypeptide,
- 5 4. harvesting the polypeptide,
5. optionally subjecting the polypeptide to post-translational modification,
6. if necessary subjecting the polypeptide to the denaturing/renaturing cycling method according to the 10 present invention, and
7. optionally subjecting the polypeptide to further modification to obtain an authentic polypeptide as defined above.

Further modifications of the polypeptides may for instance be 15 accomplished by subjecting the polypeptide molecules to carboxypeptidase A or B, whereby selected amino acid residues may be removed from the C-terminus of the polypeptide molecules. This is desirable under circumstances wherein the optimal folding of the authentic polypeptide molecules only 20 is achieved when the N-terminus is free and the cleavage directing polypeptide (such as SEQ ID NO: 37) thus is placed C-terminally of the authentic polypeptide. As is known, carboxypeptidase B cleaves sequentially from the C-terminus, and only cleaves off basic amino acids, whereas carboxypeptidase A cleaves off non-basic amino acids. By careful designing which residue is adjoined C-terminally to the authentic polypeptide it is possible to ensure that all but the authentic polypeptide is cleaved by the carboxypeptidases. If the 25 C-terminus of the authentic polypeptide is a basic amino acid residue one should assure that the C-terminally linked residue which is to be removed is non-basic and vice versa. If 30 one knows the sequence of the amino acid residues from the C-

terminus to the C-terminus of the authentic polypeptide it is possible to alternate between treatments with the two carboxypeptidases until only the naked, authentic polypeptide is left. A practical embodiment would be to use immobilized 5 carboxypeptidases.

The polypeptide produced may be isolated by a method comprising one or more steps like affinity chromatography using immobilized polypeptide or antibodies reactive with said polypeptide and/or other chromatographic and electrophoretic 10 procedures.

Also, it will be understood that a polypeptide of the invention may be prepared by the well known methods of liquid or solid phase peptide synthesis utilizing the successive coupling of the individual amino acids of the polypeptide 15 sequence. Alternatively, the polypeptide can be synthesized by the coupling of individual amino acids forming fragments of the polypeptide sequence which are later coupled so as to result in the desired polypeptide. These methods thus constitute another interesting aspect of the invention.

20 The invention also relates to the use of an artificial serine protease polypeptide as defined above for cleaving polypeptides at the cleavage site for bovine coagulation factor  $X_a$ , the cleavage site having the amino acid sequence selected from the group consisting of SEQ ID NO: 38, SEQ ID 25 NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42, and to the use of a an artificial serine protease polypeptide as defined above for cleaving polypeptides at the cleavage site for bovine coagulation factor  $X_a$ , the cleavage site having a modified version of the amino acid sequence selected from the group of 30 SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46, which has been converted to a cleavable form as described further above.

## LEGENDS TO FIGURES

Fig. 1: Schematic representation of segment of a cyclic denaturation / renaturation time-programme.

Solvent composition is expressed in terms of a binary mixture 5 of a non-denaturing 'buffer A' and a denaturing 'buffer B' in terms of relative content of buffer B. Three consecutive cycles are represented, each consisting of a renaturation phase 'F' and a denaturation phase 'D'. Changes in level of denaturing power of the solvent mixture during denaturation 10 phases in consecutive cycles are denoted 'k'.

Fig. 2: Construction of the expression plasmids pT<sub>7</sub>H<sub>6</sub>FX-h $\beta$ 2m and pT<sub>7</sub>H<sub>6</sub>FX-m $\beta$ 2m.

The amplified DNA fragments containing the reading frames of human- and murine  $\beta_2$ -microglobulin from amino acid residues 15 Ile<sub>1</sub> to Met<sub>99</sub>, fused at the 5'-end to the nucleotide sequences encoding the FX<sub>a</sub> cleavage site (SEQ ID NO: 37), were cut with the restriction endonucleases Bam HI and Hind III (purchased from Boehringer, Germany) and ligated with T<sub>4</sub> 20 DNA ligase (purchased from Boehringer, Germany) into Bam HI and Hind III cut pT<sub>7</sub>H<sub>6</sub> using standard procedures.

Fig. 3: Amino acid sequences of human- and murine  $\beta_2$ -microglobulin.

A: Predicted amino acid sequence of the full length reading frame encoding human  $\beta_2$ -microglobulin (SEQ ID NO: 49). Amino 25 acid residue one (Ile) in the processed mature protein is indicated. B: Predicted amino acid sequence of the full length reading frame encoding murine  $\beta_2$ -microglobulin (SEQ ID NO: 50). Amino acid residue one (Ile) in the processed mature protein is indicated.

30 Fig. 4: Construction of the expression plasmid pT<sub>7</sub>H<sub>6</sub>FX-hGH. The amplified DNA fragment containing the reading frame of human Growth Hormone from amino acid residues Phe<sub>1</sub> to Phe<sub>191</sub>, fused at the 5'-end to the nucleotide sequence encoding the FX<sub>a</sub> cleavage site IEGR (SEQ ID NO: 38), was cut with the

restriction endonucleases Bam HI and Hind III (purchased from Boehringer, Germany) and ligated with  $T_4$  DNA ligase (purchased from Boehringer, Germany) into Bam HI and Hind III cut pT<sub>7</sub>H<sub>6</sub> using standard procedures.

5 Fig. 5: Amino acid sequence of human Growth Hormone (Somatotropin) .

The predicted amino acid sequence of the full length reading frame encoding human Growth Hormone (SEQ ID NO: 51). The first Amino acid residue in the processed mature protein 10 (Phe<sub>1</sub>) is indicated.

Fig. 6: Construction of the plasmids pT<sub>7</sub>H<sub>6</sub>FX-#1, #2, and #3 expressing amino acid residue no. 20 (Ala) to 109 (Arg), amino acid residue no 20 (Ala) to 190 (Ala), and amino acid residue no. 20 (Ala) to 521 (Lys) of the human  $\alpha_2$ -Macroglobulin Receptor Protein ( $\alpha_2$ MR) (SEQ ID NO: 52). 15

The amplified DNA fragments derived from the reading frame of the  $\alpha_2$ MR from #1: amino acid residue no. 20 (Ala) to 109 (Arg), #2: amino acid residue no. 20 (Ala) to 190 (Ala), and #3: amino acid residue no. 20 (Ala) to 521 (Lys) , fused at 20 the 5'-end to the nucleotide sequence encoding the FX<sub>a</sub> cleavage site IEGR (SEQ ID NO: 38), were cut with the restriction endonucleases Bam HI and Hind III (purchased from Boehringer, Germany) and ligated with  $T_4$  DNA ligase (purchased from Boehringer, Germany) into Bam HI and Hind III cut pT<sub>7</sub>H<sub>6</sub> using 25 standard procedures.

Fig. 7: Construction of the plasmids pLcIIMLCH<sub>6</sub>FX-#4, #5, and #6 expressing amino acid residue no. 803 (Gly) to 1265 (Asp) , amino acid residue no. 849 (Val) to 1184 (Gln) , and amino acid residue no. 1184 (Gln) to 1582 (Lys) of the human  $\alpha_2$ - 30 Macroglobulin Receptor Protein ( $\alpha_2$ MR) (SEQ ID NO: 52).

The amplified DNA fragments derived from the reading frame of the  $\alpha_2$ MR from #4: amino acid residue no. 803 (Gly) to 1265 (Asp) , #5: amino acid residue no. 849 (Val) to 1184 (Gln) , and #6: amino acid residue no. 1184 (Gln) to 1582 (Lys) , 35 fused at the 5'-end to the nucleotide sequence encoding the

$\text{FX}_a$  cleavage site IEGR (SEQ ID NO: 38), were cut with the restriction endonucleases Bam HI or Bcl and Hind III (purchased from Boehringer, Germany) and ligated with  $\text{T}_4$  DNA ligase (purchased from Boehringer, Germany) into Bam HI and 5 Hind III cut  $\text{pLcIIMLCH}_6\text{FX}$  using standard procedures.

Fig. 8: Construction of the plasmids  $\text{pLcIIMLCH}_6\text{FX}$ -#7, #8, and #9 expressing amino acid residue no. 803 (Gly) to 1582 (Lys), amino acid residue no. 2519 (Ala) to 2941 (Ile), and amino acid residue no. 3331 (Val) to 3778 (Ile) of the human  $\alpha_2$ -Macroglobulin Receptor Protein ( $\alpha_2\text{MR}$ ) (SEQ ID NO: 52).  
10 The amplified DNA fragments derived from the reading frame of the  $\alpha_2\text{MR}$  from #7: amino acid residue no. 803 (Gly) to 1582 (Lys), #8: amino acid residue no. 2519 (Ala) to 2941 (Ile), and #9: amino acid residue no. 3331 (Val) to 3778 (Ile),  
15 fused at the 5'-end to the nucleotide sequence encoding the  $\text{FX}_a$  cleavage site IEGR (SEQ ID NO: 38), were cut with the restriction endonucleases Bam HI and Hind III (purchased from Boehringer, Germany) and ligated with  $\text{T}_4$  DNA ligase (purchased from Boehringer, Germany) into Bam HI and Hind III cut 20  $\text{pLcIIMLCH}_6\text{FX}$  using standard procedures.

Figs. 9a and 9b: Amino acid sequence of human  $\alpha_2$ -Macroglobulin Receptor Protein ( $\alpha_2\text{MR}$ ) (SEQ ID NO: 52).  
The predicted amino acid sequence of the full length reading frame encoding the  $\alpha_2\text{MR}$ . Amino acid residues present in the 25 recombinant proteins as N- or C-terminal residues are identified by their numbers above the  $\alpha_2\text{MR}$  sequence.

Fig. 10: Construction of the expression plasmid  $\text{pLcIIMLCH}_6\text{FX}\Delta\gamma$ .  
The amplified DNA fragment containing the reading frame of 30 bovine blood coagulation Factor X from amino acid residue  $\text{Ser}_{82}$  to  $\text{Trp}_{484}$ , ( $\text{FX}\Delta\gamma$ ) fused at the 5'-end to the nucleotide sequence encoding the  $\text{FX}_a$  cleavage site IEGR (SEQ ID NO: 38), was cut with the restriction endonucleases Bam HI and Hind III (purchased from Boehringer, Germany) and ligated with  $\text{T}_4$

DNA ligase (purchased from Boehringer, Germany) into Bam HI and Hind III cut pLcIIMLCH<sub>6</sub>FX using standard procedures.

Fig. 11: Amino acid sequence of bovine blood coagulation Factor X (FX).

5 The predicted amino acid sequence of the full length reading frame encoding bovine FX (SEQ ID NO: 53). The N-terminal amino acid residue Ser<sub>82</sub> and the C-terminal Trp<sub>484</sub> residue in the FXΔγ construct are identified.

Fig. 12: Construction of the expression plasmid pLcIIMLCH<sub>6</sub>FX-

10 K1.

The amplified DNA fragment containing the reading frame of human plasminogen kringle 1 (K1) from amino acid residue Ser<sub>82</sub> to Glu<sub>162</sub> (numbering as in "Glu"-plasminogen), fused at the 5'-end to the nucleotide sequence encoding the FX<sub>a</sub> cleavage site IEGR (SEQ ID NO: 38), was cut with the restriction endonucleases Bam HI and Hind III (purchased from Boehringer, Germany) and ligated with T<sub>4</sub> DNA ligase (purchased from Boehringer, Germany) into Bam HI and Hind III cut pLcIIMLCH<sub>6</sub>FX using standard procedures.

20 Fig. 13: Construction of the expression plasmid pLcIIH<sub>6</sub>FX-K4.

The amplified DNA fragment containing the reading frame of human plasminogen kringle 4 (K4) from amino acid residue Val<sub>354</sub> to Ala<sub>439</sub> (numbering as in "Glu"-plasminogen), fused at the 5'-end to the nucleotide sequence encoding the FX<sub>a</sub> cleavage site IEGR (SEQ ID NO: 38), was cut with the restriction endonucleases Bam HI and Hind III (purchased from Boehringer, Germany) and ligated with T<sub>4</sub> DNA ligase (purchased from Boehringer, Germany) into Bam HI and Hind III cut pLcIIH<sub>6</sub>FX using standard procedures.

30 Fig. 14: Amino acid sequence of human "Glu"- Plasminogen (SEQ ID NO: 54). The N- and C-terminal amino acid residues in the K1 and K4 constructs are identified by their numbers in the sequence.

Fig. 15: SDS-PAGE analysis of production and *in vitro* folding of recombinant human  $\beta_2$ -microglobulin.

Lane 1: Crude protein extract before application to the  $\text{Ni}^{2+}$ NTA-agarose column (reduced sample).

5 Lane 2: Column flow-through during application of the crude protein extract onto the  $\text{Ni}^{2+}$ NTA-agarose column (reduced sample)

Lane 3: Human  $\beta_2$ -microglobulin eluted from the  $\text{Ni}^{2+}$ NTA-agarose column after the cyclic folding procedure by the non-  
10 denaturing elution buffer (reduced sample).

Lane 4: Protein markers (Pharmacia, Sweden): From top of gel; 94 kDa, 67 kDa, 43 kDa, 30 kDa, 20.1 kDa, and 14.4 kDa (reduced sample)

Lane 5: Same as lane 3 (non-reduced sample)

15 Lane 6: Recombinant human  $\beta_2$ -microglobulin after  $\text{FX}_a$  cleavage and final purification (non-reduced sample).

Fig. 16: SDS-PAGE analysis of *in vitro* folding of recombinant human Growth Hormone; hGH (Somatotropin).

Lane 1: Protein markers (Pharmacia, Sweden): From top of gel; 94 kDa, 67 kDa, 43 kDa, 30 kDa, 20.1 kDa, and 14.4 kDa (reduced sample)

Lane 2: Human hGH eluted from the  $\text{Ni}^{2+}$ NTA-agarose column after the cyclic folding procedure by the non-denaturing elution buffer (non-reduced sample).

25 Lane 3: Human hGH eluted from the  $\text{Ni}^{2+}$ NTA-agarose column after the cyclic folding procedure by the denaturing elution buffer B from the folding procedure (non-reduced sample).

Lane 4-18: Fractions collected during the separation of monomeric hGH-fusion protein from dimer and multimer fusion  
30 proteins after the cyclic folding procedure by ion exchange chromatography on Q-Sepharose (Pharmacia, Sweden). The monomeric protein was eluted in a peak well separated from the peak containing the dimer and multimer proteins (non-reduced samples).

35 Fig. 17: SDS-PAGE analysis of *in vitro* folding of recombinant kringle 1 and 4 from human plasminogen and recombinant fusion

protein #4 derived from human  $\alpha_2$ -Macroglobulin Receptor Protein ( $\alpha_2$ MR).

Lane 1: Protein markers (Pharmacia, Sweden): From top of gel; 94 kDa, 67 kDa, 43 kDa, 30 kDa, 20.1 kDa, and 14.4 kDa

5 (reduced sample).

Lane 2: Crude K1-fusion protein extract before application to the  $\text{Ni}^{2+}$ NTA-agarose column (reduced sample).

Lane 3: K1-fusion protein eluted from the  $\text{Ni}^{2+}$ NTA-agarose column after the cyclic folding procedure by the non-denatur-10 ring elution buffer (reduced sample).

Lane 4: Same as lane 3 (non-reduced sample).

Lane 5: Flow-through from the lysine-agarose column during application of the K1-fusion protein (non-reduced sample).

Lane 6: K1-fusion protein eluted from the lysine-agarose 15 column (non-reduced sample).

Lane 7: K4-fusion protein eluted from the  $\text{Ni}^{2+}$ NTA-agarose column after the cyclic folding procedure by the non-denatur-ring elution buffer (reduced sample).

Lane 8: Same as lane 7 (non-reduced sample).

20 Lane 9:  $\alpha_2$ MR#4 fusion protein eluted from the  $\text{Ni}^{2+}$ NTA-agarose column after the cyclic folding procedure by the non-denatur-ring elution buffer (reduced sample).

Lane 10: Same as lane 9 (non-reduced sample).

Fig. 18: Construction of the expression plasmid pT<sub>7</sub>H<sub>6</sub>FX-25  $\alpha_2$ MRBDv.

The amplified DNA fragment containing the reading frame of human  $\alpha_2$ -Macroglobulin from amino acid residues Val<sub>1299</sub> to Ala<sub>1451</sub>, fused at the 5'-end to the nucleotide sequence encoding the FX<sub>a</sub> cleavage site IEGR (SEQ ID NO: 38), was cut 30 with the restriction endonucleases Bam HI and Hind III (pur-chased from Boehringer, Germany) and ligated with T<sub>4</sub> DNA ligase (purchased from Boehringer, Germany) into Bam HI and Hind III cut pT<sub>7</sub>H<sub>6</sub> using standard procedures.

Fig. 19: Amino acid sequence of the receptor-binding domain 35 of human  $\alpha_2$ -Macroglobulin (from residue Val<sub>1299</sub> to Ala<sub>1451</sub>) (SEQ ID NO: 55).

Fig. 20: Construction of the expression plasmid pT<sub>7</sub>H<sub>6</sub>FX-TETN. The amplified DNA fragment containing the reading frame of mature monomeric human Tetranectin from amino acid residues Glu<sub>1</sub> to Val<sub>181</sub>, fused at the 5'-end to the nucleotide sequence encoding the FX<sub>a</sub> cleavage site IEGR (SEQ ID NO: 38), was cut with the restriction endonucleases Bam HI and Hind III (purchased from Boehringer, Germany) and ligated with T<sub>4</sub> DNA ligase (purchased from Boehringer, Germany) into Bam HI and Hind III cut pT<sub>7</sub>H<sub>6</sub> using standard procedures.

10 Fig. 21: Amino acid sequence of human monomeric Tetranectin. The predicted amino acid sequence of the full length reading frame encoding human Tetranectin (SEQ ID NO: 56). The first Amino acid residue in the processed mature protein (Glu<sub>1</sub>) is indicated.

15 Fig. 22: Construction of the expression plasmid pT<sub>7</sub>H<sub>6</sub>FX-DB32. The amplified DNA fragment containing the reading frame of the artificial diabody DB32 from amino acid residues Gln<sub>1</sub> to Asn<sub>246</sub>, fused at the 5'-end to the nucleotide sequence encoding the FX<sub>a</sub> cleavage site IEGR (SEQ ID NO: 38), was cut with the restriction endonucleases Bam HI and Hind III (purchased from Boehringer, Germany) and ligated with T<sub>4</sub> DNA ligase (purchased from Boehringer, Germany) into Bam HI and Hind III cut pT<sub>7</sub>H<sub>6</sub> using standard procedures.

25 Fig. 23: Amino acid sequence of the artificial diabody DB32 (SEQ ID NO: 57).

Fig. 24: The expression plasmid pT<sub>7</sub>H<sub>6</sub>FX-PS.4. The construction of pT<sub>7</sub>H<sub>6</sub>FX-PS.4 expressing human psoriasin from amino acid residues Ser<sub>2</sub> to Gln<sub>101</sub> has previously been described (Hoffmann, 1994).

30 Fig. 25: Amino acid sequence of human psoriasin. The predicted amino acid sequence of the full length reading frame encoding human psoriasin (SEQ ID NO: 58).

Fig. 26: SDS-PAGE analysis of purification and FX<sub>a</sub> cleavage of recombinant Mab 32 diabody.

a: Different stages of the purification

Lanes 1 and 2: Crude product from folding.

5 Lane 3: Final purified Mab 32 diabody fusion protein product

Lane 4: Supernatant of crude folding product after 50-fold concentration and centrifugation.

Lane 5: Pellet from crude folding product after 50-fold concentration and centrifugation.

10 b: FX<sub>a</sub> cleavage of Mab 32 diabody fusion protein.

Lanes 1 and 5: Final purified Mab 32 diabody fusion protein

Lane 2: Molar ratio 1:5 FX<sub>a</sub>:Mab 32 diabody fusion protein at 37°C for 20 hours

Lane 3: Molar ratio 1:2 FX<sub>a</sub>:Mab 32 diabody fusion protein at 15 37°C for 20 hours

Lane 4: Molar ratio 1:1 FX<sub>a</sub>:Mab 32 diabody fusion protein at 37°C for 20 hours

Fig 27: Suitability of glutathione as reducing agent in cyclic refolding of human  $\beta_2$ -microglobulin fusion protein.

20 Lane 1: Reduced sample of test no. 1.

Lane 2: Non-reduced sample of test no.1.

Lane 3: Non-reduced sample of test no.2.

Lane 4: Non-reduced sample of test no.3.

Lane 5: Non-reduced sample of test no.4.

25 Lane 6: Non-reduced sample of test no.5.

Lane 7: Non-reduced sample of test no.6.

Lane 8: Non-reduced sample of test no.7.

Lane 9: Non-reduced sample of test no.8.

Lane 10: Non-reduced sample of test no.9.

30 Lane 11: Non-reduced sample of test no.10.

Lane 12: Non-reduced sample of test no.11.

Fig. 28: Suitability of L-cysteine ethyl ester as reducing agent in cyclic refolding of human  $\beta_2$ -microglobulin fusion protein.

35 Lane 1: Reduced sample of test no. 1.

Lane 2: Non-reduced sample of test no.1.

- Lane 3: Non-reduced sample of test no.2.
- Lane 4: Non-reduced sample of test no.3.
- Lane 5: Non-reduced sample of test no.4.
- Lane 6: Non-reduced sample of test no.5.
- 5 Lane 7: Non-reduced sample of test no.6.
- Lane 8: Non-reduced sample of test no.7.
- Lane 9: Non-reduced sample of test no.8.
- Lane 10: Non-reduced sample of test no.9.

Fig. 29: Suitability of 2-Mercaptoethanol as reducing agent  
10 in cyclic refolding of human  $\beta_2$ -microglobulin fusion protein.

- Lane 1: Reduced sample of test no. 1.
- Lane 2: Non-reduced sample of test no.1.
- Lane 3: Non-reduced sample of test no.2.
- Lane 4: Non-reduced sample of test no.3.
- 15 Lane 5: Non-reduced sample of test no.4.
- Lane 6: Non-reduced sample of test no.5.
- Lane 7: Non-reduced sample of test no.6.
- Lane 8: Non-reduced sample of test no.7.
- Lane 9: Non-reduced sample of test no.8.
- 20 Lane 10: Non-reduced sample of test no.9.

Fig. 30: Suitability of Mercaptosuccinic acid as reducing agent in cyclic refolding of human  $\beta_2$ -microglobulin fusion protein.

- Lane 1: Non-reduced sample of test no.1.
- 25 Lane 2: Non-reduced sample of test no.2.
- Lane 3: Non-reduced sample of test no.3.
- Lane 4: Non-reduced sample of test no.4.
- Lane 5: Non-reduced sample of test no.5.
- Lane 6: Non-reduced sample of test no.6.
- 30 Lane 7: Non-reduced sample of test no.7.
- Lane 8: Non-reduced sample of test no.8.
- Lane 9: Non-reduced sample of test no.9.

Fig. 31: Suitability of N-Acetyl-L-cysteine as reducing agent in cyclic refolding of human  $\beta_2$ -microglobulin fusion protein.

- 35 Lane 1: Reduced sample of test no. 1.

Lane 2: Non-reduced sample of test no.1.  
Lane 3: Non-reduced sample of test no.2.  
Lane 4: Non-reduced sample of test no.3.  
Lane 5: Non-reduced sample of test no.4.  
5 Lane 6: Non-reduced sample of test no.5.  
Lane 7: Non-reduced sample of test no.6.  
Lane 8: Non-reduced sample of test no.7.  
Lane 9: Non-reduced sample of test no.8.  
Lane 10: Non-reduced sample of test no.9.

10 Fig. 32: SDS-PAGE analysis of cyclic refolding of human  $\beta_2$ -microglobulin fusion protein.  
Lane 1: Crude protein extract before application to the  $\text{Ni}^{2+}\text{NTA}$ -agarose column (reduced sample).  
Lane 2: 8  $\mu\text{l}$  sample of soluble fraction of refolded  $\text{h}\beta_2\text{m}$  as  
15 described in EXAMPLE 1.  
Lane 3: 4  $\mu\text{l}$  sample of soluble fraction of refolded  $\text{h}\beta_2\text{m}$  as  
described in EXAMPLE 1.  
Lane 4: 2  $\mu\text{l}$  sample of soluble fraction of refolded  $\text{h}\beta_2\text{m}$  as  
described in EXAMPLE 1.  
20 Lane 5: 8  $\mu\text{l}$  sample of insoluble fraction of refolded  $\text{h}\beta_2\text{m}$  as  
described in EXAMPLE 1.  
Lanes 6 and 7:  $\text{h}\beta_2\text{m}$  final product after purification by ion  
exchange chromatography.  
25 Lanes 8 and 9: Refolded  $\text{h}\beta_2\text{m}$  after optimized refolding proto-  
col as described in EXAMPLE 13.

Fig. 33: SDS-PAGE analysis of refolding of human  $\beta_2$ -micro-globulin fusion protein by buffer step and linear gradient.  
Lane 1: Sample from soluble fraction of refolded  $\text{h}\beta_2\text{m}$ , folded  
by the buffer step protocol as described in EXAMPLE 13.  
30 Lane 2 and 3: Sample of insoluble fraction of refolded  $\text{h}\beta_2\text{m}$ ,  
folded by the buffer step protocol as described in EXAMPLE  
13.  
Lane 4: Protein molecular weight markers (Pharmacia, Sweden):  
From top of gel; 94 kDa, 67 kDa, 43 kDa, 30 kDa, 20.1 kDa,  
35 and 14.4 kDa (reduced sample).

Lane 5: Sample of soluble fraction of refolded  $h\beta_2m$ , folded by the linear gradient protocol as described in EXAMPLE 13  
Lane 6 and 7: Sample of insoluble fraction of refolded  $h\beta_2m$ , folded by the linear gradient protocol as described in  
5 EXAMPLE 13.

Fig. 34: The general scheme of the design of the fusion proteins described in the examples.

In the N-terminal end of the fusion protein is optionally inserted a "booster segment" enhancing the level of expression of the fusion protein in the cell expressing the DNA encoding the fusion protein. C-terminally to this, the "6H" indicates the 6 histidinyl residues which constitute an ion chelating site used as a "affinity handle" during purification and refolding of the fusion proteins. The "FX" at the C-terminal of the 6 histidinyl site is the  $FX_a$  cleavage site. Finally, the part of the fusion protein denoted "protein" represents the protein which is going to be refolded according to the method of the invention.

#### EXAMPLES

20 Examples 1 to 11 given in this section, which are used to exemplify the "cyclic folding procedure", all describe the process of folding a recombinant cleavable hybrid protein (fusion protein) produced in *E. coli*, purified from a crude protein extract and subjected to folding without further  
25 purification by one general procedure.

The nucleotide sequence encoding the recombinant protein, which is to be produced, is at the 5'-end fused to a nucleotide sequence encoding an amino acid sequence specifying a  $FX_a$  cleavage site (FX), in turn linked N-terminally to a  
30 segment containing six histidinyl residues (SEQ ID NO: 47). The linking of the  $FX_a$  cleavage site is normally achieved during a Polymerase Chain Reaction, wherein the 5'-terminal primer comprises nucleotides encoding this sequence. The linking of the six histidinyl residues is normally obtained

by employing a vector which comprises a nucleotide fragment encoding SEQ ID NO: 47. The six histidinyl residues constitute a metal ion chelating site, which is utilized as affinity handle during purification of the fusion protein and 5 subsequently as the point of contact to the solid matrix during the cyclic folding process. Occasionally 'booster segments' (e.g. a segment derived from the N-terminus of the  $\lambda$ cII protein in some cases followed by a segment derived from myosin light chain) are inserted N-terminal to the affinity 10 handle in order to improve the level of expression of the fusion protein in *E. coli*.

The fusion proteins are all designed according to the same general scheme (cf. fig. 34). The presence of booster segments, affinity handle and FX<sub>a</sub> cleavage site might complicate 15 refolding of the recombinant protein of interest. Furthermore, the cyclic folding process is initiated immediately after the affinity purification of the fusion protein. This means that fusion protein material, which have been partially degraded by the *E. coli* host is retained on the affinity 20 matrix in addition to the full length fusion protein column. This degraded fusion protein may well interfere severely with refolding of the full-length fusion protein, thereby reducing the apparent efficiency of the process. The folding efficiency results reported in Examples 1 to 11 therefore cannot 25 directly be compared to the efficiency of the process of refolding a purified fusion protein.

Examples 1 to 11 describe the refolding procedure for 21 different proteins, protein domains or domain-clusters, ranging from a size of 82 amino acids (K1, Example 6) to 780 30 amino acids ( $\alpha_2$ MR#7, Example 4), and the number of disulphide bridges in the proteins ranges from zero ( $\alpha_2$ MRAP, Example 3) to 33 ( $\alpha_2$ MR#4, Example 4) and 36 ( $\alpha_2$ MR#7, Example 4).

The efficiency of the refolding of the proteins ranges from 15 to 95%, and the yield of active protein lies in the order

of 10-100 mg for refolding on a 40 ml Ni+NTA-agarose column (NTA denotes a substituted nitrilotriacetic acid).

The following tables 1-5 demonstrate the gradient profiles used in the examples. "Time" is given in minutes and "flow" 5 in ml/min.

TABLE 1

Step	Time	Flow	%A	%B	Step	Time	Flow	%A	%B
1	0	2	100	0	61	900	2	100	0
2	45	2	100	0	62	945	2	100	0
3	46	2	0	100	63	946	2	60	40
4	52	2	0	100	64	952	2	60	40
5	60	2	100	0	65	960	2	100	0
6	105	2	100	0	66	1005	2	100	0
7	106	2	4	96	67	1006	2	62	38
8	113	2	4	96	68	1012	2	62	38
9	120	2	100	0	69	1020	2	100	0
10	165	2	100	0	70	1065	2	100	0
11	166	2	8	92	71	1066	2	64	36
12	172	2	8	92	72	1072	2	64	36
13	180	2	100	0	73	1080	2	100	0
14	225	2	100	0	74	1125	2	100	0
15	226	2	12	88	75	1126	2	66	34
16	232	2	12	88	76	1132	2	66	34
17	240	2	100	0	77	1140	2	100	0
18	285	2	100	0	78	1185	2	100	0
19	286	2	16	84	79	1186	2	68	32
20	292	2	16	84	80	1192	2	68	32
21	300	2	100	0	81	1200	2	100	0
22	345	2	100	0	82	1245	2	100	0
23	346	2	20	80	83	1246	2	70	30
24	352	2	20	80	84	1252	2	70	30
25	360	2	100	0	85	1260	2	100	0
26	405	2	100	0	86	1305	2	100	0
27	406	2	24	76	87	1306	2	72	28
28	412	2	24	76	88	1312	2	72	28
29	420	2	100	0	89	1319	2	100	0
30	465	2	100	0	90	1364	2	100	0
31	466	2	28	72	91	1365	2	74	26
32	472	2	28	72	92	1371	2	74	26
33	480	2	100	0	93	1378	2	100	0
34	525	2	100	0	94	1423	2	100	0
35	526	2	32	68	95	1424	2	76	24
36	532	2	32	68	96	1430	2	76	24
37	540	2	100	0	97	1437	2	100	0
38	585	2	100	0	98	1482	2	100	0
39	586	2	36	64	99	1483	2	78	22
40	592	2	36	64	100	1489	2	78	22
41	600	2	100	0	101	1496	2	100	0
42	645	2	100	0	102	1541	2	100	0
43	646	2	40	60	103	1542	2	80	20
44	652	2	40	60	104	1548	2	80	20
45	660	2	100	0	105	1555	2	100	0
46	705	2	100	0	106	1556	2	82	18
47	706	2	44	56	107	1562	2	82	18
48	713	2	44	56	108	1569	2	100	0
49	720	2	100	0	109	1614	2	100	0
50	765	2	100	0	110	1615	2	84	16
51	766	2	48	52	111	1621	2	84	16
52	772	2	48	52	112	1628	2	100	0
53	780	2	100	0	113	1673	2	100	0
54	825	2	100	0	114	1674	2	88	12
55	826	2	52	48	115	1732	2	88	12
56	832	2	52	48	116	1733	2	100	0
57	840	2	100	0	117	1778	2	100	0
58	885	2	100	0					
59	886	2	56	44					
60	892	2	56	44					

TABLE 2

Step	Time	Flow	%A	%B	Step	Time	Flow	%A	%B
1	0	2	100	0	49	720	2	100	0
2	45	2	100	0	50	765	2	100	0
3	46	2	0	100	51	766	2	74	26
4	52	2	0	100	52	772	2	74	26
5	60	2	100	0	53	780	2	100	0
6	105	2	100	0	54	825	2	100	0
7	106	2	8	92	55	826	2	76	24
8	113	2	8	92	56	832	2	76	24
9	120	2	100	0	57	840	2	100	0
10	165	2	100	0	58	885	2	100	0
11	166	2	20	80	59	886	2	78	22
12	172	2	20	80	60	892	2	78	22
13	180	2	100	0	61	900	2	100	0
14	225	2	100	0	62	945	2	100	0
15	226	2	28	72	63	946	2	80	20
16	232	2	28	72	64	952	2	80	20
17	240	2	100	0	65	960	2	100	0
18	285	2	100	0	66	1005	2	100	0
19	286	2	34	66	67	1006	2	82	18
20	292	2	34	66	68	1012	2	82	18
21	300	2	100	0	69	1020	2	100	0
22	345	2	100	0	70	1065	2	100	0
23	346	2	42	58	71	1066	2	84	16
24	352	2	42	58	72	1072	2	84	16
25	360	2	100	0	73	1080	2	100	0
26	405	2	100	0	74	1125	2	100	0
27	406	2	50	50	75	1126	2	86	14
28	412	2	50	50	76	1132	2	86	14
29	420	2	100	0	77	1140	2	100	0
30	465	2	100	0	78	1185	2	100	0
31	466	2	54	46	79	1186	2	88	12
32	472	2	54	46	80	1192	2	88	12
33	480	2	100	0	81	1200	2	100	0
34	525	2	100	0	82	1245	2	100	0
35	526	2	58	42	83	1246	2	90	10
36	532	2	58	42	84	1252	2	90	10
37	540	2	100	0	85	1260	2	100	0
38	585	2	100	0	86	1305	2	100	0
39	586	2	62	38	87	1306	2	95	5
40	592	2	62	38	88	1312	2	95	5
41	600	2	100	0	89	1319	2	100	0
42	645	2	100	0	90	1364	2	100	0
43	646	2	66	34					
44	652	2	66	34					
45	660	2	100	0					
46	705	2	100	0					
47	706	2	70	30					
48	713	2	70	30					

TABLE 3

Step	Time	Flow	%A	%B	Step	Time	Flow	%A	%B
1	0,0	1,0	0,0	100,0	25,0	420,5	1,0	60,0	40,0
2	10,0	1,0	0,0	100,0	26,0	430,0	1,0	60,0	40,0
3	40,0	1,0	100,0	0,0	27,0	460,0	1,0	100,0	0,0
4	70,0	1,0	100,0	0,0	28,0	490,0	1,0	100,0	0,0
5	70,5	1,0	10,0	90,0	29,0	490,5	1,0	70,0	30,0
6	80,0	1,0	10,0	90,0	30,0	500,0	1,0	70,0	30,0
7	110,0	1,0	100,0	0,0	31,0	530,0	1,0	100,0	0,0
8	140,0	1,0	100,0	0,0	32,0	560,0	1,0	100,0	0,0
9	140,5	1,0	20,0	80,0	33,0	560,5	1,0	80,0	20,0
10	150,0	1,0	20,0	80,0	34,0	570,0	1,0	80,0	20,0
11	180,0	1,0	100,0	0,0	35,0	600,0	1,0	100,0	0,0
12	210,0	1,0	100,0	0,0	36,0	630,0	1,0	100,0	0,0
13	210,5	1,0	30,0	70,0	37,0	630,5	1,0	85,0	15,0
14	220,0	1,0	30,0	70,0	38,0	640,0	1,0	85,0	15,0
15	250,0	1,0	100,0	0,0	39,0	670,0	1,0	100,0	0,0
16	280,0	1,0	100,0	0,0	40,0	700,0	1,0	100,0	0,0
17	280,5	1,0	40,0	60,0	41,0	700,5	1,0	88,0	12,0
18	290,0	1,0	40,0	60,0	42,0	710,0	1,0	88,0	12,0
19	320,0	1,0	100,0	0,0	43,0	740,0	1,0	100,0	0,0
20	350,0	1,0	100,0	0,0	44,0	770,0	1,0	100,0	0,0
21	350,5	1,0	50,0	50,0	45,0	770,5	1,0	90,0	10,0
22	360,0	1,0	50,0	50,0	46,0	780,0	1,0	90,0	10,0
23	390,0	1,0	100,0	0,0	47,0	810,0	1,0	100,0	0,0
24	420,0	1,0	100,0	0,0	48,0	850,0	1,0	100,0	0,0

TABLE 4

Step	Time	Flow	%A	%B	Step	Time	Flow	%A	%B
1	0	2	100	0	49	720	2	100	0
2	45	2	100	0	50	765	2	100	0
3	46	2	0	100	51	766	2	48	52
4	52	2	0	100	52	772	2	48	52
5	60	2	100	0	53	780	2	100	0
6	105	2	100	0	54	825	2	100	0
7	106	2	4	96	55	826	2	52	48
8	113	2	4	96	56	832	2	52	48
9	120	2	100	0	57	840	2	100	0
10	165	2	100	0	58	885	2	100	0
11	166	2	8	92	59	886	2	56	44
12	172	2	8	92	60	892	2	56	44
13	180	2	100	0	61	900	2	100	0
14	225	2	100	0	62	945	2	100	0
15	226	2	12	88	63	946	2	60	40
16	232	2	12	88	64	952	2	60	40
17	240	2	100	0	65	960	2	100	0
18	285	2	100	0	66	1005	2	100	0
19	286	2	16	84	67	1006	2	64	36
20	292	2	16	84	68	1012	2	64	36
21	300	2	100	0	69	1020	2	100	0
22	345	2	100	0	70	1065	2	100	0
23	346	2	20	80	71	1066	2	68	32
24	352	2	20	80	72	1072	2	68	32
25	360	2	100	0	73	1080	2	100	0
26	405	2	100	0	74	1125	2	100	0
27	406	2	24	76	75	1126	2	70	30
28	412	2	24	76	76	1132	2	70	30
29	420	2	100	0	77	1140	2	100	0
30	465	2	100	0	78	1185	2	100	0
31	466	2	28	72	79	1186	2	72	28
32	472	2	28	72	80	1192	2	72	28
33	480	2	100	0	81	1200	2	100	0
34	525	2	100	0	82	1245	2	100	0
35	526	2	32	68	83	1246	2	75	25
36	532	2	32	68	84	1252	2	75	25
37	540	2	100	0	85	1260	2	100	0
38	585	2	100	0	86	1305	2	100	0
39	586	2	36	64	87	1306	2	80	20
40	592	2	36	64	88	1312	2	80	20
41	600	2	100	0	89	1319	2	100	0
42	645	2	100	0	90	1364	2	100	0
43	646	2	40	60	91	1365	2	85	15
44	652	2	40	60	92	1371	2	85	15
45	660	2	100	0	93	1378	2	100	0
46	705	2	100	0	94	1423	2	100	0
47	706	2	44	56					
48	713	2	44	56					

TABLE 5

Step	Time	Flow	%A	%B	Step	Time	Flow	%A	%B
1	0	2	100	0	49	720	2	100	0
2	45	2	100	0	50	765	2	100	0
3	46	2	0	100	51	766	2	52	48
4	52	2	0	100	52	772	2	52	48
5	60	2	100	0	53	780	2	100	0
6	105	2	100	0	54	825	2	100	0
7	106	2	13	87	55	826	2	54	46
8	113	2	13	87	56	832	2	54	46
9	120	2	100	0	57	840	2	100	0
10	165	2	100	0	58	885	2	100	0
11	166	2	25	75	59	886	2	56	44
12	172	2	25	75	60	892	2	56	44
13	180	2	100	0	61	900	2	100	0
14	225	2	100	0	62	945	2	100	0
15	226	2	29	71	63	946	2	58	42
16	232	2	29	71	64	952	2	58	42
17	240	2	100	0	65	960	2	100	0
18	285	2	100	0	66	1005	2	100	0
19	286	2	34	66	67	1006	2	60	40
20	292	2	34	66	68	1012	2	60	40
21	300	2	100	0	69	1020	2	100	0
22	345	2	100	0	70	1065	2	100	0
23	346	2	38	62	71	1066	2	62	38
24	352	2	38	62	72	1072	2	62	38
25	360	2	100	0	73	1080	2	100	0
26	405	2	100	0	74	1125	2	100	0
27	406	2	40	60	75	1126	2	66	34
28	412	2	40	60	76	1132	2	66	34
29	420	2	100	0	77	1140	2	100	0
30	465	2	100	0	78	1185	2	100	0
31	466	2	42	58	79	1186	2	70	30
32	472	2	42	58	80	1192	2	70	30
33	480	2	100	0	81	1200	2	100	0
34	525	2	100	0	82	1245	2	100	0
35	526	2	44	56	83	1246	2	74	26
36	532	2	44	56	84	1252	2	74	26
37	540	2	100	0	85	1260	2	100	0
38	585	2	100	0	86	1305	2	100	0
39	586	2	46	54	87	1306	2	78	22
40	592	2	46	54	88	1312	2	78	22
41	600	2	100	0	89	1319	2	100	0
42	645	2	100	0	90	1364	2	100	0
43	646	2	48	52	91	1365	2	82	18
44	652	2	48	52	92	1371	2	82	18
45	660	2	100	0	93	1378	2	100	0
46	705	2	100	0	94	1423	2	100	0
47	706	2	50	50					
48	713	2	50	50					

## EXAMPLE 1

*Production and Folding of Human and Murine  $\beta_2$ -microglobulin*

This example describes the production in *E. coli* of both human  $\beta_2$ -microglobulin and murine  $\beta_2$ -microglobulin as FX<sub>a</sub>

5 cleavable fusion proteins, and the purification of the recombinant human and murine  $\beta_2$ -microglobulin after FX<sub>a</sub> cleavage.

Plasmid clones containing the full length cDNAs encoding the human and the murine  $\beta_2$ -microglobulin proteins (generously provided by Dr. David N. Garboczi to Dr. Søren Buus) were

10 used as templates in a Polymerase Chain Reaction (PCR) (Saiki et al., 1988) designed to produce cDNA fragments corresponding to the mature human (corresponding to amino acid residue Ile<sub>1</sub> to Met<sub>99</sub>) and the mature murine (corresponding to amino acid residue Ile<sub>1</sub> to Met<sub>99</sub>)  $\beta_2$ -microglobulin proteins, by use

15 of the primers SEQ ID NO: 3 and SEQ ID NO: 4 (for the human  $\beta_2$ -microglobulin) and SEQ ID NO: 5 and SEQ ID NO: 6 (for the murine  $\beta_2$ -microglobulin). The amplified coding reading frames were at their 5'-ends, via the PCR-reaction, linked to nucleotide sequences, included in SEQ ID NO: 3 and 5, enco-

20 ding the amino acid sequence SEQ ID NO: 37, which constitute a cleavage site for the bovine restriction protease FX<sub>a</sub> (Nagai and Thøgersen, 1987). The amplified DNA fragments were subcloned into the *E. coli* expression vector pT<sub>7</sub>H<sub>6</sub> (Christensen et al., 1991). The construction of the resulting

25 plasmids pT<sub>7</sub>H<sub>6</sub>FX-h $\beta_2$ m (expressing human  $\beta_2$ -microglobulin) and pT<sub>7</sub>H<sub>6</sub>FX-m $\beta_2$ m (expressing murine  $\beta_2$ -microglobulin) is outlined in fig. 2 and in fig. 3 is shown the amino acid sequences of the expressed proteins (in SEQ ID NO: 49 (human) and SEQ ID NO: 50 (murine) are shown the amino acid sequences encoded by

30 the full length reading frames).

Human and murine  $\beta_2$ -microglobulin were produced by growing and expressing the plasmids pT<sub>7</sub>H<sub>6</sub>FX-h $\beta_2$ m and -m $\beta_2$ m in *E. coli* BL21 cells in a medium scale (2 x 1 litre) as described by Studier and Moffat, J. Mol. Biol., 189: 113-130, 1986. Exпо-

nentially growing cultures at 37°C were at OD<sub>600</sub> 0.8 infected with bacteriophage λCE6 at a multiplicity of approximately 5. Cultures were grown at 37°C for another three hours before cells were harvested by centrifugation. Cells were lysed by 5 osmotic shock and sonification and total cellular protein extracted into phenol (adjusted to pH 8 with Tris base). Protein was precipitated from the phenol phase by addition of 2.5 volumes of ethanol and centrifugation. The protein pellet was dissolved in a buffer containing 6 M guanidinium chloride, 10 50 mM Tris-HCl pH 8 and 0.1 M dithioerythriol. Following gel filtration on Sephadex G-25 (Pharmacia, LKB, Sweden) into 8 M Urea, 1 M NaCl, 50 mM Tris-HCl pH 8, 10 mM 2-mercaptoethanol and 3 mM methionine the crude protein preparation was applied to Ni<sup>2+</sup> activated NTA-agarose columns for 15 purification (Hochuli et al., 1988.) of the fusion proteins, MGSHHHHHHGSIEGR-human and murine  $\beta_2$ -microglobulin (wherein MGSHHHHHHGSIEGR is SEQ ID NO: 48) respectively and subsequently to undergo the cyclic folding procedure.

All buffers prepared for liquid chromatography were degassed 20 under vacuum prior to addition of reductant and/or use.

Ni<sup>2+</sup> activated NTA-agarose matrix (Ni<sup>2+</sup>NTA-agarose) is commercially available from Diagen GmbH, Germany. During the course of this work it was found, however, that this commercial product did not perform as well as expected. Our observations were, that the commercial Ni<sup>2+</sup>NTA-agarose matrix was 25 easily blocked when applying the denatured and reduced total protein extract, that the capacity for fusion protein was lower than expected, and that the matrix could only be regenerated successfully a few times over.

30 In order to improve the performance of the Ni<sup>2+</sup>NTA-agarose it was decided to perform a carbodiimide coupling of the N-(5-amino-1-carboxypentyl)iminodiacetic acid metal ligand (synthesis route as described by Döbeli & Hochuli (EPO 0253 303)) to a more rigid agarose matrix (i.e. Sepharose CL-6B, 35 Pharmacia, Sweden):

8 g. of N-(5-amino-1-carboxypentyl)iminodiacetic acid from the synthesis procedure in 50 ml was adjusted to pH 10 by addition of 29 g. of Na<sub>2</sub>CO<sub>3</sub> (10 H<sub>2</sub>O) and added to a stirred suspension of activated Sepharose CL-6B in 1 M Na<sub>2</sub>CO<sub>3</sub>. Reaction was allowed overnight.

The Sepharose CL-6B (initially 100 ml. suspension) was activated after removal of water by acetone with 7 g. of 1,1'-carbonyldiimidazol under stirring for 15 to 30 min. Upon activation the Sepharose CL-6B was washed with acetone followed by water and 1 M Na<sub>2</sub>CO<sub>3</sub>. The NTA-agarose matrix was loaded into a column and "charged" with Ni<sup>2+</sup> by slowly passing through 5 column volumes of a 10% NiSO<sub>4</sub> solution. The amount of Ni<sup>2+</sup> on the NTA-agarose matrix, prepared by this procedure, has been determined to 14  $\mu$ moles per ml matrix. The Ni<sup>2+</sup>NTA-agarose matrix was packed in a standard class column for liquid chromatography (internal diameter: 2.6 cm) to a volume of 40 ml. After charging the Ni<sup>2+</sup>NTA-agarose column was washed with two column volumes of water, one column volume of 1 M Tris-HCl pH 8 and two column volumes of loading buffer before application of the crude protein extract.

Upon application of the crude protein extracts on the Ni<sup>2+</sup>NTA-agarose column, the fusion proteins, MGSHHHHHGSIEGR- $\text{h}\beta_2\text{m}$  and MGSHHHHHGSIEGR- $\text{m}\beta_2\text{m}$  (wherein MGSHHHHHGSIEGR is SEQ ID NO: 48) respectively, were purified from the majority of coli and  $\lambda$  phage proteins by washing with one column volume of the loading buffer followed by 6 M guanidinium chloride, 50 mM Tris-HCl, 10 mM 2-mercaptoethanol, and 3 mM methionine until the optical density (OD) at 280 nm of the column eluates were stable.

The fusion proteins were refolded on the Ni<sup>2+</sup>NTA-agarose column using a gradient manager profile as described in table 1 and 0.5 M NaCl, 50 mM Tris-HCl pH 8, and 1.2 mM/0.4 mM reduced/oxidized glutathione as buffer A and 8 M urea, 0.5 M NaCl, 50 mM Tris-HCl pH 8, 3 mM methionine, and 6 mM reduced

gluthatione as buffer B. The reduced/oxidized gluthatione solution was freshly prepared as a 200 times stock solution by addition of 9.9 M H<sub>2</sub>O<sub>2</sub> to a stirred solution of 0.2 M reduced gluthatione before addition to buffer A.

5 After completion of the cyclic folding procedure the h $\beta_2$ m and m $\beta_2$ m fusion proteins were eluted from the Ni<sup>2+</sup>NTA-agarose columns with a buffer containing 0.5 M NaCl, 50 mM Tris-HCl, 20 mM EDTA pH 8.

10 Fusion protein that were aggregated and precipitated on the Ni<sup>2+</sup>NTA-agarose columns were eluted in buffer B.

Approximately 75% of the fusion protein material was eluted by non-denaturing elution buffer (see Fig. 16, lanes 2 and 3).

15 As judged by non-reducing SDS-PAGE analysis approximately 70 % of the soluble h $\beta_2$ m fusion protein material (corresponding to 40 mg of h $\beta_2$ m fusion protein) appeared monomeric (see Fig. 15, lanes 5 and 3) whereas 25 % of the m $\beta_2$ m fusion protein appeared monomeric (corresponding to 20 mg of m $\beta_2$ m fusion protein). The overall efficiency of the folding procedure are 20 therefore approximately 50 % for the h $\beta_2$ m fusion protein and less than 20% for the m $\beta_2$ m fusion protein.

Monomeric h $\beta_2$ m and m $\beta_2$ m fusion proteins were purified from dimer and higher order multimers by ion exchange chromatography on S-Sepharose (Pharmacia, Sweden): The fusion proteins 25 eluted by the non denaturing elution buffer (approximately 70 % of the fusion protein material) was gelfiltrated into a buffer containing 5 mM NaCl and 5 mM Tris-HCl pH 8 on Sephadex G-25 and diluted 1:1 with water before applied onto the S-Sepharose ion exchange columns. Fusion proteins were eluted over 5 column volumes with a liner gradient from 2.5 mM NaCl, 30 2.5 mM Tris-HCl pH 8 to 100 mM NaCl, 25 mM Tris-HCl pH 8. The monomeric h $\beta_2$ m as well as m $\beta_2$ m fusion proteins eluted in the very beginning of the gradient, whereas dimers and higher order multimers eluted later. Fractions containing the

monomeric fusion proteins were diluted with water and reloaded to the S-Sepharose columns and one-step eluted in 1 M NaCl, 50 mM Tris-HCl pH 8.

5 The monomeric fusion proteins were cleaved with the restriction protease FX<sub>a</sub> overnight at room temperature in a weight to weight ratio of approximately 200 to one.

After cleavage the recombinant h $\beta_2$ m and m $\beta_2$ m proteins were purified from the N-terminal fusion tail, liberated from the cleaved fusion protein and FX<sub>a</sub> by ion exchange chromatography 10 on Q-Sepharose columns (Pharmacia, Sweden): Upon gelfiltration on Sephadex G-25 into 5 mM NaCl, 5 mM Tris-HCl pH 8 and 1:1 dilution with water, recombinant h $\beta_2$ m and m $\beta_2$ m were eluted in a linear gradient (over 5 column volumes) from 2.5 mM NaCl, 2.5 mM Tris-HCl pH 8 to 100 mM NaCl, 25 mM Tris-HCl 15 pH 8. Fractions containing the cleaved recombinant proteins were diluted with water and reloaded to the Q-Sepharose columns and one-step eluted in 1 M NaCl, 50 mM Tris-HCl pH 8. Recombinant h $\beta_2$ m and m $\beta_2$ m proteins were gelfiltrated into freshly prepared 20 mM NH<sub>4</sub>HCO<sub>3</sub> and lyophilized twice.

20 SDS-PAGE analysis of the production of recombinant human  $\beta_2$ -microglobulin is presented in fig. 15.

The yield of fully processed recombinant human  $\beta_2$ -microglobulin produced by this procedure was 30 mg.

25 The yield of fully processed recombinant murine  $\beta_2$ -microglobulin produced by this procedure was 10 mg.

Comparison of recombinant human with purified natural human  $\beta_2$ -microglobulin  $\beta_2$ -microglobulin was kindly carried out by Dr. Søren Buus in two different assays:

30 1. It was found that Recombinant human  $\beta_2$ -microglobulin and natural human  $\beta_2$ -microglobulin reacted with both a monoclonal- and a monospecific antibody with identical affinity.

2. Recombinant human  $\beta_2$ -microglobulin and natural human  $\beta_2$ -microglobulin were in an binding inhibition experiment using radiolabelled ligands found to bind natural affinity purified heavy chain class I K<sup>d</sup> molecules with an identical affinity.
- 5 Recombinant murine  $\beta_2$ -microglobulin was found to bind natural class I heavy chain molecules with an affinity 5 times lower than the human  $\beta_2$ -microglobulin. This result is in good agreement with previous results from the literature using natural material.

10 EXAMPLE 2

*Production and folding of Human Growth Hormone (Somatotropin)*

This example describes the production in *E. coli* of human growth hormone (hGH) as a FX<sub>a</sub> cleavable fusion protein, and the purification of the recombinant hGH after FX<sub>a</sub> cleavage.

- 15 A plasmid clone containing the cDNA encoding the hGH (generously provided by Dr. Henrik Dalbøge (Dalbøge et al., 1987) were used as template in a Polymerase Chain Reaction (PCR) (Saiki et al., 1988), using the primers SEQ ID NO: 7 and SEQ ID NO: 8, designed to produce a cDNA fragment corresponding
- 20 to the mature hGH (corresponding to amino acid residue Phe<sub>1</sub> to Phe<sub>191</sub>) protein. The amplified coding reading frame was at the 5'-end, via the PCR-reaction, linked to a nucleotide sequence, included in SEQ ID NO: 7, encoding the amino acid sequence SEQ ID NO: 37 which constitute a cleavage site for
- 25 the bovine restriction protease FX<sub>a</sub> (Nagai and Thøgersen, 1987). The amplified DNA fragment was subcloned into the *E. coli* expression vector pT<sub>7</sub>H<sub>6</sub> (Christensen et al., 1991). The construction of the resulting plasmid pT<sub>7</sub>H<sub>6</sub>FX-hGH (expressing human Growth Hormone) is outlined in fig. 4 and in fig. 5 is
- 30 shown the amino acid sequence of the expressed protein (in SEQ ID NO: 51 is shown the amino acid sequence encoded by the full length reading frame).

Recombinant human Growth Hormone was produced by growing and expressing the plasmid pT<sub>7</sub>H<sub>6</sub>FX-hGH in *E. coli* BL21 cells in a medium scale (2 x 1 litre) as described by Studier and Mof-  
fat, *J. Mol. Biol.*, 189: 113-130, 1986. Exponentially growing  
5 cultures at 37°C were at OD<sub>600</sub> 0.8 infected with bacteriophage λCE6 at a multiplicity of approximately 5. Cultures were grown at 37°C for another three hours before cells were harvested by centrifugation. Cells were lysed by osmotic shock and sonification and total cellular protein  
10 extracted into phenol (adjusted to pH 8 with Trisma base). Protein was precipitated from the phenol phase by addition of 2.5 volumes of ethanol and centrifugation. The protein pellet was dissolved in a buffer containing 6 M guanidinium chlo-  
ride, 50 mM Tris-HCl pH 8 and 50 mM dithioerythriol. Follow-  
15 ing gel filtration on Sephadex G-25 (Pharmacia, LKB, Sweden) into 8 M Urea, 1 M NaCl, 50 mM Tris-HCl pH 8, 5 mM 2-mercaptop-  
toethanol and 1 mM methionine the crude protein preparation was applied to a Ni<sup>2+</sup> activated NTA-agarose column (Ni<sup>2+</sup>NTA-  
agarose) for purification (Hochuli et al., 1988) of the  
20 fusion protein, MGSHHHHHGSIEGR-hGH (wherein MGSHHHHHGSIEGR is SEQ ID NO: 48) and subsequently to undergo the cyclic folding procedure.

Preparation and "charging" of the Ni<sup>2+</sup>NTA-agarose column is described under Example 1.

25 All buffers prepared for liquid chromatography were degassed under vacuum prior to addition of reductant and/or use.

Upon application of the crude protein extract on the Ni<sup>2+</sup>NTA-  
agarose column, the fusion protein, MGSHHHHHGSIEGR-hGH (wherein MGSHHHHHGSIEGR is SEQ ID NO: 48) was purified from  
30 the majority of coli and λ phage proteins by washing with one column volume of the loading buffer followed by 6 M guanidinium chloride, 50 mM Tris-HCl, 5 mM 2-mercaptopethanol, and 1 mM methionine until the optical density (OD) at 280 nm of the eluate was stable.

The fusion protein was refolded on the  $\text{Ni}^{2+}$ NTA-agarose column using a gradient manager profile as described in table 2 and 0.5 M NaCl, 50 mM Tris-HCl pH 8, and 1.0 mM/0.1 mM reduced/oxidized glutathione as buffer A and 8 M urea, 0.5 M 5 NaCl, 50 mM Tris-HCl pH 8, 1 mM methionine, and 5 mM reduced glutathione as buffer B. The reduced/oxidized glutathione solution was freshly prepared as a 200 times stock solution by addition of 9.9 M  $\text{H}_2\text{O}_2$  to a stirred solution of 0.2 M reduced glutathione before addition to buffer A.

10 After completion of the cyclic folding procedure the hGH fusion protein was eluted from the  $\text{Ni}^{2+}$ NTA-agarose column with a buffer containing 0.5 M NaCl, 50 mM Tris-HCl, 20 mM EDTA pH 8. Fusion protein that were aggregated and precipitated on the  $\text{Ni}^{2+}$ NTA-agarose column was eluted in buffer B.

15 Approximately 80% of the fusion protein material was eluted by the non denaturing elution buffer (see Fig. 16, lanes 2 and 3). As judged by non-reducing SDS-PAGE analysis 90 % of the soluble fusion protein material (corresponding to approximately 70 mg of fusion protein) appeared monomeric (see Fig. 20, lane 2) yielding an overall efficiency of the folding procedure of approximately 70 %.

Monomeric hGH fusion protein was purified from dimer and higher order multimers by ion exchange chromatography on Q-Sepharose (Pharmacia, Sweden): After gelfiltration into a 25 buffer containing 25 mM NaCl and 25 mM Tris-HCl pH 8 on Sephadex G-25 the fusion protein material, eluted by the non-denaturing buffer, was applied onto a Q-Sepharose ion exchange column. Fusion protein were eluted over 5 column volumes with a linear gradient from 25 mM NaCl, 25 mM Tris- 30 HCl pH 8 to 200 mM NaCl, 50 mM Tris-HCl pH 8. The monomeric hGH fusion protein eluted in the beginning of the gradient, whereas dimers and higher order multimers eluted later. Fractions containing the pure monomeric fusion protein was added  $\text{NiSO}_4$  and iminodiacetic acid (IDA, adjusted pH 8 with 35 NaOH) to 1 mM and cleaved with the restriction protease FX<sub>a</sub>

for 5 hours at 37°C in a weight to weight ratio of approximately 100 to one. FX<sub>a</sub> is inhibited after cleavage by addition of Benzamidine hydrochloride to 1 mM.

After cleavage the recombinant hGH protein was isolated from 5 uncleaved fusion protein and the liberated fusion tail, upon gelfiltration on Sephadex G-25 into 8 M Urea, 50 mM Tris-HCl pH 8, to remove Ni<sup>2+</sup>IDA and Benzamidine, by passage through a small Ni<sup>2+</sup>NTA-agarose column followed inline by a small Nd<sup>3+</sup>NTA agarose column and subsequently a non Ni<sup>2+</sup>activated 10 NTA-agarose column to ensure complete removal of FX<sub>a</sub> and of Ni<sup>2+</sup> and Nd<sup>3+</sup>, respectively. Recombinant hGH was purified from a minor fraction of recombinant breakdown product by ion exchange chromatography on Q-Sepharose: hGH was eluted in a linear gradient (over 5 column volumes) from 8 M Urea, 50 mM 15 Tris-HCl pH 8 to 8 M Urea, 250 mM NaCl, 25 mM Tris-HCl pH 8. Fractions containing the cleaved purified recombinant protein was gelfiltrated into freshly prepared 20 mM NH<sub>4</sub>HCO<sub>3</sub> and lyophilized twice.

SDS-PAGE analysis of the production and folding of recombinant human growth hormone is presented in fig. 16.

The yield of fully processed recombinant human growth hormone produced by this procedure was 10 mg.

The recombinant human growth hormone produced by this procedure co-migrated both in reducing and non-reducing SDS-PAGE 25 and in non-denaturing PAGE analysis with biologically active recombinant human growth hormone generously provided by Novo-Nordisk A/S.

#### EXAMPLE 3

##### *Production and folding of human $\alpha_2$ MRAP*

30 The plasmid used for expression in *E. coli* BL21 cells of the human  $\alpha_2$ -Macroglobulin Receptor Associated Protein ( $\alpha_2$ MRAP),

pT7H6FX- $\alpha_2$ MRAP and the conditions used for production of the fusion protein has previously been described by us in, Nykjaer et al., J. Biol. Chem. 267: 14543-14546, 1992. The primers SEQ ID NO: 9 and SEQ ID NO: 10 were used in the PCR employed 5 for multiplying the  $\alpha_2$ MRAP encoding DNA.

Crude protein extract precipitated from the phenol phase of the protein extraction of cells from 2 litres of culture of MGSHHHHHHGSIEGR- $\alpha_2$ MRAP (wherein MGSHHHHHHGSIEGR is SEQ ID NO: 48) expressing *E. coli* BL21 cells was dissolved in a buffer 10 containing 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 50 mM dithioerythriol. Following gel filtration on Sephadex G-25 (Pharmacia, Sweden) into 8 M Urea, 0.5 M NaCl, 50 mM Tris-HCl pH 8, and 1 mM methionine the crude protein preparation was applied to a Ni<sup>2+</sup>activated NTA-agarose matrix 15 (Ni<sup>2+</sup>NTA-agarose) for purification (Hochuli et al., 1988) of the fusion protein, MGSHHHHHHGSIEGR- $\alpha_2$ MRAP (wherein MGSHHHHHHGSIEGR is SEQ ID NO: 48) and subsequently to undergo the cyclic folding process.

All buffers prepared for liquid chromatography were degassed 20 under vacuum prior to addition of reductant and/or use.

Preparation and "charging" of the Ni<sup>2+</sup>NTA-agarose column is described under Example 1.

Upon application of the crude protein extract on the Ni<sup>2+</sup>NTA-agarose column, the fusion protein, MGSHHHHHHGSIEGR- $\alpha_2$ MRAP 25 (wherein MGSHHHHHHGSIEGR is SEQ ID NO: 48) was purified from the majority of coli and  $\lambda$  phage proteins by washing with one column volume of the loading buffer followed by 6 M guanidinium chloride, 50 mM Tris-HCl, and 1 mM methionine until the optical density (OD) at 280 nm of the eluate was stable.

30 The fusion protein was refolded on the Ni<sup>2+</sup>NTA-agarose column using a gradient manager profile as described in table 3 and 0.5 M NaCl, 50 mM Tris-HCl pH 8, 2 mM CaCl<sub>2</sub> and 1 mM 2-mercaptoethanol as buffer A and 6 M guanidinium chloride, 50 mM

Tris-HCl pH 8, 2 mM CaCl<sub>2</sub> and 1 mM 2-mercaptoethanol as buffer B.

After completion of the cyclic folding procedure the  $\alpha_2$ MRAP fusion protein was eluted from the Ni<sup>2+</sup>NTA-agarose column 5 with a buffer containing 0.5 M NaCl, 50 mM Tris-HCl, 20 mM EDTA pH 8.

Virtually no fusion protein was found to be aggregated or precipitated on the Ni<sup>2+</sup>NTA-agarose column. The estimated yield of  $\alpha_2$ MRAP fusion protein was 60 mg and the efficiency 10 of the folding procedure close to 95%.

The fusion protein MGSHHHHHHGSIEGR- $\alpha_2$ MRAP (wherein MGSHHHHHHGSIEGR is SEQ ID NO: 48) was cleaved with the bovine restriction protease FX<sub>a</sub> overnight at room temperature in a weight to weight ratio of 200:1 in the elution buffer. Upon 15 gelfiltration on Sephadex G-25 into 100 mM NaCl, 25 mM Tris-HCl pH 8, the protein solution was passed through a Ni<sup>2+</sup>NTA-agarose column thereby removing uncleaved fusion protein and the liberated fusion N-terminal tail originating from cleaved fusion proteins. Finally the protein solution was diluted 1:4 20 with water and the  $\alpha_2$ MRAP protein purified from FX<sub>a</sub> by ion exchange chromatography on Q-Sepharose (Pharmacia, Sweden). The Q-Sepharose column was eluted with a linear gradient over 6 column volumes from 25 mM NaCl, 25 mM Tris-HCl pH 8 to 250 mM NaCl, 25 mM Tris-HCl pH 8. The  $\alpha_2$ MRAP protein eluted in 25 the very beginning of the linear gradient whereas FX<sub>a</sub> eluted later.

The yield of  $\alpha_2$ MRAP protein produced and refolded by this procedure was 40 mg.

The ligand binding characteristics (i.e. binding to the  $\alpha_2$ - 30 Macroglobulin Receptor and interference with the binding of human Urokinase Plasminogen Activator - Plasminogen Activator Inhibitor type-I complex to the  $\alpha_2$ -M Receptor) has, according

to Dr. Nykjær, been found identical to the ligand binding characteristics of the purified natural protein.

#### EXAMPLE 4

##### *Production and folding of domains and domain-clusters from the $\alpha_2$ -M Receptor*

The human  $\alpha_2$ -Macroglobulin Receptor/Low Density Lipoprotein Receptor-Related Protein ( $\alpha_2$ MR) is a 600 kDa endocytotic membrane receptor.  $\alpha_2$ -MR is synthesized as a 4524 amino acid single chain precursor protein. The precursor is processed into a 85 kDa transmembrane  $\beta$ -chain and a 500 kDa  $\alpha$ -chain, non-covalently bound to the extracellular domain of the  $\beta$ -chain. The  $\alpha_2$ -MR is known to bind  $\text{Ca}^{2+}$  in a structure dependent manner (i.e. the reduced protein does not bind  $\text{Ca}^{2+}$ ) and is believed to be multifunctional in the sense that  $\alpha_2$ -MR binds ligands of different classes.

The entire amino acid sequence of the  $\alpha$ -chain can be represented by clusters of three types of repeats also found in other membrane bound receptors and in various plasma proteins:

- 20 A: This type of repeat span approximately 40 amino acid residues and is characterised by the sequential appearance of the six cysteinyl residues contained in the repeat. Some authors has named this repeat complement-type domain.
- 25 B: This type of repeat also span approximately 40 amino acid residues and is characterised by the sequential appearance of the six cysteinyl residues contained in the repeat. In the literature this repeat has been named EGF-type domains.
- 30 C: This type of repeat span approximately 55 amino acid residues and is characterised by the presence of the consensus sequence SEQ ID NO: 39.

This example describes the production in *E. coli* of a number of domains and domain-clusters derived from the  $\alpha_2$ -MR protein as FX<sub>a</sub> cleavable fusion proteins and the purification, *in vitro* folding, and the FX<sub>a</sub> cleavage and processing of these 5 recombinant proteins.

A plasmid clone containing the full length cDNA encoding the human  $\alpha_2$ -MR protein (generously provided by Dr. Joachim Herz; Herz et al., EMBO J., 7: 4119-4127, 1988) were used as template in a series of Polymerase Chain Reactions (PCR) 10 designed to produce cDNA fragments corresponding to a number of polypeptides representing domains and domain-clusters derived from the  $\alpha_2$ -MR protein:

#1: Contains two domains of the A-type, corresponding to amino acid residue 20 to 109 in the  $\alpha_2$ -MR protein. The 15 primers SEQ ID NO: 11 and SEQ ID NO: 12 were used in the PCR.

#2: Contains two domains of the A-type followed by two type-B domains, corresponding to amino acid residue 20 to 190 in the  $\alpha_2$ -MR protein. The primers SEQ ID NO: 11 and SEQ ID NO: 13 were used in the PCR.

20 #3: Identical to #2 followed by a region containing YWTD repeats, corresponding to amino acid residue 20 to 521. The primers SEQ ID NO: 11 and SEQ ID NO: 14 were used in the PCR.

#4: Contains one type-B domain, followed by 8 type-A domains and finally two type-B domains, corresponding to amino acid 25 residue 803 to 1265 in the  $\alpha_2$ -MR protein. The primers SEQ ID NO: 15 and SEQ ID NO: 16 were used in the PCR.

#5: Contains only the 8 type-A domains also present in #4, corresponding to amino acid residue 849 to 1184 in the  $\alpha_2$ -MR protein. The primers SEQ ID NO: 17 and SEQ ID NO: 18 were 30 used in the PCR.

#6: Contains the two C-terminal type-B domains from #4, followed by 8 YWTD repeats and one type-B domain, corresponding to amino acid residue 1184 to 1582 in the  $\alpha_2$ -MR protein. The primers SEQ ID NO: 19 and SEQ ID NO: 20 were used in the  
5 PCR.

#7: Contains the whole region included in constructs #4 to #6, corresponding to amino acid residue 803 to 1582 in the  $\alpha_2$ -MR protein. The primers SEQ ID NO: 15 and SEQ ID NO: 20 were used in the PCR.

10 #8: Contains 10 type-A domains, corresponding to amino acid residue 2520 to 2941 in the  $\alpha_2$ -MR protein. The primers SEQ ID NO: 21 and SEQ ID NO: 22 were used in the PCR.

15 #9: Contains 11 type-A domains, corresponding to amino acid residue 3331 to 3778 in the  $\alpha_2$ -MR protein. The primers SEQ ID NO: 23 and SEQ ID NO: 24 were used in the PCR.

The amplified nucleotide sequences encoding the domains and domain-clusters were at their 5'-end, via the PCR-reaction, linked to nucleotide sequences (included in SEQ ID NO: 11, 15, 17, 19, 21 and 23) encoding the amino acid sequence SEQ  
20 ID NO: 37 which constitute a cleavage site for the bovine restriction protease FX<sub>a</sub> (Nagai and Thøgersen, Methods in Enzymology, 152: 461-481, 1987). The amplified DNA fragments were either subcloned into the *E. coli* expression vector pT<sub>7</sub>H<sub>6</sub> (Christensen et al., FEBS Letters. 295: 181-184, 1991)  
25 or the expression plasmid pLcIIMLCH<sub>6</sub>, which is modified from pLcIIMLC (Nagai et al., Nature, 332: 284-286, 1988) by the insertion of an oligonucleotide encoding six histidinyl residues C-terminal of the myosin light chain fragment. The construction of the resulting plasmids pT<sub>7</sub>H<sub>6</sub>FX-#1 to #3 and  
30 pLcIIMLCH<sub>6</sub>FX-#4 to #9 is outlined in fig. 6-8 and in figure 9 is shown the amino acid sequence of the expressed protein (in SEQ ID NO: 52 is shown the amino acid sequence encoded by the full length reading frame).

The domains and domain-clusters subcloned in the pT<sub>7</sub>H<sub>6</sub>FX series were grown and expressed in *E. coli* BL21 cells in a medium scale (2 litre) as described by Studier, and Moffat, J. Mol. Biol., 189: 113-130, 1986. Exponentially growing cultures at 37°C were at OD<sub>600</sub> 0.8 infected with bacteriophage λCE6 at a multiplicity of approximately 5. Cultures were grown at 37°C for another three hours before cells were harvested by centrifugation. Cells were lysed by osmotic shock and sonification and total cellular protein extracted 10 into phenol (adjusted to pH 8 with Trisma base).

The domain-clusters subcloned in the pLcIIMLCH<sub>6</sub> series were grown and expressed in *E. coli* QY13 cells as described in Nagai and Thøgersen. Methods in Enzymology, 152: 461-481, 1987. Exponentially growing cultures (4 litre) at 30°C were 15 at OD<sub>600</sub> 1.0 transferred to 42°C for 15 min. This heat shock induces synthesis of the fusion proteins. The cultures are further incubated at 37°C for three to four hours before cells are harvested by centrifugation. Cells were lysed by osmotic shock and sonification and total cellular protein 20 extracted into phenol (adjusted to pH 8 with Trisma base).

Crude protein was precipitated from the phenol phase by addition of 2.5 volumes of ethanol and centrifugation. The protein pellet was dissolved in a buffer containing 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 0.1 M dithio-25 erythriol. Following gel filtration on Sephadex G-25 (Pharmacia, Sweden) into 8 M Urea, 1 M NaCl, 50 mM Tris-HCl pH 8, 10 mM 2-mercaptoethanol and 2 mM methionine the crude protein preparations were applied to a Ni<sup>2+</sup> activated NTA-agarose columns for purification (Hochuli et al., 1988) of the fusion 30 proteins and subsequently to undergo the cyclic folding procedure.

All buffers prepared for liquid chromatography were degassed under vacuum prior to addition of reductant and/or use.

Preparation and "charging" of the  $\text{Ni}^{2+}$ NTA-agarose column is described under Example 1.

Upon application of the crude protein extracts on the  $\text{Ni}^{2+}$ NTA-agarose column, the fusion proteins were purified

5 from the majority of coli and  $\lambda$  phage proteins by washing with one column volume of the loading buffer followed by 6 M guanidinium chloride, 50 mM Tris-HCl, 10 mM 2-mercaptoethanol, and 2 mM methionine until the optical density (OD) at 280 nm of the eluate was stable.

10 Each of the fusion proteins were refolded on the  $\text{Ni}^{2+}$ NTA-agarose column using a gradient manager profile as described in table 4 and 0.5 M NaCl, 50 mM Tris-HCl pH 8, 2 mM  $\text{CaCl}_2$ , 0.33 mM methionine, and 2.0 mM/0.2 mM reduced/oxidized glutathione as buffer A and 4 M urea, 0.5 M NaCl, 50 mM Tris-HCl

15 pH 8, 2 mM  $\text{CaCl}_2$ , 2 mM methionine, and 3 mM reduced glutathione as buffer B. The reduced/oxidized glutathione solution was freshly prepared as a 100 times stock solution by addition of 9.9 M  $\text{H}_2\text{O}_2$  to a stirred solution of 0.2 M reduced glutathione before addition to buffer A.

20 After completion of the cyclic folding procedure the fusion proteins representing domains and domain-clusters derived from the  $\alpha_2$ -MR protein were eluted from the  $\text{Ni}^{2+}$ NTA-agarose column with a buffer containing 0.5 M NaCl, 50 mM Tris-HCl, 5 mM EDTA pH 8. Fusion proteins that were aggregated and pre-

25 cipitated on the  $\text{Ni}^{2+}$ NTA-agarose column were eluted in buffer B.

Approximately 75% of the fusion protein material expressed from the plasmids pT<sub>7</sub>H<sub>6</sub>FX-#1 and #2, representing the N-terminal two and four cysteine-rich domains of the  $\alpha_2$ -MR

30 protein were eluted from the  $\text{Ni}^{2+}$ NTA-agarose column by the non denaturing buffer. The majority of this fusion protein material appeared as monomeric as judged by non reducing SDS-PAGE analysis. The yield of monomeric fusion protein #1 and #2 were estimated to approximately 50 mg.

Approximately 50% of the fusion protein material expressed from all other expression plasmids representing domain-clusters derived from the  $\alpha_2$ -MR protein were eluted from the Ni<sup>2+</sup>NTA-agarose column by the non denaturing buffer. Between 5 30% (fusion proteins #5 and #7) and 65% (fusion protein #4) of these fusion proteins appeared as monomeric as judged by non reducing SDS-PAGE analysis (see Fig. 17, lanes 9 and 10).

Each fusion protein eluted by the non denaturing elution buffer was cleaved with the restriction protease FX<sub>a</sub> over-10 night at room temperature in an estimated weight to weight ratio of 100 to one.

Upon gelfiltration on Sephadex G-25 into 100 mM NaCl, 25 mM Tris-HCl pH 8, the protein solution was passed through a Ni<sup>2+</sup>NTA-agarose column thereby removing uncleaved fusion 15 protein and the liberated N-terminal fusion tail originating from the cleaved fusion proteins. FX<sub>a</sub> was removed from the solution by passing the recombinant protein solutions through a small column of SBTI-agarose (Soy Bean Trypsin Inhibitor immobilized on Sepharose CL-6B (Pharmacia, Sweden)).

20 SDS-PAGE analysis of the refolded, soluble fusion protein product #4 is presented in fig. 17, lanes 9 and 10, showing reduced and unreduced samples, respectively. The mobility increase observed for the unreduced sample reflects the compactness of the polypeptide due to the presence of 33 25 disulphide bridges.

Each of the recombinant proteins were found to bind Ca<sup>2+</sup> in a structure dependent manner.

It was found by Dr. Søren Moestrup that a monoclonal antibody, A2MR $\alpha$ -5 derived from the natural human  $\alpha_2$ -MR, bound the 30 recombinant proteins expressed by the constructs #4, #6, and #7 whereas a monospecific antibody, A2MR $\alpha$ -3 derived also from natural  $\alpha_2$ -MR, was found to bind the recombinant protein

expressed by construct #8. The binding specificity of both antibodies is structure dependent (i.e. the antibodies do neither react with reduced  $\alpha_2$ -MR nor with reduced recombinant protein)

## 5 EXAMPLE 5

### *Production and folding of bovine coagulation Factor X<sub>a</sub> (FX<sub>a</sub>)*

This example describes the production in *E. coli* of one fragment derived from bovine FX<sub>a</sub> as a FX<sub>a</sub> cleavable fusion protein and the purification, *in vitro* folding, and the 10 processing of the recombinant protein.

The cDNA encoding bovine FX was cloned by specific amplification in a Polymerase Chain Reaction (PCR) of the nucleotide sequences encoding bovine FX from amino acid residue Ser<sub>82</sub> to Trp<sub>484</sub> (SEQ ID NO: 2, residues 82-484) (FX $\Delta$  $\gamma$ , amino acid 15 numbering relates to the full coding reading frame) using 1<sup>st</sup> strand oligo-dT primed cDNA synthesized from total bovine liver RNA as template. Primers used in the PCR were SEQ ID NO: 25 and SEQ ID NO: 26. RNA extraction and cDNA synthesis were performed using standard procedures.

20 The amplified reading frame encoding FX $\Delta$  $\gamma$  was at the 5'-end, via the PCR-reaction, linked to nucleotide sequences encoding the amino acid sequence SEQ ID NO: 37 which constitute a cleavage site for the bovine restriction protease FX<sub>a</sub> (Nagai, and Thøgersen. Methods in Enzymology, 152: 461-481, 1987).

25 The amplified DNA fragments was cloned into the *E. coli* expression vector pLcIIMLCH<sub>6</sub>, which is modified from pLcIIMLC (Nagai et al., Nature, 332: 284-286, 1988) by the insertion of an oligonucleotide encoding six histidinyl residues C-terminal of the myosin light chain fragment. The construction of 30 the resulting plasmid pLcIIMLCH<sub>6</sub>FX-FX $\Delta$  $\gamma$  is outlined in fig. 10 and in figure 11 is shown the amino acid sequence of the

expressed protein (in SEQ ID NO: 53 is shown the amino acid sequence encoded by the full length reading frame).

The pLcIIIMLCH<sub>6</sub>-FXΔγ plasmid was grown and expressed in *E. coli* QY13 cells as described in Nagai and Thøgersen (Methods 5 in Enzymology, 152: 461-481, 1987). Exponentially growing cultures at 30°C were at OD<sub>600</sub> 1.0 incubated at 42°C for 15 min. This heat shock induces synthesis of the fusion proteins. The cultures are further incubated at 37°C for three to four hours before cells are harvested by centrifugation. 10 Cells were lysed by osmotic shock and sonification and total cellular protein extracted into phenol (adjusted to pH 8 with Trisma base).

Crude protein was precipitated from the phenol phase by addition of 2.5 volumes of ethanol and centrifugation. The 15 protein pellet was dissolved in a buffer containing 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 0.1 M dithio-erythriol. Following gel filtration on Sephadex G-25 (Pharmacia, LKB, Sweden) into 8 M Urea, 1 M NaCl, 50 mM Tris-HCl pH 8, 10 mM 2-mercaptoethanol the crude protein preparation 20 was applied to a Ni<sup>2+</sup> activated NTA-agarose matrix for purification (Hochuli et al., 1988.) of the FXΔγ fusion protein and subsequently to undergo the cyclic folding procedure.

All buffers prepared for liquid chromatography were degassed under vacuum prior to addition of reductant and/or use.

25 Preparation and "charging" of the Ni<sup>2+</sup>NTA-agarose column is described under Example 1.

Upon application of the crude protein extracts on the Ni<sup>2+</sup>NTA-agarose column, the fusion proteins were purified from the majority of coli and λ phage proteins by washing 30 with one column volume of the loading buffer followed by 6 M guanidinium chloride, 50 mM Tris-HCl, and 10 mM 2-mercaptoethanol until the optical density (OD) at 280 nm of the eluate was stable.

The fusion protein was refolded on the  $\text{Ni}^{2+}$ NTA-agarose column using a gradient manager profile as described in table 5 and 0.5 M NaCl, 50 mM Tris-HCl pH 8, 2 mM  $\text{CaCl}_2$ , and 2.0 mM/0.2 mM reduced/oxidized glutathione as buffer A and 8 M urea, 0.5 M NaCl, 50 mM Tris-HCl pH 8, 2 mM  $\text{CaCl}_2$ , and 3 mM reduced glutathione as buffer B. The reduced/oxidized glutathione solution was freshly prepared as a 100 times stock solution by addition of 9.9 M  $\text{H}_2\text{O}_2$  to a stirred solution of 0.2 M reduced glutathione before addition to buffer A.

5 10 After completion of the cyclic folding procedure the  $\text{FX}\Delta\gamma$  fusion protein was eluted from the  $\text{Ni}^{2+}$ NTA-agarose column with a buffer containing 0.5 M NaCl, 50 mM Tris-HCl, 5 mM EDTA pH 8. Fusion protein that was aggregated and precipitated on the  $\text{Ni}^{2+}$ NTA-agarose column was eluted in buffer B.

15 20 Approximately 33% of the  $\text{FX}\Delta\gamma$  fusion protein material was eluted from the  $\text{Ni}^{2+}$ NTA-agarose column by the non denaturing buffer. The amount of  $\text{FX}\Delta\gamma$  fusion protein was estimated to 15 mg. Only about one third of this fusion protein material appeared as monomeric as judged by non reducing SDS-PAGE analysis corresponding to an overall efficiency of the folding procedure of approximately 10%.

$\text{FX}\Delta\gamma$  fusion protein in non denaturing buffer was activated by passing the recombinant protein solution through a small column of trypsin-agarose (trypsin immobilized on Sepharose 25 CL-6B (Pharmacia, Sweden)).

The activated recombinant  $\text{FX}\Delta\gamma$  fusion protein was assayed for proteolytic activity and substrate specificity profile using standard procedures with chromogenic substrates. The activity and substrate specificity profile was indistinguishable from 30 that obtained for natural bovine  $\text{FX}_a$

## EXAMPLE 6

*Production and folding of kringle domains 1 and 4 from human plasminogen*

This example describes the production in *E. coli* of the 5 lysine binding kringle domains 1 and 4 from human plasminogen (K1 and K4, respectively) as FX<sub>a</sub> cleavable fusion proteins and the purification and *in vitro* folding of the K1- and K4-fusion proteins.

A plasmid clone containing the full length cDNA encoding 10 human plasminogen cloned into the general cloning vector pUC18 (generously provided by Dr. Earl Davie, Seattle, USA) were used as template in a Polymerase Chain Reaction (PCR) designed to produce cDNA fragments corresponding to K1 (corresponding to amino acid residue Ser<sub>81</sub> to Glu<sub>162</sub> in so-called 15 Glu-plasminogen) and K4 (corresponding to amino acid residue Val<sub>354</sub> to Ala<sub>439</sub> in so-called Glu-plasminogen). The primers SEQ ID NO: 27 and SEQ ID NO: 28 were used in the PCR producing K1 and the primers SEQ ID NO: 29 and SEQ ID NO: 30 were used in the PCR producing K4.

20 The amplified reading frames encoding K1 and K4 were at their 5'-ends, via the PCR-reaction, linked to nucleotide sequences, included in SEQ ID NO: 27 and SEQ ID NO: 29, encoding the amino acid sequence SEQ ID NO: 37 which constitute a cleavage site for the bovine restriction protease 25 FX<sub>a</sub> (Nagai and Thøgersen. *Methods in Enzymology*, 152: 461-481, 1987). The amplified K1 DNA fragment was cloned into the *E. coli* expression vector pLcIIMLCH<sub>6</sub>, which is modified from pLcIIMLC (Nagai et al., *Nature*, 332: 284-286, 1988) by the insertion of an oligonucleotide encoding six histidinyl 30 residues C-terminal of the myosin light chain fragment. The construction of the resulting plasmid pLcIIMLCH<sub>6</sub>FX-K1 is outlined in fig. 12. The amplified K4 DNA fragment was cloned into the *E. coli* expression vector pLcIIH<sub>6</sub>, which is modified from pLcII (Nagai and Thøgersen. *Methods in Enzymology*, 152:

461-481, 1987) by the insertion of an oligonucleotide encoding six histidinyl residues C-terminal of the cII fragment. The construction of the resulting plasmid pLcIIH<sub>6</sub>FX-K4 is outlined in fig. 13 and in fig. 14 is shown the amino acid 5 sequence of human "Glu"-plasminogen (SEQ ID NO: 54).

Both the pLcIIIMLCH<sub>6</sub>-K1 plasmid and the pLcIIH<sub>6</sub>FX-K4 plasmid were grown and expressed in *E. coli* QY13 cells as described in Nagai and Thøgersen. Methods in Enzymology, 152: 461-481, 1987. Exponentially growing cultures at 30°C were at OD<sub>600</sub> 10 1.0 transferred to 42°C for 15 min. This heat shock induces synthesis of the fusion proteins. The cultures are further incubated at 37°C for three to four hours before cells are harvested by centrifugation. Cells were lysed by osmotic shock and sonification and total cellular protein extracted 15 into phenol (adjusted to pH 8 with Trisma base).

Crude protein was precipitated from the phenol phase by addition of 2.5 volumes of ethanol and centrifugation. The protein pellet was dissolved in a buffer containing 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 0.1 M dithio-20 erythriol. Following gel filtration on Sephadex G-25 (Pharmacia, Sweden) into 8 M Urea, 1 M NaCl, 50 mM Tris-HCl pH 8, 10 mM 2-mercaptoethanol, and 2 mM methionine the crude protein preparation was applied to a Ni<sup>2+</sup> activated NTA-agarose 25 matrix for purification (Hochuli et al., 1988.) of the K1- and K4-fusion proteins and subsequently to undergo the cyclic folding procedure.

All buffers prepared for liquid chromatography were degassed under vacuum prior to addition of reductant and/or use.

Preparation and "charging" of the Ni<sup>2+</sup>NTA-agarose column is 30 described under Example 1.

Upon application of the crude protein extracts on the Ni<sup>2+</sup>NTA-agarose column, the fusion proteins were purified from the majority of coli and λ phage proteins by washing

with one column volume of the loading buffer followed by 6 M guanidinium chloride, 50 mM Tris-HCl, 10 mM 2-mercaptoethanol, and 2 mM methionine until the optical density (OD) at 280 nm of the column eluate was stable.

- 5 The fusion protein was refolded on the  $\text{Ni}^{2+}$ NTA-agarose column using a gradient manager profile as described in table 4 with 0.5 M NaCl, 50 mM Tris-HCl pH 8, 10 mM 6 aminohexanoic acid ( $\epsilon$ -aminocapronic acid,  $\epsilon$ -ACA), 0.33 mM methionine, and 2.0 mM/0.2 mM reduced/oxidized glutathione as buffer A and 4 M
- 10 Urea, 0.5 M NaCl, 50 mM Tris-HCl pH 8, 10 mM  $\epsilon$ -ACA, 2 mM methionine, and 3 mM reduced glutathione as buffer B. The reduced/oxidized glutathione solution was freshly prepared as a 100 times stock solution by addition of 9.9 M  $\text{H}_2\text{O}_2$  to a stirred solution of 0.2 M reduced glutathione before addition
- 15 to buffer A.

After completion of the cyclic folding procedure each of the K1- and K4 fusion proteins were eluted from the  $\text{Ni}^{2+}$ NTA-agarose column with a buffer containing 0.5 M NaCl, 50 mM Tris-HCl, 5 mM EDTA pH 8. Fusion proteins that were aggregated and precipitated on the  $\text{Ni}^{2+}$ NTA-agarose column was eluted in buffer B.

Virtually all of the K1- and K4-fusion protein material were eluted from the  $\text{Ni}^{2+}$ NTA-agarose columns by the non denaturing buffer. The estimated yield of K1-fusion protein and K4-fusion protein were approximately 60 mg. Virtually all of the K1-fusion protein as well as the K4-fusion protein appeared as monomeric as judged by non reducing SDS-PAGE analysis corresponding to an efficiency of the folding procedure above 90%.

- 25
- 30 SDS-PAGE analysis of the production of recombinant plasminogen kringle 1 and 4 is presented in fig. 17.

The K1-fusion protein and the K4-fusion protein were further purified by affinity chromatography on lysine-Sepharose CL-6B

(Pharmacia, Sweden). The fusion proteins were eluted from the affinity columns by a buffer containing 0.5 M NaCl, 50 mM Tris-HCl pH 8, 10 mM  $\epsilon$ -ACA.

5 Binding to lysine-Sepharose is normally accepted as indication of correct folding of lysine binding kringle domains.

The three dimensional structure of recombinant K1 and K4 protein domains, produced by this cyclic folding procedure and which have been fully processed by liberation from the N-terminal fusion tail and subsequently purified by ion 10 exchange chromatography, have been confirmed by X-ray diffraction (performed by Dr. Robert Huber) and two dimensional NMR analysis (performed by stud. scient. Peter Reinholdt and Dr. Flemming Poulsen).

15 The general yield of fully processed recombinant K1 and K4 protein domains by this procedure is 5 mg/litre culture.

#### EXAMPLE 7

##### *Production in E. coli and refolding of recombinant fragments derived from human $\alpha_2$ -Macroglobulin and chicken Ovostatin*

This example describes the production in *E. coli* of the 20 receptor-binding domain of human  $\alpha_2$ -Macroglobulin ( $\alpha_2$ -MRBDv) as a FX<sub>a</sub> cleavable fusion protein, and the purification of the recombinant  $\alpha_2$ -MRBDv after FX<sub>a</sub> cleavage.

The 462 bp DNA fragment encoding the  $\alpha_2$ -Macroglobulin reading frame from amino acid residue Val<sub>1299</sub> to Ala<sub>1451</sub> ( $\alpha_2$ -MRDv) was 25 amplified in a Polymerase Chain Reaction (PCR), essentially following the protocol of Saiki et al., (1988). pA2M (generously provided by Dr. T. Kristensen) containing the full length cDNA of human  $\alpha_2$ -Macroglobulin was used as template, and the oligonucleotides SEQ ID NO: 31 and SEQ ID NO: 32 as 30 primers. The amplified coding reading frame was at the

5'-end, via the PCR-reaction, linked to a nucleotide sequence, included in SEQ ID NO: 7, encoding the amino acid sequence SEQ ID NO: 37 which constitute a cleavage site for the bovine restriction protease FX<sub>a</sub> (Nagai and Thøgersen, 5 1987). The amplified DNA fragment was subcloned into the *E. coli* expression vector pT<sub>7</sub>H<sub>6</sub> (Christensen et al., 1991). The construction of the resulting plasmid pT<sub>7</sub>H<sub>6</sub>FX- $\alpha_2$ MRDv (expressing human  $\alpha_2$ -MRDv) is outlined in fig. 18 and the amino acid sequence of the expressed protein is shown in fig. 19 (SEQ ID 10 NO: 55).

Recombinant human  $\alpha_2$ MRDv was produced by growing and expressing the plasmid pT<sub>7</sub>H<sub>6</sub>FX- $\alpha_2$ MRDv in *E. coli* BL21 cells in a medium scale (2x1 litre) as described by Studier and Moffat, J. Mol. Biol., 189: 113-130, 1986. Exponentially growing 15 cultures at 37°C were at OD<sub>600</sub> 0.8 infected with bacteriophage  $\lambda$ CE6 at a multiplicity of approximately 5. Cultures were grown at 37°C for another three hours before cells were harvested by centrifugation. Cells were lysed by osmotic shock and sonification and total cellular protein 20 extracted into phenol (adjusted to pH 8 with Trisma base). Protein was precipitated from the phenol phase by addition of 2.5 volumes of ethanol and centrifugation. The protein pellet was dissolved in a buffer containing 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 50 mM dithioerythriol. Following 25 gel filtration on Sephadex G-25 (Pharmacia, LKB, Sweden) into 8 M Urea, 1 M NaCl, 50 mM Tris-HCl pH 8, and 10 mM 2-mercaptoethanol the crude protein preparation was applied to a Ni<sup>2+</sup> activated NTA-agarose column (Ni<sup>2+</sup>NTA- agarose) for purification (Hochuli et al., 1988) of the fusion protein, 30 MGSHHHHHHGSIEGR- $\alpha_2$ MRDv (wherein MGSHHHHHHGSIEGR is SEQ ID NO: 48) and subsequently to undergo the cyclic folding procedure.

Preparation and "charging" of the Ni<sup>2+</sup>NTA-agarose column is described under Example 1.

All buffers prepared for liquid chromatography were degassed 35 under vacuum prior to addition of reductant and/or use.

Upon application of the crude protein extract on the  $\text{Ni}^{2+}$ NTA-agarose column, the fusion protein, MGSHHHHHGSIEGR- $\alpha_2$ MRDv (wherein MGSHHHHHGSIEGR is SEQ ID NO: 48) was purified from the majority of coli and  $\lambda$  phage proteins by washing with one column volume of the loading buffer followed by 6 M guanidinium chloride, 50 mM Tris-HCl, and 10 mM 2-mercaptoethanol, until the optical density (OD) at 280 nm of the eluate was stable.

The fusion protein was refolded on the  $\text{Ni}^{2+}$ NTA-agarose column using a gradient manager profile as described in table 4 and 10 0.5 M NaCl, 50 mM Tris-HCl pH 8, and 2.0 mM/0.2 mM reduced/oxidized glutathione as buffer A and 8 M urea, 0.5 M NaCl, 50 mM Tris-HCl pH 8, and 5 mM reduced glutathione as buffer B. The reduced/oxidized glutathione solution was 15 freshly prepared as a 200 times stock solution by addition of 9.9 M  $\text{H}_2\text{O}_2$  to a stirred solution of 0.2 M reduced glutathione before addition to buffer A.

After completion of the cyclic folding procedure the  $\alpha_2$ MRDv fusion protein was eluted from the  $\text{Ni}^{2+}$ NTA-agarose column 20 with a buffer containing 0.5 M NaCl, 50 mM Tris-HCl, 20 mM EDTA pH 8. Fusion protein that were aggregated and precipitated on the  $\text{Ni}^{2+}$ NTA-agarose column was eluted in buffer B.

Approximately 50% of the fusion protein material was eluted in the aqueous elution buffer. Half of this fusion protein 25 material appeared monomeric and folded as judged by non-reducing SDS-PAGE analysis.

Recombinant  $\alpha_2$ MRDv protein was liberated from the N-terminal fusion tail by cleavage with the restriction protease FX<sub>a</sub> at room temperature in a weight to weight ratio of approximately 30 50 to one for four hours. After cleavage the  $\alpha_2$ MRDv protein was isolated from uncleaved fusion protein, the liberated fusion tail, and FX<sub>a</sub>, by gelfiltration on Sephadex G-25 into 10 mM NaCl, 50 mM Tris-HCl pH 8, followed by ion exchange chromatography on Q-Sepharose:  $\alpha_2$ MRDv was eluted in a linear

gradient (over 10 column volumes) from 10 mM NaCl, 10 mM Tris-HCl pH 8 to 500 mM NaCl, 10 mM Tris-HCl pH 8. The  $\alpha_2$ MRDv protein eluted at 150 mM NaCl.

5 The recombinant  $\alpha_2$ MRDv domain binds to the  $\alpha_2$ M-receptor with a similar affinity for the receptor as exhibited by the complete  $\alpha_2$ -Macroglobulin molecule (referring to the estimated  $K_D$  in one ligand-one receptor binding (Moestrup and Gliemann 1991)). Binding analysis was performed by Dr. Søren K. Moestrup and stud. scient. Kåre Lehmann).

10 EXAMPLE 8

*Production in E. coli and refolding of recombinant fragments derived from the trout virus VHS envelope glycoprotein G*

15 Expression and *in vitro* refolding of recombinant fragments derived from the envelope glycoprotein G from the trout virus VHS in E. coli as FX<sub>a</sub> cleavable fusion proteins is performed using general strategies and methods analogous to those outlined in the general description of the "cyclic refolding procedure" and given in Examples 1 through 6.

EXAMPLE 9

20 *Production in E. coli and refolding of recombinant human Tetranectin and recombinant fragments derived from human Tetranectin*

25 Tetranectin is a tetrameric protein consisting of four identical and non-covalently linked single chain subunits of 181 amino acid residues (17 kDa). Each subunit contains three disulphide bridges and binds Ca<sup>2+</sup>. Tetranectin is found in plasma and associated with extracellular matrix. Tetranectin binds specifically to plasminogen kringle 4. This binding can be specifically be titrated by lysine or  $\omega$ -amino acids.

The cDNA encoding the reading frame corresponding to the mature tetranectin single chain subunit was cloned by specific amplification in a Polymerase Chain Reaction (PCR) (Saiki et al., 1988) of the nucleotide sequences from amino acid 5 residue Glu<sub>1</sub> to Val<sub>181</sub> using 1<sup>st</sup> strand oligo-dT primed cDNA synthesized from total human placental RNA as template. Primers used in the PCR were SEQ ID NO: 33 and SEQ ID NO: 34. RNA extraction and cDNA synthesis were performed using standard procedures.

10 The amplified reading frame encoding the monomer subunit of tetranectin was at the 5'-end, via the PCR-reaction, linked to nucleotide sequences encoding the amino acid sequence SEQ ID NO: 37 which constitute a cleavage site for the bovine restriction protease FX<sub>a</sub> (Nagai, and Thøgersen, 1987). A 15 glycine residue was, due to the specific design of the 5'-PCR primer (SEQ. ID NO. 33), inserted between the C-terminal arginine residue of the FX<sub>a</sub> cleavage site (SEQ ID NO. 37) and the tetranectin Glu<sub>1</sub>-residue. The amplified DNA fragment was subcloned into the *E. coli* expression vector pT<sub>7</sub>H<sub>6</sub> (Christensen et al., 1991). The construction of the resulting plasmid pT<sub>7</sub>H<sub>6</sub>FX-TETN (expressing the tetranectin monomer) is outlined in fig. 20 and the amino acid sequence of the expressed protein is shown in fig. 21 (in SEQ ID NO: 56 is shown the amino acid sequence encoded by the full length reading 20 frame). 25

To prepare the tetranectin monomer, the plasmid pT<sub>7</sub>H<sub>6</sub>FX-TETN was grown in medium scale (4 x 1 litre; 2xTY medium, 5 mM MgSO<sub>4</sub> and 100 µg ampicillin) in *E. coli* BL21 cells, as described by Studier and Moffat, J. Mol. Biol., 189: 113-130, 30 1986. Exponentially growing cultures at 37°C were at OD<sub>600</sub> 0.8 infected with bacteriophage λCE6 at a multiplicity of approximately 5. Cultures were grown at 37°C for another three hours and the cells harvested by centrifugation. Cells were resuspended in 150 ml of 0.5 M NaCl, 10 mM Tris-HCl pH 35 8, and 1 mM EDTA pH 8. Phenol (100 ml adjusted to pH 8) was added and the mixture sonicated to extract the total protein.

Protein was precipitated from the phenol phase by 2.5 volumes of ethanol and centrifugation.

The protein pellet was dissolved in a buffer containing 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 0.1 M dithio-5 erythriol. Following gel filtration on Sephadex G-25 (Pharmacia, LKB, Sweden) into 8 M Urea, 1 M NaCl, 50 mM Tris-HCl pH 8 and 10 mM 2-mercaptoethanol, the crude protein preparation was applied to a  $\text{Ni}^{2+}$  activated NTA-agarose column ( $\text{Ni}^{2+}$ NTA-agarose, 75 ml pre-washed with 8 M urea, 1 M NaCl, 10 50 mM Tris-HCl pH 8, and 10 mM 2-mercaptoethanol) for purification (Hochuli et al., 1988) of the fusion protein, MGSHHHHHHGSIEGR-TETN (wherein MGSHHHHHHGSIEGR is SEQ ID NO: 48).

Preparation and "charging" of the  $\text{Ni}^{2+}$ NTA-agarose column is 15 described under example 1.

All buffers prepared for liquid chromatography were degassed under vacuum prior to addition of reductant and/or use.

The column was washed with 200 ml of 8 M urea, 1 M NaCl, 50 mM Tris-HCl pH 8, and 10 mM 2-mercaptoethanol (Buffer I) and 20 100 ml 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 10 mM 2-mercaptoethanol (Buffer II). The MGSHHHHHHGSIEGR-TETN fusion protein was eluted with Buffer II containing 10 mM EDTA pH 8 and the elute was gel filtered on Sephadex G25 using Buffer I as eluant.

25 The protein eluted was then refolded. The fusion protein MGSHHHHHHGSIEGR-TETN (wherein MGSHHHHHHGSIEGR is SEQ ID NO: 48) was mixed with 100 ml  $\text{Ni}^{2+}$ NTA-agarose. The resin containing bound protein was packed into a 5 cm diameter column and washed with Buffer I supplemented with  $\text{CaCl}_2$  to 2 mM. The 30 fusion protein was refolded on the  $\text{Ni}^{2+}$ NTA-agarose column at 11-12°C using a gradient manager profile as described in table 4 and 0.5 M NaCl, 50 mM Tris-HCl pH 8, 2 mM  $\text{CaCl}_2$  and 2.0 mM/0.2 mM reduced/oxidized glutathione as buffer A and 8

M urea, 1 M NaCl, 50 mM Tris-HCl pH 8, 2 mM CaCl<sub>2</sub> and 3 mM reduced glutathione as buffer B. The reduced/oxidized glutathione solution was freshly prepared as a 200 times stock solution by addition of 9.9 M H<sub>2</sub>O<sub>2</sub> to a stirred solution of 5 0.2 M reduced glutathione before addition to buffer A.

After completion of the cyclic folding procedure the tetranectin fusion protein was eluted from the Ni<sup>2+</sup>NTA-agarose column with a buffer containing 0.5 M NaCl, 50 mM Tris-HCl, 25 mM EDTA pH 8. The tetranectin fusion protein was cleaved 10 with FX<sub>a</sub> at 4°C overnight in a molar ratio of 1:300. After FX<sub>a</sub> cleavage the protein sample was concentrated 10 fold by ultrafiltration on a YM10 membrane (Amicon). Recombinant tetranectin was, after ten times dilution of the protein sample with 2 mM CaCl<sub>2</sub>, isolated by ion-exchange chromatography 15 on Q-Sepharose (Pharmacia, Sweden) in a liner gradient over 10 column volumes from 10 mM Tris-HCl pH 8, 2 mM CaCl<sub>2</sub> to 10 mM Tris-HCl pH 8, 2 mM CaCl<sub>2</sub>, and 0.5 M NaCl.

Recombinant tetranectin produced by this procedure was analyzed by Dr. Inge Clemmensen Rigshospitalet, Copenhagen. Dr. 20 Clemmensen found that the recombinant tetranectin with respect to binding to plasminogen kringle 4 and expression of antigenic sites behaved identically to naturally isolated human tetranectin.

Preliminary experiments comparing the efficiency of refolding, 25 using the "cyclic refolding procedure", of recombinant Tetranectin fusion protein bound to the Ni<sup>2+</sup>NTA-agarose column versus recombinant Tetranectin contained in a dialysis bag indicate a significantly improved yield of soluble monomer from the solution refolding strategy. However, if either 30 product of the cycling procedures is subjected to disulphide re-shuffling in solution in the presence of 5 mM CaCl<sub>2</sub> virtually all of the polypeptide material is converted to the correctly folded Tetranectin tetramer.

Denatured and reduced recombinant authentic Tetranectin contained in a dialysis bag, was refolded over 15 cyclic exposures to buffer B (6 M Urea, 100 mM NaCl, 50 mM Tris-HCl pH=8, 2 mM/0.2 mM reduced/oxidized glutathione, 2 mM CaCl<sub>2</sub> 5 and 0.5 mM methionine) and buffer A (100 mM NaCl, 50 mM Tris-HCl pH 8, 2 mM/0.2 mM reduced/oxidized glutathione, 2 mM CaCl<sub>2</sub>, and 0.5 mM methionine).

#### EXAMPLE 10

10 *Production and folding of a diabody expressed intracellularly in E. coli: Mab 32 diabody directed against tumour necrosis factor.*

Diabodies (described in Holliger et al., 1993) are artificial bivalent and bispecific antibody fragments.

This example describes the production in *E. coli* of a diabody 15 directed against tumour necrosis factor alpha (TNF- $\alpha$ ), derived from the mouse monoclonal antibody Mab 32 (Rathjen et al., 1991, 1992; Australian Patent Appl. 7,576; EP-A-486,526).

A phagemid clone, pCANTAB5-myc-Mab32-5, containing Mab32 20 encoded in the diabody format (PCT/GB93/02492) was generously provided by Dr. G. Winter, Cambridge Antibody Technology (CAT) Ltd., Cambridge, UK. pCANTAB5-myc-Mab32-5 DNA was used as template in a Polymerase Chain Reaction (PCR) (Saiki et al., 1988), using the primers SEQ ID NO: 35 and SEQ ID NO: 25 36, designed to produce a cDNA fragment corresponding to the complete artificial diabody. The amplified coding reading frame was at the 5'-end, via the PCR-reaction, linked to a nucleotide sequence, included in SEQ ID NO: 35, encoding the amino acid sequence SEQ ID NO: 37 which constitute a cleavage 30 site for the bovine restriction protease FX<sub>a</sub> (Nagai and Thøgersen, 1987). The amplified DNA fragment was subcloned into the *E. coli* expression vector pT<sub>7</sub>H<sub>6</sub> (Christensen et al., 1991). The construction of the resulting plasmid pT<sub>7</sub>H<sub>6</sub>FX-DB32

(expressing the Mab32 diabody) is outlined in fig. 22 and the amino acid sequence of the expressed protein is shown in fig. 23 (in SEQ ID NO: 57 is shown the amino acid sequence encoded by the full length reading frame).

- 5 To prepare the diabody fragment, the plasmid pT<sub>7</sub>H<sub>6</sub>FX-DB32 was grown in medium scale (4 x 1 litre; 2xTY medium, 5 mM MgSO<sub>4</sub> and 100 µg ampicillin) in *E. coli* BL21 cells, as described by Studier and Moffat, J. Mol. Biol., 189: 113-130, 1986. Exponentially growing cultures at 37°C were at OD<sub>600</sub> 0.8 infected
- 10 with bacteriophage λCE6 at a multiplicity of approximately 5. Forty minutes after infection, rifampicin was added (0.2 g in 2 ml methanol per litre media). Cultures were grown at 37°C for another three hours and the cells harvested by centrifugation. Cells were resuspended in 150 ml of 0.5 M
- 15 NaCl, 10 mM Tris-HCl pH 8, and 1 mM EDTA pH 8. Phenol (100 ml adjusted to pH 8) was added and the mixture sonicated to extract the total protein. Protein was precipitated from the phenol phase by 2.5 volumes of ethanol and centrifugation.

- 20 The protein pellet was dissolved in a buffer containing 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 0.1 M dithio-erythriol. Following gel filtration on Sephadex G-25 (Pharmacia, LKB, Sweden) into 8 M Urea, 1 M NaCl, 50 mM Tris-HCl pH 8 and 10 mM 2-mercaptoethanol, the crude protein preparation was applied to a Ni<sup>2+</sup> activated NTA-agarose column
- 25 (Ni<sup>2+</sup>NTA-agarose, 75 ml pre-washed with 8 M urea, 1 M NaCl, 50 mM Tris-HCl pH 8, and 10 mM 2-mercaptoethanol) for purification (Hochuli *et al.*, 1988) of the fusion protein, MGSHHHHHGSIEGR-DB32 (wherein MGSHHHHHGSIEGR is SEQ ID NO: 48).
- 30 Preparation and "charging" of the Ni<sup>2+</sup>NTA-agarose column is described under example 1.

All buffers prepared for liquid chromatography were degassed under vacuum prior to addition of reductant and/or use.

The column was washed with 200 ml of 8 M urea, 1 M NaCl, 50 mM Tris-HCl pH 8, and 10 mM 2-mercaptoethanol (Buffer I) and 100 ml 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 10 mM 2-mercaptoethanol (Buffer II). The MGSHHHHHGSIEGR-DB32 fusion protein was eluted with Buffer II containing 10 mM EDTA pH 8 and the elute was gel filtered on Sephadex G25 using Buffer I as eluant.

The protein eluted was then refolded. The fusion protein MGSHHHHHGSIEGR-DB32 (wherein MGSHHHHHGSIEGR is SEQ ID NO: 10 48) was mixed with 100 ml Ni<sup>2+</sup>NTA-agarose. The resin containing bound protein was packed into a 5 cm diameter column and washed with Buffer I. The fusion protein was refolded on the Ni<sup>2+</sup>NTA-agarose column at 11-12°C using a gradient manager profile as described in table 4 and 0.5 M NaCl, 50 mM 15 Tris-HCl pH 8, and 2.0 mM/0.2 mM reduced/oxidized glutathione as buffer A and 8 M urea, 1 M NaCl, 50 mM Tris-HCl pH 8, and 3 mM reduced glutathione as buffer B. The reduced/oxidized glutathione solution was freshly prepared as a 200 times stock solution by addition of 9.9 M H<sub>2</sub>O<sub>2</sub> to a stirred solution of 0.2 M reduced glutathione before addition to buffer 20 A.

After completion of the cyclic folding procedure the DB32 fusion protein was eluted from the Ni<sup>2+</sup>NTA-agarose column with a buffer containing 0.5 M NaCl, 50 mM Tris-HCl, 25 mM 25 EDTA pH 8 and adjusted to 5 mM GSH, 0.5 mM GSSG and incubated for 12 to 15 hours at 20°C. The fusion protein was then concentrated 50 fold by ultrafiltration using YM10 membranes and clarified by centrifugation.

The DB32 fusion protein dimer was purified by gel filtration 30 using a Superose 12 column (Pharmacia, Sweden) with PBS as eluant.

The overall yield of correctly folded DB32 fusion protein from this procedure was 4 mg per litre.

An analysis by non-reducing SDS-PAGE from different stages of the purification is shown in fig. 26.

The MGSHHHHHGSIEGR (SEQ ID NO: 48) N-terminal fusion peptide was cleaved off the DB32 protein by cleavage with the restriction protease FX<sub>a</sub> (molar ratio 1:5 FX<sub>a</sub>:DB32 fusion protein) at 37°C for 20 hours. This is shown as the appearance of a lower molecular weight band just below the uncleaved fusion protein in fig. 26.

The refolded DB32 protein was analyzed by Cambridge Antibody Technology Ltd. (CAT). DB32 was found to bind specifically to TNF- $\alpha$  and to compete with the Mab32 whole antibody for binding to TNF- $\alpha$ . Furthermore both DB32 and Mab32 were competed in binding to TNF- $\alpha$  by sheep anti-301 antiserum, which has been raised by immunizing sheep with a peptide encoding the first 18 amino acids of human TNF- $\alpha$  and comprise at least part of the epitope recognised by the murine Mab32.

#### EXAMPLE 11

##### *Production and refolding of human psoriasis in E. coli.*

Psoriasis is a single domain Ca<sup>2+</sup>- binding protein of 100 amino acid residues (11.5 kDa). Psoriasis contains a single disulphide bridge. The protein which is believed to be a member of the S100 Protein family is highly up-regulated in psoriatic skin and in primary human keratinocytes undergoing abnormal differentiation.

The plasmid pT<sub>7</sub>H<sub>6</sub>FX-PS.4 (kindly provided by Dr. P. Madsen, Institute of Medical Biochemistry, University of Aarhus, Denmark) has previously been described by Hoffmann et al., (1994). The nucleotide sequence encoding the psoriasis protein from Ser<sub>2</sub> to Gln<sub>101</sub> is in the 5'-end linked to the nucleotide sequence encoding the amino acid sequence MGSHHHHHGSIEGR (SEQ ID NO: 48). A map of pT<sub>7</sub>H<sub>6</sub>FX-PS.4 is given in fig. 24 and the amino acid sequence of human psoria-

sin is listed in fig. 25 (in SEQ ID NO: 58 is shown the amino acid sequence encoded by the full length reading frame).

Recombinant human psoriasin was grown and expressed from the plasmid pT<sub>7</sub>H<sub>6</sub>FX-PS.4 in *E. coli* BL21 cells and total cellular 5 protein extracted as described (Hoffmann et al., 1994). Ethanol precipitated total protein was dissolved in a buffer containing 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 50 mM dithioerythriol. Following gel filtration on Sephadex G-25 (Pharmacia, LKB, Sweden) into 8 M Urea, 0.5 M NaCl, 50 10 mM Tris-HCl pH 8 and 5 mM 2-mercaptoethanol the crude protein preparation was applied to a Ni<sup>2+</sup> activated NTA-agarose column (Ni<sup>2+</sup>NTA-agarose) for purification (Hochuli et al., 1988) of the fusion protein, MGSHHHHHGSIEGR-psoriasin 15 (wherein MGSHHHHHGSIEGR is SEQ ID NO: 48) and subsequently to undergo the cyclic folding procedure.

Preparation and "charging" of the Ni<sup>2+</sup>NTA-agarose column is described under Example 1.

All buffers prepared for liquid chromatography were degassed under vacuum prior to addition of reductant and/or use.

20 Upon application of the crude protein extract on the Ni<sup>2+</sup>NTA-agarose column, the fusion protein, MGSHHHHHGSIEGR-psoriasin (wherein MGSHHHHHGSIEGR is SEQ ID NO: 48) was purified from the majority of coli and  $\lambda$  phage proteins by washing with one column volume of the loading buffer followed by 6 M guanidinium 25 chloride, 50 mM Tris-HCl, and 5 mM 2-mercaptoethanol until the optical density (OD) at 280 nm of the eluate was stable.

The fusion protein was refolded on the Ni<sup>2+</sup>NTA-agarose column using a gradient manager profile as described in table 4 and 30 0.5 M NaCl, 50 mM Tris-HCl pH 8, 2 mM CaCl<sub>2</sub>, and 1.0 mM/0.1 mM reduced/oxidized glutathione as buffer A and 8 M urea, 0.5 M NaCl, 50 mM Tris-HCl pH 8, 2 mM CaCl<sub>2</sub>, and 5 mM reduced glutathione as buffer B. The reduced/oxidized glutathione so-

lution was freshly prepared as a 200 times stock solution by addition of 9.9 M H<sub>2</sub>O<sub>2</sub> to a stirred solution of 0.2 M reduced glutathione before addition to buffer A.

After completion of the cyclic folding procedure the psoriasis fusion protein was eluted from the Ni<sup>2+</sup>NTA-agarose column with a buffer containing 0.5 M NaCl, 50 mM Tris-HCl, 10 mM EDTA pH 8. Fusion protein that were aggregated and precipitated on the Ni<sup>2+</sup>NTA-agarose column was eluted in buffer B.

10 Approximately 95% of the fusion protein material was eluted by the non denaturing elution buffer. As judged by non-reducing SDS-PAGE analysis 75% of the soluble fusion protein material appeared to be monomeric yielding an overall efficiency of the folding procedure of approximately 70%. The 15 efficiency of the previously described refolding procedure for production of recombinant human psoriasis (Hoffman et al., 1994) was estimated to be less than 25%.

The psoriasis fusion protein was cleaved with FX<sub>a</sub> in a molar ratio of 100:1 for 48 hrs at room temperature. After gelfiltration into a buffer containing 20 mM Na-acetate pH 5 and 20 mM NaCl on Sephadex G-25 the protein sample was applied onto a S-Sepharose ion exchange column (Pharmacia). Monomeric recombinant psoriasis was eluted over 5 column volumes with a linear gradient from 20 mM Na-acetate pH 5, 20 mM NaCl to 0.5 M NaCl. Monomeric psoriasis eluted at 150 mM NaCl. Dimeric and higher order multimers of psoriasis together with uncleaved fusion protein eluted later in the gradient. Fractions containing the cleaved purified recombinant protein was gelfiltrated on Sephadex G25 into a buffer containing 150 mM NaCl, 10 mM Tris-HCl pH 7.4 and stored at 4°C.

#### EXAMPLE 12

*Evaluation procedure for suitability testing of thiol compounds for use as reducing agents in cyclic refolding and*

*determination of optimal levels of denaturants and disulphide reshuffling agents for optimization of cyclic refolding procedures.*

In order to improve the yield of correctly folded protein  
5 obtainable from cyclic refolding the number of productive cycles should be maximized (see SUMMARY OF THE INVENTION). Productive cycles are characterized by steps of denaturation where misfolded protein, en route to dead-end aggregate conformational states, is salvaged into unfolded conformational states while most of the already correctly folded protein remains in conformational states able to snap back into the refolded state during the refolding step of the cycle.

A number of disulphide bridge containing proteins, like  $\beta_2$ -microglobulin, are known to refold with high efficiency  
15 (>95%) when subjected to high levels of denaturing agents as long as their disulphide bridges remain intact.

This example describes how to evaluate suitability of a thiol compound for use in cyclic refolding on the basis of its ability to discriminate correct from incorrect disulphide  
20 bridges and how to optimize levels of denaturing agent and/or reducing agent to be used in the denaturation steps in order to maximize the number of productive cycles. As model system we chose a mixture of mono-, di- and multimeric forms of purified recombinant human  $\beta_2$ -microglobulin. Our specific aim  
25 was to analyze the stability of different topological forms of human  $\beta_2$ -microglobulin against reduction by five different reducing agents at various concentrations of denaturing agent.

Human  $\beta_2$ -microglobulin (produced as described in Example 13)  
30 in 6 M guanidinium chloride, 50 mM Tris-HCl and 10 mM 2-mercaptoethanol pH 8 was gelfiltrated into non-denaturing buffer (50 mM Tris-HCl, 0.5 M NaCl pH 8). Only a fraction of the protein in the sample was soluble in the non-denaturing buffer. After 48 hours exposure to air, the protein solution

appeared unclear. Non-reducing SDS-PAGE analysis showed that most of the protein had been oxidized into multimeric forms and only a small fraction was oxidized and monomeric (Fig. 27, lane 1).

5 The protein solution was aliquoted into a number of tubes and varying amounts of urea added while keeping the concentration of protein and salt at a constant level.

Reducing agent, either glutathione, cysteine ethyl ester, N-acetyl-L-cysteine, mercaptosuccinic acid or 2-mercaptopethanol 10 was added to the ensemble of protein samples with varying urea concentrations. Each reducing agents was added to a final concentration of 4 mM. The protein samples were incubated at room temperature for 10 min and then free thiol groups were blocked by addition of iodoacetic acid to a final 15 concentration of 12 mM. Finally, the protein samples were analyzed by non-reducing SDS-PAGE (fig. 27 - 32). The compositions of the test-samples used in the non-reducing SDS-PAGE as well as the results are given below in the following 20 tables; in the rows indicating the ability of the chosen reducing agent to reduce disulphide bridges the marking "+++" indicates good ability, "++" indicates intermediate ability, "+" indicates weak ability, whereas no marking indicates that no measurable effect could be observed.

Composition of samples used in SDS-PAGE of fig. 27

Test no.	1	2	3	4	5	6	7	8	9	10	11
μl protein solution	36	36	36	36	36	36	36	36	36	36	36
μl Buffer A	160	160	140	120	100	80	70	60	50	40	20
5 μl Buffer B	0	0	20	40	60	80	90	100	110	120	140
μl GSH	0	4	4	4	4	4	4	4	4	4	4
M urea	0	0	1	2	3	4	4.5	5	5.5	6	7
Ability to reduce wrong disulphide bridges		+	+	++	++	+++	+++	+++	+++	+++	+++
10 Ability to reduce correct disulphide bridges										+	+++

15 Buffer A : 50 mM Tris.HCl pH 8, 0.5 M NaCl  
 Buffer B: 10 M urea, 50 mM Tris.HCl pH 8, 0.5 M NaCl  
 GSH: 0.2 M Gluthatione  
 Protein solution: 2 mg/ml hβ<sub>2</sub>m, 50 mM Tris.HCl pH 8, 0.5 M NaCl

Composition of samples used in SDS-PAGE of fig. 28

Test no.	1	2	3	4	5	6	7	8	9
20 μl protein solution	36	36	36	36	36	36	36	36	36
μl Buffer A	160	160	140	120	100	80	60	40	20
μl Buffer B	0	0	20	40	60	80	100	120	140
μl CE	0	4	4	4	4	4	4	4	4
M urea	0	0	1	2	3	4	5	6	7
25 Ability to reduce wrong disulphide bridges	++	++	++	+++	+++	+++	+++	+++	+++
Ability to reduce correct disulphide bridges									

30 Buffer A : 50 mM Tris.HCl pH 8, 0.5 M NaCl  
 Buffer B: 10 M urea, 50 mM Tris.HCl pH 8, 0.5 M NaCl  
 CE: 0.2 M L-cysteine ethyl ester  
 Protein solution: 2 mg/ml hβ<sub>2</sub>m, 50 mM Tris.HCl pH 8, 0.5 M NaCl

Composition of samples used in SDS-PAGE of fig. 29

Test no.	1	2	3	4	5	6	7	8	9
μl protein solution	36	36	36	36	36	36	36	36	36
μl Buffer A	160	160	140	120	100	80	60	40	20
5 μl Buffer B	0	0	20	40	60	80	100	120	140
μl ME	0	4	4	4	4	4	4	4	4
M urea	0	0	1	2	3	4	5	6	7
Ability to reduce wrong disulphide bridges	++	++	++	+++	+++	+++	+++	+++	+++
10 Ability to reduce correct disulphide bridges					+	++	+++	+++	+++

Buffer A : 50 mM Tris.HCl pH 8, 0.5 M NaCl

Buffer B: 10 M urea, 50 mM Tris.HCl pH 8, 0.5 M NaCl

ME: 0.2 M 2-mercaptoethanol

15 Protein solution: 2 mg/ml hβ<sub>2</sub>m, 50 mM Tris.HCl pH 8, 0.5 M NaCl

Composition of samples used in SDS-PAGE of fig. 30

Test no.	1	2	3	4	5	6	7	8	9
μl protein solution	36	36	36	36	36	36	36	36	36
μl Buffer A	160	160	140	120	100	80	60	40	20
20 μl Buffer B	0	0	20	40	60	80	100	120	140
μl MSA	0	4	4	4	4	4	4	4	4
M urea	0	0	1	2	3	4	5	6	7
Ability to reduce wrong disulphide bridges	++	++	++	++	++	+++	+++	+++	+++
25 Ability to reduce correct disulphide bridges						++	+++	+++	+++

Buffer A : 50 mM Tris.HCl pH 8, 0.5 M NaCl

Buffer B: 10 M urea, 50 mM Tris.HCl pH 8, 0.5 M NaCl

MSA: 0.2 M Mercaptosuccinic acid

30 Protein solution: 2 mg/ml hβ<sub>2</sub>m, 50 mM Tris.HCl pH 8, 0.5 M NaCl

Composition of samples used in SDS-PAGE of fig. 31

Test no.	1	2	3	4	5	6	7	8	9
μl protein solution	36	36	36	36	36	36	36	36	36
μl Buffer A	160	160	140	120	100	80	60	40	20
5 μl Buffer B	0	0	20	40	60	80	100	120	140
μl AC	0	4	4	4	4	4	4	4	4
M urea	0	0	1	2	3	4	5	6	7
Ability to reduce wrong disulphide bridges		+	++	++	+++	+++	+++	+++	+++
10 Ability to reduce correct disulphide bridges					+	++	+++	+++	+++

Buffer A : 50 mM Tris.HCl pH 8, 0.5 M NaCl

Buffer B: 10 M urea, 50 mM Tris.HCl pH 8, 0.5 M NaCl

AC: 0.2 M N-acetyl-L-cysteine

15 Protein solution: 2 mg/ml hβ<sub>2</sub>m, 50 mM Tris.HCl pH 8, 0.5 M NaCl

The different topological forms of β<sub>2</sub>-m may be separated by non-reducing SDS-PAGE gel electrophoresis. The fastest migrating band represents the oxidized monomeric form. This band is immediately followed by the reduced β<sub>2</sub>-m with a slightly 20 slower migration rate, whereas the multimeric forms of the protein are migrating much slower in the gel.

In this analysis we are probing for the ability of each of the five reducing agents tested, to reduce the disulphide bridges of multimeric forms of β<sub>2</sub>-microglobulin without 25 significantly reducing the correctly formed disulphide bridge of the monomeric oxidized form.

The results from the analyses (fig. 27 - 32) are, in summary, as follows: N-acetyl-L-cysteine and mercaptosuccinic acid are, under the conditions used, essentially unable to discriminate correct and incorrect disulphide bridges. 30 Glutathione, cysteine ethyl ester and 2-mercaptopethanol are all capable of - within 10 min and within individual characteristic ranges of urea concentrations - significantly reducing disulphide bridges of multimeric forms while most of

the oxidised monomeric  $\beta_2\text{-m}$  remains in the oxidised form. Gluthatione has clearly the capacity of selectively reducing incorrect disulphide bridges at higher concentrations of urea compared to cysteine ethyl ester and 2-mercaptoethanol and 5 therefore glutathione among the selection of thiols tested would be the reducing agent of choice for cyclic refolding of human  $\beta_2$ -microglobulin. As a consequence of these experiments the concentration of urea in the reducing buffer B for the refolding procedure used in Example 13 was lowered from 8 M 10 (Example 1) to 6 M, which led to an improvement of overall refolding yield of human  $\beta_2$ -microglobulin from 53% to 87%..

#### EXAMPLE 13

##### *Refolding of purified human $\beta_2$ -microglobulin: Comparative analysis of three refolding procedures*

15 The following set of experiments were undertaken to obtain comparable quantitative data to evaluate the importance of cycling for refolding yield versus simple refolding procedures involving a stepwise or a gradual one-pass transition from strongly denaturing and reducing conditions to non- 20 denaturing and non-reducing conditions.

Purified refolded recombinant human  $\beta_2$ -microglobulin fusion protein, obtained as described in EXAMPLE 1, was reduced and denatured to obtain starting materials devoid of impurities, such as proteolytic breakdown products or minor fractions of 25 fusion protein damaged by irreversible oxidation or other chemical derivatization.

In a first step the optimization procedure described in EXAMPLE 12 was used to modify the conditions for cyclic refolding described in EXAMPLE 1 to increase the number of 30 productive cycles. The optimized refolding protocol was identical to that described in EXAMPLE 1, as were buffers and other experimental parameters, except that the Buffer B in

the present experiments was 6 M urea, 50 mM Tris-HCl pH 8, 0.5 M NaCl, 4 mM glutathione.

Three batches of pure fusion protein were refolded while attached to Ni<sup>++</sup> -loaded NTA-agarose as described in EXAMPLE 5 1, using the present Buffer B composition. One batch was submitted to buffer cycling as described in EXAMPLE 1, for batch two and three cycling was replaced by a monotonous linear buffer gradient (100% B to 0% B over 24 hours) and a step gradient (100% B to 0% B in one step, followed by 0% B 10 buffer for 24 hours), respectively. In each refolding experiment all of the polypeptide material was recovered as described in EXAMPLE 1 as a soluble fraction elutable under non-denaturing conditions and a remaining insoluble fraction elutable only under denaturing and reducing conditions. The 15 yields of correctly folded fusion protein were measured by quantitative densitometric analysis (Optical scanner HW and GS-370 Densitometric Analysis SW package from Hoeffer Scientific, CA, USA) of Coomassie stained SDS-PAGE gels on which suitably diluted measured aliquots of soluble and 20 insoluble fractions had been separated under reducing or non-reducing condition, as required to allow separation of correctly disulphide-bridged monomer from soluble polymers in soluble fractions. Where required to obtain reliable 25 densitometric data both for intense and faint bands in a gel lane several sample dilutions were scanned and analyzed to obtain rescaled data sets.

#### *Experimental details and results*

##### **Purified denatured and reduced fusion protein:**

A batch of human  $\beta_2$ -microglobulin fusion protein was refolded 30 as described in EXAMPLE 1. 96% of the fusion protein was recovered in the soluble fraction (Fig 32, lanes 2-5). 56% of this soluble fraction was in the monomeric and disulphide-bridged form. Hence, the overall refolding efficiency obtained was 53%. Monomeric fusion protein was purified from

multimers by ion exchange chromatography on S-Sepharose (Pharmacia, Sweden): The soluble fraction obtained after refolding was gel filtered on Sephadex G-25 (Pharmacia, Sweden) into a buffer containing 5 mM NaCl and 5 mM Tris-HCl pH 8, diluted to double volume with water and then applied to the S-Sepharose column, which was then eluted using a gradient (5 column volumes from 2.5 mM Tris-HCl pH 8, 2.5 mM NaCl to 25 mM Tris-HCl pH 8, 100 mM NaCl): The monomeric correctly folded fusion protein purified to >95% purity (Fig. 32, lanes 5 6 and 7) was then made 6 M in guanidinium hydrochloride and 10 0.1 M in DTE, gel filtrated into a buffer containing 8 M urea, 50 mM Tris-HCl pH 8, 1 M NaCl and 10 mM 2-mercaptoethanol and then divided into aliquots to be used as starting material for the refolding experiments described below.

15 **Cyclic refolding of purified fusion protein:**

An aliquot of denatured reduced fusion protein was applied to a Ni<sup>++</sup> -loaded NTA column which was then washed with one column volume of a buffer containing 6 M guanidinium hydrochloride, 50 mM Tris-HCl pH 8 and 10 mM 2-mercaptoethanol. 20

The fusion protein was then subjected to buffer cycling according to the scheme shown in Table 1 using Buffer A: 50 mM Tris-HCl pH 8, 0.5 M NaCl and 3.2 mM/0.4 mM reduced/oxidized glutathione and Buffer B: 50 mM Tris-HCl pH 25 8, 0.5 M NaCl, 6 M urea and 4 mM reduced glutathione. After completion of buffer cycling the fusion protein was recovered quantitatively in a soluble form by elution of the column with a buffer containing 50 mM Tris-HCl pH 8, 0.5 M NaCl and 30 20 mM EDTA. 87% was obtained in the correct monomeric disulphide-bridged form (Fig. 32 lanes 8 and 9).

**Refolding of purified fusion protein by linear gradient:**

An aliquot of denatured reduced fusion protein was applied to a Ni<sup>++</sup> -loaded NTA column which was then washed with one

column volume of a buffer containing 6 M guanidinium hydrochloride, 50 mM Tris-HCl pH 8 and 10 mM 2-mercaptoethanol followed by 1 column volume of a buffer containing 50 mM Tris-HCl pH 8, 0.5 M NaCl, 6 M urea and 4 mM reduced 5 glutathione.

A 24 hour linear gradient from 100% B to 100% A was then applied at 2 ml/min, using Buffer A: 50 mM Tris-HCl pH 8, 0.5 M NaCl and 3.2 mM/0.4 mM reduced/oxidized glutathione and Buffer B: 50 mM Tris-HCl pH 8, 0.5 M NaCl, 6 M urea and 4 mM 10 reduced glutathione. After completion of the gradient the soluble fraction of fusion protein was eluted in a buffer containing 50 mM Tris-HCl pH 8, 0.5 M NaCl and 20 mM EDTA. The remaining insoluble fraction was extracted from column in a buffer containing 50 mM Tris-HCl pH 8, 1 M NaCl, 8 M urea, 15 10 mM 2-mercaptoethanol and 20 mM EDTA.

48% of the fusion protein was recovered in the soluble fraction and 60% of the soluble fraction was recovered in the correct monomeric disulphide-bridged form. The overall efficiency of folding obtained was therefore 29% (Fig 33, lanes 20 5-7).

#### **Refolding of purified fusion protein by buffer step:**

An aliquot of denatured reduced fusion protein was applied to a Ni<sup>++</sup> -loaded NTA column which was then washed with one column volume of a buffer containing 6 M guanidinium 25 hydrochloride, 50 mM Tris-HCl pH 8 and 10 mM 2-mercaptoethanol.

Buffer containing 50 mM Tris-HCl pH 8, 0.5 M NaCl and 3.2 mM/0.4 mM reduced/oxidized glutathione was then applied to the column at 2 ml/min for 24 hours before recovering the 30 soluble fraction of fusion protein in a buffer containing 50 mM Tris-HCl pH 8, 0.5 M NaCl and 20 mM EDTA. The remaining insoluble fraction was extracted from column in a buffer

containing 50 mM Tris-HCl pH 8, 1 M NaCl, 8 M urea, 10 mM 2-mercaptoethanol and 20 mM EDTA.

34% of the fusion protein was recovered in the soluble fraction and 28% of the soluble fraction was recovered in the 5 correct monomeric disulphide-bridged form. The overall efficiency of folding obtained was therefore 9.5% (Fig 33, lanes 1-3).

### Conclusions

In summary, using human  $\beta_2$ -microglobulin as a model protein, 10 it may be concluded that (a) straightforward buffer optimization and improved purification of fusion protein prior to cyclic refolding increased refolding yield significantly (from 53% to 87%) and (b) progressive denaturation - renaturation cycling is superior to single-pass refolding 15 under otherwise comparable experimental conditions by a very large factor (87% versus 29% or 9.5% yields).

### REFERENCES:

Christensen, J.H., Hansen, P.K., Lillelund, O., and Thøgersen, H.C. (1991). Sequence-specific binding of the N-terminal 20 three-finger fragment of *Xenopus* transcription factor IIIA to the internal control region of a 5S RNA gene. *FEBS Letters*, 295: 181 - 184.

Dalbøge, H., Dahl, H.-H., M., Pedersen, J., Hansen, J., W., and T., Kristensen (1987). A Novel Enzymatic Method for 25 Production of Authentic hGH From an *Eschericia coli* Produced hGh-Precursor. *Bio/Technology*, 5: 161-164.

Datar, R., V., Cartwright, T., and C.-G. Rosen (1993). Process Economics of Animal Cell and Bacterial Fermentations: A Case Study Analysis of Tissue Plasminogen Activator. 30 *Bio/Technology*, 11: 349 - 357.

Herz, J., Hanmann, U., Rogne, S., Myklebost, O., Gausepohl, H., and Stanley, K.K. (1988), Surface location and high affinity for calcium of a 500 kd liver membrane protein closely related to the LDL-receptor suggest a physiological 5 role as lipoprotein receptor. *EMBO J.*, 7: 4119-4127.

Hoffmann, H. J., Olsen, E., Etzerodt, M., Madsen, P., Thøgersen, H. C., Kruse, T., and Celis J. E. (1994). Psoriasin Binds Calcium and Is Differentially Regulated With Respect to Other Members of the S100 Protein Family. *J. Dermatol.* 10 *Invest.* In press.

Hochuli, E., W. Bannwarth, H. Döbeli, R. Gentz, and D. Stüber. 1988. Genetic approach to facilitate purification of recombinant proteins with a novel metal chelate adsorbent. *Bio/Technology*, 6: 1321-1325.

15 Holliger., P., Prospero, T., and G. Winter (1993). "Diabodies": Small bivalent and bispecific antibody fragments. *Proc. Natl. Acad. Sci. USA.* 90: 6444 - 6448.

Maniatis, T., E.F. Fritsch, and J. Sambrook. 1982. *Molecular cloning*. Cold Spring Harbor Laboratory, Cold Spring Harbor, 20 N.Y.

Nagai, K., and H.C. Thøgersen. 1987. Synthesis and Sequence-Specific Proteolysis of Hybrid Proteins Produced in *Escherichia coli*. *Methods in Enzymology*, 152: 461-481.

25 Nagai, K., Nakaseko, Y., Nasmyth, K., and Rhodes, D. (1988). Zinc-finger motifs expressed in *E. coli* and folded *in vitro* direct specific binding to DNA. *Nature*, 332: 284 - 286.

Nykjær A., Petersen C.M., Møller B., Jensen P.H., Moestrup S.K., Holtet T.L., Etzerodt M., Thøgersen H.C., Munch M., Andreasen P.A., and Gliemann J. (1992). Purified  $\alpha_2$ -Macro- 30 globulin Receptor/LDL Receptor-related Protein Binds Uroki-

111

nase-Plasminogen Activator Inhibitor Type-1 Complex. *J. Biol. Chem.* **267**: 14543-14546.

Rathjen, D. et al. (1991), *Mol. Immunol.* **28**, p29.

Rathjen, D. et al. (1992), *Brit. J. Cancer* **65**, 852-856.

5 Saiki, R.K., Gelfant, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K. B., and Erlich, H. A. (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* **239**: 487 -491.

10 Studier, F.W. and Moffat, B.A. 1986. Use of Bacteriophage T7 RNA Polymerase to Direct Selective High-level Expression of Cloned Genes. *J. Mol. Biol.*, **189**: 113 - 130.

The Regents of the University of California. Enterokinase-- cleavable linker sequence. EP 035384.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: Denzyme ApS
- (B) STREET: Gustav Wieds Vej 10
- (C) CITY: Aarhus C
- (E) COUNTRY: Denmark
- (F) POSTAL CODE (ZIP): 8000

(ii) TITLE OF INVENTION: Improved method for the refolding of proteins

(iii) NUMBER OF SEQUENCES: 47

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1554 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: YES

(iii) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Bos taurus

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 76..1551

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

AGCCTGGCG AGCGGACCTT GCCCTGGAGG CCTGTTGCGG CAGGGACTCA CGGCTGTCCT 60

CGGAAGGGCC CCACC ATG GCG GGC CTG CTG CAT CTC GTT CTG CTC AGC ACC 111  
 Met Ala Gly Leu Leu His Leu Val Leu Leu Ser Thr  
 1 5 10

GCC CTG GGC GGC CTC CTG CGG CCG GCG GGG AGC GTG TTC CTG CCC CGG 159  
 Ala Leu Gly Leu Leu Arg Pro Ala Gly Ser Val Phe Leu Pro Arg  
 15 20 25

GAC CAG GCC CAC CGT GTC CTG CAG AGA GCC CGC AGG GCC AAC TCA TTC 207  
 Asp Gln Ala His Arg Val Leu Gln Arg Ala Arg Arg Ala Asn Ser Phe  
 30 35 40

113

TTG GAG GAG GTG AAG CAG GGA AAC CTG GAG CGA GAG TGC CTG GAG GAG	255
Leu Glu Glu Val Lys Gln Gly Asn Leu Glu Arg Glu Cys Leu Glu Glu	
45 50 55 60	
GCC TGC TCA CTA GAG GAG GCC CGC GAG GTC TTC GAG GAC GCA GAG CAG	303
Ala Cys Ser Leu Glu Ala Arg Glu Val Phe Glu Asp Ala Glu Gln	
65 70 75	
ACG GAT GAA TTC TGG AGT AAA TAC AAA GAT GGA GAC CAG TGT GAA GGC	351
Thr Asp Glu Phe Trp Ser Lys Tyr Lys Asp Gly Asp Gln Cys Glu Gly	
80 85 90	
CAC CCG TGC CTG AAT CAG GGC CAC TGT AAA GAC GGC ATC GGA GAC TAC	399
His Pro Cys Leu Asn Gln Gly His Cys Lys Asp Gly Ile Gly Asp Tyr	
95 100 105	
ACC TGC ACC TGT GCG GAA GGG TTT GAA GGC AAA AAC TGC GAG TTC TCC	447
Thr Cys Thr Cys Ala Glu Gly Phe Glu Gly Lys Asn Cys Glu Phe Ser	
110 115 120	
ACG CGT GAG ATC TGC AGC CTG GAC AAT GGA GGC TGC GAC CAG TTC TGC	495
Thr Arg Glu Ile Cys Ser Leu Asp Asn Gly Gly Cys Asp Gln Phe Cys	
125 130 135 140	
AGG GAG GAG CGC AGC GAG GTG CGG TGC TCC TGC GCG CAC GGC TAC GTG	543
Arg Glu Glu Arg Ser Glu Val Arg Cys Ser Cys Ala His Gly Tyr Val	
145 150 155	
CTG GGC GAC GAC AGC AAG TCC TGC GTG TCC ACA GAG CGC TTC CCC TGT	591
Leu Gly Asp Asp Ser Lys Ser Cys Val Ser Thr Glu Arg Phe Pro Cys	
160 165 170	
GGG AAG TTC ACG CAG GGA CGC AGC CGG CGG TGG GCC ATC CAC ACC AGC	639
Gly Lys Phe Thr Gln Gly Arg Ser Arg Arg Trp Ala Ile His Thr Ser	
175 180 185	
GAG GAC GCG CTT GAC GCC AGC GAG CTG GAG CAC TAC GAC CCT GCA GAC	687
Glu Asp Ala Leu Asp Ala Ser Glu Leu Glu His Tyr Asp Pro Ala Asp	
190 195 200	
CTG AGC CCC ACA GAG AGC TCC TTG GAC CTG CTG GGC CTC AAC AGG ACC	735
Leu Ser Pro Thr Glu Ser Ser Leu Asp Leu Leu Gly Leu Asn Arg Thr	
205 210 215 220	
GAG CCC AGC GCC GGG GAG GAC GGC AGC CAG GTG GTC CGG ATA GTG GGC	783
Glu Pro Ser Ala Gly Glu Asp Gly Ser Gln Val Val Arg Ile Val Gly	
225 230 235	
GGC AGG GAC TGC GCG GAG GGC GAG TGC CCA TGG CAG GCT CTG CTG GTC	831
Gly Arg Asp Cys Ala Glu Gly Glu Cys Pro Trp Gln Ala Leu Leu Val	
240 245 250	
AAC GAA GAG AAC GAG GGA TTC TGC GGG GGC ACC ATC CTG AAC GAG TTC	879
Asn Glu Glu Asn Glu Gly Phe Cys Gly Gly Thr Ile Leu Asn Glu Phe	
255 260 265	

TAC GTC CTC ACG GCT GCC CAC TGC CTG CAC CAG GCC AAG AGG TTC ACG	927
Tyr Val Leu Thr Ala Ala His Cys Leu His Gln Ala Lys Arg Phe Thr	
270 275 280	
 GTG AGG GTC GGC GAC CGG AAC ACA GAG CAG GAG GGC AAC GAG ATG	975
Val Arg Val Gly Asp Arg Asn Thr Glu Gln Glu Glu Gly Asn Glu Met	
285 290 295 300	
 GCA CAC GAG GTG GAG ATG ACT GTG AAG CAC AGC CGC TTT GTC AAG GAG	1023
Ala His Glu Val Glu Met Thr Val Lys His Ser Arg Phe Val Lys Glu	
305 310 315	
 ACC TAC GAC TTC GAC ATC GCG GTG CTG AGG CTC AAG ACG CCC ATC CGG	1071
Thr Tyr Asp Phe Asp Ile Ala Val Leu Arg Leu Lys Thr Pro Ile Arg	
320 325 330	
 TTC CGC CGG AAC GTG GCG CCC GCC TGC CTG CCC GAG AAG GAC TGG GCG	1119
Phe Arg Arg Asn Val Ala Pro Ala Cys Leu Pro Glu Lys Asp Trp Ala	
335 340 345	
 GAG GCC ACG CTG ATG ACC CAG AAG ACG GGC ATC GTC AGC GGC TTC GGG	1167
Glu Ala Thr Leu Met Thr Gln Lys Thr Gly Ile Val Ser Gly Phe Gly	
350 355 360	
 CGC ACG CAC GAG AAG GGC CGC CTG TCG TCC ACG CTC AAG ATG CTG GAG	1215
Arg Thr His Glu Lys Gly Arg Leu Ser Ser Thr Leu Lys Met Leu Glu	
365 370 375 380	
 GTG CCC TAC GTG GAC CGC AGC ACC TGT AAG CTG TCC AGC AGC TTC ACC	1263
Val Pro Tyr Val Asp Arg Ser Thr Cys Lys Leu Ser Ser Ser Phe Thr	
385 390 395	
 ATT ACG CCC AAC ATG TTC TGC GCC GGC TAC GAC ACC CAG CCC GAG GAC	1311
Ile Thr Pro Asn Met Phe Cys Ala Gly Tyr Asp Thr Gln Pro Glu Asp	
400 405 410	
 GCC TGC CAG GGC GAC AGT GGC GGC CCC CAC GTC ACC CGC TTC AAG GAC	1359
Ala Cys Gln Gly Asp Ser Gly Gly Pro His Val Thr Arg Phe Lys Asp	
415 420 425	
 ACC TAC TTC GTC ACA GGC ATC GTC AGC TGG GGA GAA GGG TGC GCG CGC	1407
Thr Tyr Phe Val Thr Gly Ile Val Ser Trp Gly Glu Gly Cys Ala Arg	
430 435 440	
 AAG GGC AAG TTC GGC GTC TAC ACC AAG GTC TCC AAC TTC CTC AAG TGG	1455
Lys Gly Lys Phe Gly Val Tyr Thr Lys Val Ser Asn Phe Leu Lys Trp	
445 450 455 460	
 ATC GAC AAG ATC ATG AAG GCC AGG GCA GGG GCC GCG GGC AGC CGC GGC	1503
Ile Asp Lys Ile Met Lys Ala Arg Ala Gly Ala Gly Ser Arg Gly	
465 470 475	
 CAC AGT GAA GCC CCT GCC ACC TGG ACG GTC CCG CCG CCC CTC CCC CTC	1551
His Ser Glu Ala Pro Ala Thr Trp Thr Val Pro Pro Pro Leu Pro Leu	
480 485 490	
 TAA	1554

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 492 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Ala Gly Leu Leu His Leu Val Leu Leu Ser Thr Ala Leu Gly Gly  
1 5 10 15

Leu Leu Arg Pro Ala Gly Ser Val Phe Leu Pro Arg Asp Gln Ala His  
20 25 30

Arg Val Leu Gln Arg Ala Arg Arg Ala Asn Ser Phe Leu Glu Glu Val  
35 40 45

Lys Gln Gly Asn Leu Glu Arg Glu Cys Leu Glu Glu Ala Cys Ser Leu  
50 55 60

Glu Glu Ala Arg Glu Val Phe Glu Asp Ala Glu Gln Thr Asp Glu Phe  
65 70 75 80

Trp Ser Lys Tyr Lys Asp Gly Asp Gln Cys Glu Gly His Pro Cys Leu  
85 90 95

Asn Gln Gly His Cys Lys Asp Gly Ile Gly Asp Tyr Thr Cys Thr Cys  
100 105 110

Ala Glu Gly Phe Glu Gly Lys Asn Cys Glu Phe Ser Thr Arg Glu Ile  
115 120 125

Cys Ser Leu Asp Asn Gly Gly Cys Asp Gln Phe Cys Arg Glu Glu Arg  
130 135 140

Ser Glu Val Arg Cys Ser Cys Ala His Gly Tyr Val Leu Gly Asp Asp  
145 150 155 160

Ser Lys Ser Cys Val Ser Thr Glu Arg Phe Pro Cys Gly Lys Phe Thr  
165 170 175

Gln Gly Arg Ser Arg Arg Trp Ala Ile His Thr Ser Glu Asp Ala Leu  
180 185 190

Asp Ala Ser Glu Leu Glu His Tyr Asp Pro Ala Asp Leu Ser Pro Thr  
195 200 205

Glu Ser Ser Leu Asp Leu Leu Gly Leu Asn Arg Thr Glu Pro Ser Ala  
210 215 220

Gly Glu Asp Gly Ser Gln Val Val Arg Ile Val Gly Gly Arg Asp Cys  
225 230 235 240

Ala Glu Gly Glu Cys Pro Trp Gln Ala Leu Leu Val Asn Glu Glu Asn  
245 250 255

Glu Gly Phe Cys Gly Gly Thr Ile Leu Asn Glu Phe Tyr Val Leu Thr  
 260 265 270  
 Ala Ala His Cys Leu His Gln Ala Lys Arg Phe Thr Val Arg Val Gly  
 275 280 285  
 Asp Arg Asn Thr Glu Gln Glu Glu Gly Asn Glu Met Ala His Glu Val  
 290 295 300  
 Glu Met Thr Val Lys His Ser Arg Phe Val Lys Glu Thr Tyr Asp Phe  
 305 310 315 320  
 Asp Ile Ala Val Leu Arg Leu Lys Thr Pro Ile Arg Phe Arg Arg Asn  
 325 330 335  
 Val Ala Pro Ala Cys Leu Pro Glu Lys Asp Trp Ala Glu Ala Thr Leu  
 340 345 350  
 Met Thr Gln Lys Thr Gly Ile Val Ser Gly Phe Gly Arg Thr His Glu  
 355 360 365  
 Lys Gly Arg Leu Ser Ser Thr Leu Lys Met Leu Glu Val Pro Tyr Val  
 370 375 380  
 Asp Arg Ser Thr Cys Lys Leu Ser Ser Ser Phe Thr Ile Thr Pro Asn  
 385 390 395 400  
 Met Phe Cys Ala Gly Tyr Asp Thr Gln Pro Glu Asp Ala Cys Gln Gly  
 405 410 415  
 Asp Ser Gly Gly Pro His Val Thr Arg Phe Lys Asp Thr Tyr Phe Val  
 420 425 430  
 Thr Gly Ile Val Ser Trp Gly Glu Gly Cys Ala Arg Lys Gly Lys Phe  
 435 440 445  
 Gly Val Tyr Thr Lys Val Ser Asn Phe Leu Lys Trp Ile Asp Lys Ile  
 450 455 460  
 Met Lys Ala Arg Ala Gly Ala Ala Gly Ser Arg Gly His Ser Glu Ala  
 465 470 475 480  
 Pro Ala Thr Trp Thr Val Pro Pro Pro Leu Pro Leu  
 485 490

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (synthetic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CGTCCTGGAT CCATCGAGGG TAGAATCCAG CGTACTCCAA AG

42

## (2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GCGAAGCTTG ATCACATGTC TCG

23

## (2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CGTCCTGGAT CCATCGAGGG TAGAATCCAG AAAACCCCTC AAAT

44

## (2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GCGAAGCTTA CATGTCTCGA TC

22

## (2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CCTGGATCCA TCGAGGGTAG GTTCCCAACC ATTCCCTTAT

40

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

CCGAAGCTTA GAAGCCACAG CTGCC

26

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CGTCCTGGAT CCATCGAGGG TAGGTACTCG CGGGAGAAG

39

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

CGACCGAAGC TTCAGAGTTC GTTGTG

26

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

119

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CGTCCTGGAT CCATCGAGGG TAGGGCTATC GACGCCCTA AG

42

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CGACCGAAGC TTATCGGCAG TGGGGCCCT

30

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CGACCGAAGC TTAGGCCTTG CAGGAGCGG

29

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

CGACCGAAGC TTACTTCTTG CATGACTTCC CG

32

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

120

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CGTCCTGGAT CCATCGAGGG TAGGGGCACC AACAAATGCC GG

42

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

CGACCGAAGC TTAGTCCAGG CTGCGGCAG

29

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

CGTCCTGGAT CCATCGAGGG TAGGGTGCCT CCACCCAGT G

41

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

CGACCGAAGC TTACTGGTCG CAGAGCTCG

29

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs

121

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

CCTTGATCAA TCGAGGGTAG GGGTGGTCAG TGCTCTCTGA ATAACG

46

(2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

CGCAAGCTTA CTTAAACTCA TAGCAGGTG

29

(2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 44 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

CGTCCTGGAT CCATCGAGGG TAGGGCGGTG AATTCCCTTT GCCG

44

(2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

CGACCGAAGC TTAGATGTGG CAGCCACGCT

30

(2) INFORMATION FOR SEQ ID NO: 23:

122

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 42 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

CGTCCTGGAT CCATCGAGGG TAGGGTGTCC AACTGCACGG CT

42

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

CGACCGAACG TTAGATGCTG CAGTCCTCCT

31

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 47 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

CGTCCTGGAT CCATCGAGGG TAGGAGTAAA TACAAAGATG GAGACCA

47

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

CGACCGAACG TTACCGAGGTG GCAGGGGCTT

30

## (2) INFORMATION FOR SEQ ID NO: 27:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 46 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

CTGCCTGGAT CCATCGAGGG TAGGAAAGTG TATCTCTCAT CAGAGTGCAA GACTGGGAAT GG 62

## (2) INFORMATION FOR SEQ ID NO: 28:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 33 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

CGACCGAAGC TTATTCACAC TCAAGAATGT CGC 33

## (2) INFORMATION FOR SEQ ID NO: 29:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 41 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

CTGCCTGGAT CCATCGAGGG TAGGGTCCAG GACTGCTACC AT 42

## (2) INFORMATION FOR SEQ ID NO: 30:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 31 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

CGACCGAAGC TTACGCTTCT GTTCCTGAGC A 31

## (2) INFORMATION FOR SEQ ID NO: 31:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

CCTGGATCCA TCGAGGGTAG GGTCTACCTC CAGACATCCT

40

## (2) INFORMATION FOR SEQ ID NO: 32:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

CCGAAGCTTC AAGCATTTC AAGATC

26

## (2) INFORMATION FOR SEQ ID NO: 33:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

CCTGGATCCA TCGAGGGTAG GGGCGAGCCA CCAACCCAG

39

## (2) INFORMATION FOR SEQ ID NO: 34:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

125

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

CCGAAGCTTA CACGATCCCG AACTG

25

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

CCGAGATCTA TCGAGGGTAG GCAGGTCAAA CTGCAGCA

38

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

GCCAAGCTTA ATTCAAGATCC TCTTCTGAG

29

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

Gly Ser Ile Glu Gly Arg  
1 5

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

Ile Glu Gly Arg  
1

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

Tyr Trp Thr Asp  
1

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

Ile Gln Gly Arg  
1

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

Ala Glu Gly Arg  
1

## (2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

Ala Gln Gly Arg

1

## (2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

Ile Cys Gly Arg

1

## (2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

Ala Cys Gly Arg

1

## (2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

Ile Met Gly Arg  
1

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Ala Met Gly Arg  
1

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

His His His His His His  
1 5

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

Met Gly Ser His His His His His His Gly Ser Ile Glu Gly Arg  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 119 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

Met Ser Arg Ser Val Ala Leu Ala Val Leu Ala Leu Leu Ser Leu Ser  
1 5 10 15

Gly Leu Glu Ala Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg  
20 25 30

His Pro Ala Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser  
35 40 45

Gly Phe His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu  
50 55 60

Arg Ile Glu Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp  
65 70 75 80

Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp  
85 90 95

Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile  
100 105 110

Val Lys Trp Asp Arg Asp Met  
115

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 119 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

Met Ala Arg Ser Val Thr Leu Val Phe Leu Val Leu Val Ser Leu Thr  
1 5 10 15

Gly Leu Tyr Ala Ile Gln Lys Thr Pro Gln Ile Gln Val Tyr Ser Arg  
20 25 30

His Pro Pro Glu Asn Gly Lys Pro Asn Ile Leu Asn Cys Tyr Val Thr  
35 40 45

Gln Phe His Pro Pro His Ile Glu Ile Gln Met Leu Lys Asn Gly Lys  
50 55 60

130

Lys	Ile	Pro	Lys	Val	Glu	Met	Ser	Asp	Met	Ser	Phe	Ser	Lys	Asp	Trp
65				70					75				80		
Ser	Phe	Tyr	Ile	Leu	Ala	His	Thr	Glu	Phe	Thr	Pro	Thr	Glu	Thr	Asp
	85						90					95			
Thr	Tyr	Ala	Cys	Arg	Val	Lys	His	Asp	Ser	Met	Ala	Glu	Pro	Lys	Thr
		100					105				110				
Val	Tyr	Trp	Asp	Arg	Asp	Met									
		115													

## (2) INFORMATION FOR SEQ ID NO: 51:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 217 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

Met	Ala	Thr	Gly	Ser	Arg	Thr	Ser	Leu	Leu	Leu	Ala	Phe	Gly	Leu	Leu
1				5					10					15	

Cys	Leu	Pro	Trp	Leu	Gln	Glu	Gly	Ser	Ala	Phe	Pro	Thr	Ile	Pro	Leu
	20				25							30			

Ser	Arg	Leu	Phe	Asp	Asn	Ala	Ser	Leu	Arg	Ala	His	Arg	Leu	His	Gln
	35				40						45				

Leu	Ala	Phe	Asp	Thr	Tyr	Gln	Glu	Phe	Glu	Glu	Ala	Tyr	Ile	Pro	Lys
	50				55					60					

Glu	Gln	Lys	Tyr	Ser	Phe	Leu	Gln	Asn	Pro	Gln	Thr	Ser	Leu	Cys	Phe
	65				70					75			80		

Ser	Glu	Ser	Ile	Pro	Thr	Pro	Ser	Asn	Arg	Glu	Glu	Thr	Gln	Gln	Lys
	85				90					95					

Ser	Asn	Leu	Glu	Leu	Leu	Arg	Ile	Ser	Leu	Leu	Leu	Ile	Gln	Ser	Trp
		100				105					110				

Leu	Glu	Pro	Val	Gln	Phe	Leu	Arg	Ser	Val	Phe	Ala	Asn	Ser	Leu	Val
	115				120						125				

Tyr	Gly	Ala	Ser	Asp	Ser	Asn	Val	Tyr	Asp	Leu	Leu	Lys	Asp	Leu	Glu
	130				135			140							

Glu	Gly	Ile	Gln	Thr	Leu	Met	Gly	Arg	Leu	Glu	Asp	Gly	Ser	Pro	Arg
	145				150				155			160			

Thr	Gly	Gln	Ile	Phe	Lys	Gln	Thr	Tyr	Ser	Lys	Phe	Asp	Thr	Asn	Ser
	165				170			175							

131

His	Asn	Asp	Asp	Ala	Leu	Leu	Lys	Asn	Tyr	Gly	Leu	Leu	Tyr	Cys	Phe
180							185						190		
Arg	Lys	Asp	Met	Asp	Lys	Val	Glu	Thr	Phe	Leu	Arg	Ile	Val	Gln	Cys
195						200					205				
Arg	Ser	Val	Glu	Gly	Ser	Cys	Gly	Phe							
210					215										

## (2) INFORMATION FOR SEQ ID NO: 52:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4544 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

Met	Leu	Thr	Pro	Pro	Leu	Leu	Leu	Leu	Leu	Pro	Leu	Leu	Ser	Ala	Leu
1					5					10				15	

Val	Ala	Ala	Ala	Ile	Asp	Ala	Pro	Lys	Thr	Cys	Ser	Pro	Lys	Gln	Phe
				20				25				30			

Ala	Cys	Arg	Asp	Gln	Ile	Thr	Cys	Ile	Ser	Lys	Gly	Trp	Arg	Cys	Asp
				35				40				45			

Gly	Glu	Arg	Asp	Cys	Pro	Asp	Gly	Ser	Asp	Glu	Ala	Pro	Glu	Ile	Cys
				50			55			60					

Pro	Gln	Ser	Lys	Ala	Gln	Arg	Cys	Gln	Pro	Asn	Glu	His	Asn	Cys	Leu
65					70				75			80			

Gly	Thr	Glu	Leu	Cys	Val	Pro	Met	Ser	Arg	Leu	Cys	Asn	Gly	Val	Gln
					85			90				95			

Asp	Cys	Met	Asp	Gly	Ser	Asp	Glu	Gly	Pro	His	Cys	Arg	Glu	Leu	Gln
					100			105			110				

Gly	Asn	Cys	Ser	Arg	Leu	Gly	Cys	Gln	His	His	Cys	Val	Pro	Thr	Leu
					115			120			125				

Asp	Gly	Pro	Thr	Cys	Tyr	Cys	Asn	Ser	Ser	Phe	Gln	Leu	Gln	Ala	Asp
					130			135			140				

Gly	Lys	Thr	Cys	Lys	Asp	Phe	Asp	Glu	Cys	Ser	Val	Tyr	Gly	Thr	Cys
					145			150			155		160		

Ser	Gln	Leu	Cys	Thr	Asn	Thr	Asp	Gly	Ser	Phe	Ile	Cys	Gly	Cys	Val
					165			170			175				

Glu	Gly	Tyr	Leu	Leu	Gln	Pro	Asp	Asn	Arg	Ser	Cys	Lys	Ala	Lys	Asn
					180			185			190				

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn  
195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro  
210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu  
225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu  
245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr  
260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp  
275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile  
290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu  
305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys  
325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp  
340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe  
355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala  
370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly  
385 390 395 400

Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu  
405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn  
420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr  
435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile  
450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn  
465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala  
485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu  
500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu  
515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly  
530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn  
545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala  
565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu  
580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala  
595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys  
610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys  
625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp  
645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys  
660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His  
675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu  
690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr  
705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val  
725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly  
740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu  
755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser  
770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln  
785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser  
805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp  
820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr  
835 840 845

Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser  
850 855 860

Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu  
865 870 875 880

Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro  
885 890 895

Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp  
900 905 910

Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn  
915 920 925

Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala  
930 935 940

Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp  
945 950 955 960

Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys  
965 970 975

Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn Gly Arg Cys Ile Asn Ile  
980 985 990

Asn Trp Arg Cys Asp Asn Asp Asn Cys Gly Asp Asn Ser Asp Glu  
995 1000 1005

Ala Gly Cys Ser His Ser Cys Ser Ser Thr Gln Phe Lys Cys Asn Ser  
1010 1015 1020

Gly Arg Cys Ile Pro Glu His Trp Thr Cys Asp Gly Asp Asn Asp Cys  
1025 1030 1035 1040

Gly Asp Tyr Ser Asp Glu Thr His Ala Asn Cys Thr Asn Gln Ala Thr  
1045 1050 1055

Arg Pro Pro Gly Gly Cys His Thr Asp Glu Phe Gln Cys Arg Leu Asp  
1060 1065 1070

Gly Leu Cys Ile Pro Leu Arg Trp Arg Cys Asp Gly Asp Thr Asp Cys  
1075 1080 1085

Met Asp Ser Ser Asp Glu Lys Ser Cys Glu Gly Val Thr His Val Cys  
1090 1095 1100

135

Asp Pro Ser Val Lys Phe Gly Cys Lys Asp Ser Ala Arg Cys Ile Ser  
1105 1110 1115 1120

Lys Ala Trp Val Cys Asp Gly Asp Asn Asp Cys Glu Asp Asn Ser Asp  
1125 1130 1135

Glu Glu Asn Cys Glu Ser Leu Ala Cys Arg Pro Pro Ser His Pro Cys  
1140 1145 1150

Ala Asn Asn Thr Ser Val Cys Leu Pro Pro Asp Lys Leu Cys Asp Gly  
1155 1160 1165

Asn Asp Asp Cys Gly Asp Gly Ser Asp Glu Gly Glu Leu Cys Asp Gln  
1170 1175 1180

Cys Ser Leu Asn Asn Gly Gly Cys Ser His Asn Cys Ser Val Ala Pro  
1185 1190 1195 1200

Gly Glu Gly Ile Val Cys Ser Cys Pro Leu Gly Met Glu Leu Gly Pro  
1205 1210 1215

Asp Asn His Thr Cys Gln Ile Gln Ser Tyr Cys Ala Lys His Leu Lys  
1220 1225 1230

Cys Ser Gln Lys Cys Asp Gln Asn Lys Phe Ser Val Lys Cys Ser Cys  
1235 1240 1245

Tyr Glu Gly Trp Val Leu Glu Pro Asp Gly Glu Ser Cys Arg Ser Leu  
1250 1255 1260

Asp Pro Phe Lys Pro Phe Ile Ile Phe Ser Asn Arg His Glu Ile Arg  
1265 1270 1275 1280

Arg Ile Asp Leu His Lys Gly Asp Tyr Ser Val Leu Val Pro Gly Leu  
1285 1290 1295

Arg Asn Thr Ile Ala Leu Asp Phe His Leu Ser Gln Ser Ala Leu Tyr  
1300 1305 1310

Trp Thr Asp Val Val Glu Asp Lys Ile Tyr Arg Gly Lys Leu Leu Asp  
1315 1320 1325

Asn Gly Ala Leu Thr Ser Phe Glu Val Val Ile Gln Tyr Gly Leu Ala  
1330 1335 1340

Thr Pro Glu Gly Leu Ala Val Asp Trp Ile Ala Gly Asn Ile Tyr Trp  
1345 1350 1355 1360

Val Glu Ser Asn Leu Asp Gln Ile Glu Val Ala Lys Leu Asp Gly Thr  
1365 1370 1375

Leu Arg Thr Thr Leu Leu Ala Gly Asp Ile Glu His Pro Arg Ala Ile  
1380 1385 1390

Ala Leu Asp Pro Arg Asp Gly Ile Leu Phe Trp Thr Asp Trp Asp Ala  
1395 1400 1405

Ser Leu Pro Arg Ile Glu Ala Ala Ser Met Ser Gly Ala Gly Arg Arg  
1410 1415 1420

Thr Val His Arg Glu Thr Gly Ser Gly Gly Trp Pro Asn Gly Leu Thr  
1425 1430 1435 1440

Val Asp Tyr Leu Glu Lys Arg Ile Leu Trp Ile Asp Ala Arg Ser Asp  
1445 1450 1455

Ala Ile Tyr Ser Ala Arg Tyr Asp Gly Ser Gly His Met Glu Val Leu  
1460 1465 1470

Arg Gly His Glu Phe Leu Ser His Pro Phe Ala Val Thr Leu Tyr Gly  
1475 1480 1485

Gly Glu Val Tyr Trp Thr Asp Trp Arg Thr Asn Thr Leu Ala Lys Ala  
1490 1495 1500

Asn Lys Trp Thr Gly His Asn Val Thr Val Val Gln Arg Thr Asn Thr  
1505 1510 1515 1520

Gln Pro Phe Asp Leu Gln Val Tyr His Pro Ser Arg Gln Pro Met Ala  
1525 1530 1535

Pro Asn Pro Cys Glu Ala Asn Gly Gly Gln Gly Pro Cys Ser His Leu  
1540 1545 1550

Cys Leu Ile Asn Tyr Asn Arg Thr Val Ser Cys Ala Cys Pro His Leu  
1555 1560 1565

Met Lys Leu His Lys Asp Asn Thr Thr Cys Tyr Glu Phe Lys Lys Phe  
1570 1575 1580

Leu Leu Tyr Ala Arg Gln Met Glu Ile Arg Gly Val Asp Leu Asp Ala  
1585 1590 1595 1600

Pro Tyr Tyr Asn Tyr Ile Ile Ser Phe Thr Val Pro Asp Ile Asp Asn  
1605 1610 1615

Val Thr Val Leu Asp Tyr Asp Ala Arg Glu Gln Arg Val Tyr Trp Ser  
1620 1625 1630

Asp Val Arg Thr Gln Ala Ile Lys Arg Ala Phe Ile Asn Gly Thr Gly  
1635 1640 1645

Val Glu Thr Val Val Ser Ala Asp Leu Pro Asn Ala His Gly Leu Ala  
1650 1655 1660

Val Asp Trp Val Ser Arg Asn Leu Phe Trp Thr Ser Tyr Asp Thr Asn  
1665 1670 1675 1680

Lys Lys Gln Ile Asn Val Ala Arg Leu Asp Gly Ser Phe Lys Asn Ala  
1685 1690 1695

Val Val Gln Gly Leu Glu Gln Pro His Gly Leu Val Val His Pro Leu  
1700 1705 1710

Arg Gly Lys Leu Tyr Trp Thr Asp Gly Asp Asn Ile Ser Met Ala Asn  
1715 1720 1725

Met Asp Gly Ser Asn Arg Thr Leu Leu Phe Ser Gly Gln Lys Gly Pro  
1730 1735 1740

Val Gly Leu Ala Ile Asp Phe Pro Glu Ser Lys Leu Tyr Trp Ile Ser  
1745 1750 1755 1760

Ser Gly Asn His Thr Ile Asn Arg Cys Asn Leu Asp Gly Ser Gly Leu  
1765 1770 1775

Glu Val Ile Asp Ala Met Arg Ser Gln Leu Gly Lys Ala Thr Ala Leu  
1780 1785 1790

Ala Ile Met Gly Asp Lys Leu Trp Trp Ala Asp Gln Val Ser Glu Lys  
1795 1800 1805

Met Gly Thr Cys Ser Lys Ala Asp Gly Ser Gly Ser Val Val Leu Arg  
1810 1815 1820

Asn Ser Thr Thr Leu Val Met His Met Lys Val Tyr Asp Glu Ser Ile  
1825 1830 1835 1840

Gln Leu Asp His Lys Gly Thr Asn Pro Cys Ser Val Asn Asn Gly Asp  
1845 1850 1855

Cys Ser Gln Leu Cys Leu Pro Thr Ser Glu Thr Thr Arg Ser Cys Met  
1860 1865 1870

Cys Thr Ala Gly Tyr Ser Leu Arg Ser Gly Gln Gln Ala Cys Glu Gly  
1875 1880 1885

Val Gly Ser Phe Leu Leu Tyr Ser Val His Glu Gly Ile Arg Gly Ile  
1890 1895 1900

Pro Leu Asp Pro Asn Asp Lys Ser Asp Ala Leu Val Pro Val Ser Gly  
1905 1910 1915 1920

Thr Ser Leu Ala Val Gly Ile Asp Phe His Ala Glu Asn Asp Thr Ile  
1925 1930 1935

Tyr Trp Val Asp Met Gly Leu Ser Thr Ile Ser Arg Ala Lys Arg Asp  
1940 1945 1950

Gln Thr Trp Arg Glu Asp Val Val Thr Asn Gly Ile Gly Arg Val Glu  
1955 1960 1965

Gly Ile Ala Val Asp Trp Ile Ala Gly Asn Ile Tyr Trp Thr Asp Gln  
1970 1975 1980

Gly Phe Asp Val Ile Glu Val Ala Arg Leu Asn Gly Ser Phe Arg Tyr  
1985 1990 1995 2000

Val Val Ile Ser Gln Gly Leu Asp Lys Pro Arg Ala Ile Thr Val His  
2005 2010 2015

Pro Glu Lys Gly Tyr Leu Phe Trp Thr Glu Trp Gly Gln Tyr Pro Arg  
2020 2025 2030

Ile Glu Arg Ser Arg Leu Asp Gly Thr Glu Arg Val Val Leu Val Asn  
2035 2040 2045

Val Ser Ile Ser Trp Pro Asn Gly Ile Ser Val Asp Tyr Gln Asp Gly  
2050 2055 2060

Lys Leu Tyr Trp Cys Asp Ala Arg Thr Asp Lys Ile Glu Arg Ile Asp  
2065 2070 2075 2080

Leu Glu Thr Gly Glu Asn Arg Glu Val Val Leu Ser Ser Asn Asn Met  
2085 2090 2095

Asp Met Phe Ser Val Ser Val Phe Glu Asp Phe Ile Tyr Trp Ser Asp  
2100 2105 2110

Arg Thr His Ala Asn Gly Ser Ile Lys Arg Gly Ser Lys Asp Asn Ala  
2115 2120 2125

Thr Asp Ser Val Pro Leu Arg Thr Gly Ile Gly Val Gln Leu Lys Asp  
2130 2135 2140

Ile Lys Val Phe Asn Arg Asp Arg Gln Lys Gly Thr Asn Val Cys Ala  
2145 2150 2155 2160

Val Ala Asn Gly Gly Cys Gln Gln Leu Cys Leu Tyr Arg Gly Arg Gly  
2165 2170 2175

Gln Arg Ala Cys Ala Cys Ala His Gly Met Leu Ala Glu Asp Gly Ala  
2180 2185 2190

Ser Cys Arg Glu Tyr Ala Gly Tyr Leu Leu Tyr Ser Glu Arg Thr Ile  
2195 2200 2205

Leu Lys Ser Ile His Leu Ser Asp Glu Arg Asn Leu Asn Ala Pro Val  
2210 2215 2220

Gln Pro Phe Glu Asp Pro Glu His Met Lys Asn Val Ile Ala Leu Ala  
2225 2230 2235 2240

Phe Asp Tyr Arg Ala Gly Thr Ser Pro Gly Thr Pro Asn Arg Ile Phe  
2245 2250 2255

Phe Ser Asp Ile His Phe Gly Asn Ile Gln Gln Ile Asn Asp Asp Gly  
2260 2265 2270

Ser Arg Arg Ile Thr Ile Val Glu Asn Val Gly Ser Val Glu Gly Leu  
2275 2280 2285

Ala Tyr His Arg Gly Trp Asp Thr Leu Tyr Trp Thr Ser Tyr Thr Thr  
2290 2295 2300

Ser Thr Ile Thr Arg His Thr Val Asp Gln Thr Arg Pro Gly Ala Phe  
2305 2310 2315 2320

139

Glu Arg Glu Thr Val Ile Thr Met Ser Gly Asp Asp His Pro Arg Ala  
2325 2330 2335

Phe Val Leu Asp Glu Cys Gln Asn Leu Met Phe Trp Thr Asn Trp Asn  
2340 2345 2350

Glu Gln His Pro Ser Ile Met Arg Ala Ala Leu Ser Gly Ala Asn Val  
2355 2360 2365

Leu Thr Leu Ile Glu Lys Asp Ile Arg Thr Pro Asn Gly Leu Ala Ile  
2370 2375 2380

Asp His Arg Ala Glu Lys Leu Tyr Phe Ser Asp Ala Thr Leu Asp Lys  
2385 2390 2395 2400

Ile Glu Arg Cys Glu Tyr Asp Gly Ser His Arg Tyr Val Ile Leu Lys  
2405 2410 2415

Ser Glu Pro Val His Pro Phe Gly Leu Ala Val Tyr Gly Glu His Ile  
2420 2425 2430

Phe Trp Thr Asp Trp Val Arg Arg Ala Val Gln Arg Ala Asn Lys His  
2435 2440 2445

Val Gly Ser Asn Met Lys Leu Leu Arg Val Asp Ile Pro Gln Gln Pro  
2450 2455 2460

Met Gly Ile Ile Ala Val Ala Asn Asp Thr Asn Ser Cys Glu Leu Ser  
2465 2470 2475 2480

Pro Cys Arg Ile Asn Asn Gly Gly Cys Gln Asp Leu Cys Leu Leu Thr  
2485 2490 2495

His Gln Gly His Val Asn Cys Ser Cys Arg Gly Arg Ile Leu Gln  
2500 2505 2510

Asp Asp Leu Thr Cys Arg Ala Val Asn Ser Ser Cys Arg Ala Gln Asp  
2515 2520 2525

Glu Phe Glu Cys Ala Asn Gly Glu Cys Ile Asn Phe Ser Leu Thr Cys  
2530 2535 2540

Asp Gly Val Pro His Cys Lys Asp Lys Ser Asp Glu Lys Pro Ser Tyr  
2545 2550 2555 2560

Cys Asn Ser Arg Arg Cys Lys Lys Thr Phe Arg Gln Cys Ser Asn Gly  
2565 2570 2575

Arg Cys Val Ser Asn Met Leu Trp Cys Asn Gly Ala Asp Asp Cys Gly  
2580 2585 2590

Asp Gly Ser Asp Glu Ile Pro Cys Asn Lys Thr Ala Cys Gly Val Gly  
2595 2600 2605

Glu Phe Arg Cys Arg Asp Gly Thr Cys Ile Gly Asn Ser Ser Arg Cys  
2610 2615 2620

140

Asn Gln Phe Val Asp Cys Glu Asp Ala Ser Asp Glu Met Asn Cys Ser  
2625 2630 2635 2640

Ala Thr Asp Cys Ser Ser Tyr Phe Arg Leu Gly Val Lys Gly Val Leu  
2645 2650 2655

Phe Gln Pro Cys Glu Arg Thr Ser Leu Cys Tyr Ala Pro Ser Trp Val  
2660 2665 2670

Cys Asp Gly Ala Asn Asp Cys Gly Asp Tyr Ser Asp Glu Arg Asp Cys  
2675 2680 2685

Pro Gly Val Lys Arg Pro Arg Cys Pro Leu Asn Tyr Phe Ala Cys Pro  
2690 2695 2700

Ser Gly Arg Cys Ile Pro Met Ser Trp Thr Cys Asp Lys Glu Asp Asp  
2705 2710 2715 2720

Cys Glu His Gly Glu Asp Glu Thr His Cys Asn Lys Phe Cys Ser Glu  
2725 2730 2735

Ala Gln Phe Glu Cys Gln Asn His Arg Cys Ile Ser Lys Gln Trp Leu  
2740 2745 2750

Cys Asp Gly Ser Asp Asp Cys Gly Asp Gly Ser Asp Glu Ala Ala His  
2755 2760 2765

Cys Glu Gly Lys Thr Cys Gly Pro Ser Ser Phe Ser Cys Pro Gly Thr  
2770 2775 2780

His Val Cys Val Pro Glu Arg Trp Leu Cys Asp Gly Asp Lys Asp Cys  
2785 2790 2795 2800

Ala Asp Gly Ala Asp Glu Ser Ile Ala Ala Gly Cys Leu Tyr Asn Ser  
2805 2810 2815

Thr Cys Asp Asp Arg Glu Phe Met Cys Gln Asn Arg Gln Cys Ile Pro  
2820 2825 2830

Lys His Phe Val Cys Asp His Asp Arg Asp Cys Ala Asp Gly Ser Asp  
2835 2840 2845

Glu Ser Pro Glu Cys Glu Tyr Pro Thr Cys Gly Pro Ser Glu Phe Arg  
2850 2855 2860

Cys Ala Asn Gly Arg Cys Leu Ser Ser Arg Gln Trp Glu Cys Asp Gly  
2865 2870 2875 2880

Glu Asn Asp Cys His Asp Gln Ser Asp Glu Ala Pro Lys Asn Pro His  
2885 2890 2895

Cys Thr Ser Pro Glu His Lys Cys Asn Ala Ser Ser Gln Phe Leu Cys  
2900 2905 2910

Ser Ser Gly Arg Cys Val Ala Glu Ala Leu Leu Cys Asn Gly Gln Asp  
2915 2920 2925

Asp Cys Gly Asp Ser Ser Asp Glu Arg Gly Cys His Ile Asn Glu Cys  
 2930 2935 2940

Leu Ser Arg Lys Leu Ser Gly Cys Ser Gln Asp Cys Glu Asp Leu Lys  
 2945 2950 2955 2960

Ile Gly Phe Lys Cys Arg Cys Arg Pro Gly Phe Arg Leu Lys Asp Asp  
 2965 2970 2975

Gly Arg Thr Cys Ala Asp Val Asp Glu Cys Ser Thr Thr Phe Pro Cys  
 2980 2985 2990

Ser Gln Arg Cys Ile Asn Thr His Gly Ser Tyr Lys Cys Leu Cys Val  
 2995 3000 3005

Glu Gly Tyr Ala Pro Arg Gly Gly Asp Pro His Ser Cys Lys Ala Val  
 3010 3015 3020

Thr Asp Glu Glu Pro Phe Leu Ile Phe Ala Asn Arg Tyr Tyr Leu Arg  
 3025 3030 3035 3040

Lys Leu Asn Leu Asp Gly Ser Asn Tyr Thr Leu Leu Lys Gln Gly Leu  
 3045 3050 3055

Asn Asn Ala Val Ala Leu Asp Phe Asp Tyr Arg Glu Gln Met Ile Tyr  
 3060 3065 3070

Trp Thr Asp Val Thr Thr Gln Gly Ser Met Ile Arg Arg Met His Leu  
 3075 3080 3085

Asn Gly Ser Asn Val Gln Val Leu His Arg Thr Gly Leu Ser Asn Pro  
 3090 3095 3100

Asp Gly Leu Ala Val Asp Trp Val Gly Gly Asn Leu Tyr Trp Cys Asp  
 3105 3110 3115 3120

Lys Gly Arg Asp Thr Ile Glu Val Ser Lys Leu Asn Gly Ala Tyr Arg  
 3125 3130 3135

Thr Val Leu Val Ser Ser Gly Leu Arg Glu Pro Arg Ala Leu Val Val  
 3140 3145 3150

Asp Val Gln Asn Gly Tyr Leu Tyr Trp Thr Asp Trp Gly Asp His Ser  
 3155 3160 3165

Leu Ile Gly Arg Ile Gly Met Asp Gly Ser Ser Arg Ser Val Ile Val  
 3170 3175 3180

Asp Thr Lys Ile Thr Trp Pro Asn Gly Leu Thr Leu Asp Tyr Val Thr  
 3185 3190 3195 3200

Glu Arg Ile Tyr Trp Ala Asp Ala Arg Glu Asp Tyr Ile Glu Phe Ala  
 3205 3210 3215

Ser Leu Asp Gly Ser Asn Arg His Val Val Leu Ser Gln Asp Ile Pro  
 3220 3225 3230

His Ile Phe Ala Leu Thr Leu Phe Glu Asp Tyr Val Tyr Trp Thr Asp  
3235 3240 3245

Trp Glu Thr Lys Ser Ile Asn Arg Ala His Lys Thr Thr Gly Thr Asn  
3250 3255 3260

Lys Thr Leu Leu Ile Ser Thr Leu His Arg Pro Met Asp Leu His Val  
3265 3270 3275 3280

Phe His Ala Leu Arg Gln Pro Asp Val Pro Asn His Pro Cys Lys Val  
3285 3290 3295

Asn Asn Gly Gly Cys Ser Asn Leu Cys Leu Leu Ser Pro Gly Gly  
3300 3305 3310

His Lys Cys Ala Cys Pro Thr Asn Phe Tyr Leu Gly Ser Asp Gly Arg  
3315 3320 3325

Thr Cys Val Ser Asn Cys Thr Ala Ser Gln Phe Val Cys Lys Asn Asp  
3330 3335 3340

Lys Cys Ile Pro Phe Trp Trp Lys Cys Asp Thr Glu Asp Asp Cys Gly  
3345 3350 3355 3360

Asp His Ser Asp Glu Pro Pro Asp Cys Pro Glu Phe Lys Cys Arg Pro  
3365 3370 3375

Gly Gln Phe Gln Cys Ser Thr Gly Ile Cys Thr Asn Pro Ala Phe Ile  
3380 3385 3390

Cys Asp Gly Asp Asn Asp Cys Gln Asp Asn Ser Asp Glu Ala Asn Cys  
3395 3400 3405

Asp Ile His Val Cys Leu Pro Ser Gln Phe Lys Cys Thr Asn Thr Asn  
3410 3415 3420

Arg Cys Ile Pro Gly Ile Phe Arg Cys Asn Gly Gln Asp Asn Cys Gly  
3425 3430 3435 3440

Asp Gly Glu Asp Glu Arg Asp Cys Pro Glu Val Thr Cys Ala Pro Asn  
3445 3450 3455

Gln Phe Gln Cys Ser Ile Thr Lys Arg Cys Ile Pro Arg Val Trp Val  
3460 3465 3470

Cys Asp Arg Asp Asn Asp Cys Val Asp Gly Ser Asp Glu Pro Ala Asn  
3475 3480 3485

Cys Thr Gln Met Thr Cys Gly Val Asp Glu Phe Arg Cys Lys Asp Ser  
3490 3495 3500

Gly Arg Cys Ile Pro Ala Arg Trp Lys Cys Asp Gly Glu Asp Asp Cys  
3505 3510 3515 3520

Gly Asp Gly Ser Asp Glu Pro Lys Glu Glu Cys Asp Glu Arg Thr Cys  
3525 3530 3535

Glu Pro Tyr Gln Phe Arg Cys Lys Asn Asn Arg Cys Val Pro Gly Arg  
3540 3545 3550

Trp Gln Cys Asp Tyr Asp Asn Asp Cys Gly Asp Asn Ser Asp Glu Glu  
3555 3560 3565

Ser Cys Thr Pro Arg Pro Cys Ser Glu Ser Glu Phe Ser Cys Ala Asn  
3570 3575 3580

Gly Arg Cys Ile Ala Gly Arg Trp Lys Cys Asp Gly Asp His Asp Cys  
3585 3590 3595 3600

Ala Asp Gly Ser Asp Glu Lys Asp Cys Thr Pro Arg Cys Asp Met Asp  
3605 3610 3615

Gln Phe Gln Cys Lys Ser Gly His Cys Ile Pro Leu Arg Trp Arg Cys  
3620 3625 3630

Asp Ala Asp Ala Asp Cys Met Asp Gly Ser Asp Glu Glu Ala Cys Gly  
3635 3640 3645

Thr Gly Val Arg Thr Cys Pro Leu Asp Glu Phe Gln Cys Asn Asn Thr  
3650 3655 3660

Leu Cys Lys Pro Leu Ala Trp Lys Cys Asp Gly Glu Asp Asp Cys Gly  
3665 3670 3675 3680

Asp Asn Ser Asp Glu Asn Pro Glu Glu Cys Ala Arg Phe Val Cys Pro  
3685 3690 3695

Pro Asn Arg Pro Phe Arg Cys Lys Asn Asp Arg Val Cys Leu Trp Ile  
3700 3705 3710

Gly Arg Gln Cys Asp Gly Thr Asp Asn Cys Gly Asp Gly Thr Asp Glu  
3715 3720 3725

Glu Asp Cys Glu Pro Pro Thr Ala His Thr Thr His Cys Lys Asp Lys  
3730 3735 3740

Lys Glu Phe Leu Cys Arg Asn Gln Arg Cys Leu Ser Ser Ser Leu Arg  
3745 3750 3755 3760

Cys Asn Met Phe Asp Asp Cys Gly Asp Gly Ser Asp Glu Glu Asp Cys  
3765 3770 3775

Ser Ile Asp Pro Lys Leu Thr Ser Cys Ala Thr Asn Ala Ser Ile Cys  
3780 3785 3790

Gly Asp Glu Ala Arg Cys Val Arg Thr Glu Lys Ala Ala Tyr Cys Ala  
3795 3800 3805

Cys Arg Ser Gly Phe His Thr Val Pro Gly Gln Pro Gly Cys Gln Asp  
3810 3815 3820

Ile Asn Glu Cys Leu Arg Phe Gly Thr Cys Ser Gln Leu Cys Asn Asn  
3825 3830 3835 3840

Thr Lys Gly Gly His Leu Cys Ser Cys Ala Arg Asn Phe Met Lys Thr  
3845 3850 3855

His Asn Thr Cys Lys Ala Glu Gly Ser Glu Tyr Gln Val Leu Tyr Ile  
3860 3865 3870

Ala Asp Asp Asn Glu Ile Arg Ser Leu Phe Pro Gly His Pro His Ser  
3875 3880 3885

Ala Tyr Glu Gln Ala Phe Gln Gly Asp Glu Ser Val Arg Ile Asp Ala  
3890 3895 3900

Met Asp Val His Val Lys Ala Gly Arg Val Tyr Trp Thr Asn Trp His  
3905 3910 3915 3920

Thr Gly Thr Ile Ser Tyr Arg Ser Leu Pro Pro Ala Ala Pro Pro Thr  
3925 3930 3935

Thr Ser Asn Arg His Arg Arg Gln Ile Asp Arg Gly Val Thr His Leu  
3940 3945 3950

Asn Ile Ser Gly Leu Lys Met Pro Arg Gly Ile Ala Ile Asp Trp Val  
3955 3960 3965

Ala Gly Asn Val Tyr Trp Thr Asp Ser Gly Arg Asp Val Ile Glu Val  
3970 3975 3980

Ala Gln Met Lys Gly Glu Asn Arg Lys Thr Leu Ile Ser Gly Met Ile  
3985 3990 3995 4000

Asp Glu Pro His Ala Ile Val Val Asp Pro Leu Arg Gly Thr Met Tyr  
4005 4010 4015

Trp Ser Asp Trp Gly Asn His Pro Lys Ile Glu Thr Ala Ala Met Asp  
4020 4025 4030

Gly Thr Leu Arg Glu Thr Leu Val Gln Asp Asn Ile Gln Trp Pro Thr  
4035 4040 4045

Gly Leu Ala Val Asp Tyr His Asn Glu Arg Leu Tyr Trp Ala Asp Ala  
4050 4055 4060

Lys Leu Ser Val Ile Gly Ser Ile Arg Leu Asn Gly Thr Asp Pro Ile  
4065 4070 4075 4080

Val Ala Ala Asp Ser Lys Arg Gly Leu Ser His Pro Phe Ser Ile Asp  
4085 4090 4095

Val Phe Glu Asp Tyr Ile Tyr Gly Val Thr Tyr Ile Asn Asn Arg Val  
4100 4105 4110

Phe Lys Ile His Lys Phe Gly His Ser Pro Leu Val Asn Leu Thr Gly  
4115 4120 4125

Gly Leu Ser His Ala Ser Asp Val Val Leu Tyr His Gln His Lys Gln  
4130 4135 4140

145

Pro Glu Val Thr Asn Pro Cys Asp Arg Lys Lys Cys Glu Trp Leu Cys  
4145 4150 4155 4160

Leu Leu Ser Pro Ser Gly Pro Val Cys Thr Cys Pro Asn Gly Lys Arg  
4165 4170 4175

Leu Asp Asn Gly Thr Cys Val Pro Val Pro Ser Pro Thr Pro Pro Pro  
4180 4185 4190

Asp Ala Pro Arg Pro Gly Thr Cys Asn Leu Gln Cys Phe Asn Gly Gly  
4195 4200 4205

Ser Cys Phe Leu Asn Ala Arg Arg Gln Pro Lys Cys Arg Cys Gln Pro  
4210 4215 4220

Arg Tyr Thr Gly Asp Lys Cys Glu Leu Asp Gln Cys Trp Glu His Cys  
4225 4230 4235 4240

Arg Asn Gly Gly Thr Cys Ala Ala Ser Pro Ser Gly Met Pro Thr Cys  
4245 4250 4255

Arg Cys Pro Thr Gly Phe Thr Gly Pro Lys Cys Thr Gln Gln Val Cys  
4260 4265 4270

Ala Gly Tyr Cys Ala Asn Asn Ser Thr Cys Thr Val Asn Gln Gly Asn  
4275 4280 4285

Gln Pro Gln Cys Arg Cys Leu Pro Gly Phe Leu Gly Asp Arg Cys Gln  
4290 4295 4300

Tyr Arg Gln Cys Ser Gly Tyr Cys Glu Asn Phe Gly Thr Cys Gln Met  
4305 4310 4315 4320

Ala Ala Asp Gly Ser Arg Gln Cys Arg Cys Thr Ala Tyr Phe Glu Gly  
4325 4330 4335

Ser Arg Cys Glu Val Asn Lys Cys Ser Arg Cys Leu Glu Gly Ala Cys  
4340 4345 4350

Val Val Asn Lys Gln Ser Gly Asp Val Thr Cys Asn Cys Thr Asp Gly  
4355 4360 4365

Arg Val Ala Pro Ser Cys Leu Thr Cys Val Gly His Cys Ser Asn Gly  
4370 4375 4380

Gly Ser Cys Thr Met Asn Ser Lys Met Met Pro Glu Cys Gln Cys Pro  
4385 4390 4395 4400

Pro His Met Thr Gly Pro Arg Cys Glu Glu His Val Phe Ser Gln Gln  
4405 4410 4415

Gln Pro Gly His Ile Ala Ser Ile Leu Ile Pro Leu Leu Leu Leu  
4420 4425 4430

Leu Leu Val Leu Val Ala Gly Val Val Phe Trp Tyr Lys Arg Arg Val  
4435 4440 4445

146

Gln Gly Ala Lys Gly Phe Gln His Gln Arg Met Thr Asn Gly Ala Met  
 4450 4455 4460

Asn Val Glu Ile Gly Asn Pro Thr Tyr Lys Met Tyr Glu Gly Gly Glu  
 4465 4470 4475 4480

Pro Asp Asp Val Gly Gly Leu Leu Asp Ala Asp Phe Ala Leu Asp Pro  
 4485 4490 4495

Asp Lys Pro Thr Asn Phe Thr Asn Pro Val Tyr Ala Thr Leu Tyr Met  
 4500 4505 4510

Gly Gly His Gly Ser Arg His Ser Leu Ala Ser Thr Asp Glu Lys Arg  
 4515 4520 4525

Glu Leu Leu Gly Arg Gly Pro Glu Asp Glu Ile Gly Asp Pro Leu Ala  
 4530 4535 4540

## (2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 487 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

Met Ala Gly Leu Leu His Leu Val Leu Leu Ser Thr Ala Leu Gly Gly  
 1 5 10 15

Leu Leu Arg Pro Ala Gly Ser Val Phe Leu Pro Arg Asp Gln Ala His  
 20 25 30

Arg Val Leu Gln Arg Ala Arg Arg Ala Asn Ser Phe Leu Glu Glu Val  
 35 40 45

Lys Gln Gly Asn Leu Glu Arg Glu Cys Leu Glu Glu Ala Cys Ser Leu  
 50 55 60

Glu Glu Ala Arg Glu Val Phe Glu Asp Ala Glu Gln Thr Asp Glu Phe  
 65 70 75 80

Trp Ser Lys Tyr Lys Asp Gly Asp Gln Cys Glu Gly His Pro Cys Leu  
 85 90 95

Asn Gln Gly His Cys Lys Asp Gly Ile Gly Asp Tyr Thr Cys Thr Cys  
 100 105 110

Ala Glu Gly Phe Glu Gly Lys Asn Cys Glu Phe Ser Thr Arg Glu Ile  
 115 120 125

Cys Ser Leu Asp Asn Gly Gly Cys Asp Gln Phe Cys Arg Glu Glu Arg  
 130 135 140

147

Ser Glu Val Arg Cys Ser Cys Ala His Gly Tyr Val Leu Gly Asp Asp  
145 150 155 160

Ser Lys Ser Cys Val Ser Thr Glu Arg Phe Pro Cys Gly Lys Phe Thr  
165 170 175

Gln Gly Arg Ser Arg Arg Trp Ala Ile His Thr Ser Glu Asp Ala Leu  
180 185 190

Asp Ala Ser Glu Leu Glu His Tyr Asp Pro Ala Asp Leu Ser Pro Thr  
195 200 205

Glu Ser Ser Leu Asp Leu Leu Gly Leu Asn Arg Thr Glu Pro Ser Ala  
210 215 220

Gly Glu Asp Gly Ser Gln Val Val Arg Ile Val Gly Gly Arg Asp Cys  
225 230 235 240

Ala Glu Gly Glu Cys Pro Trp Gln Ala Leu Leu Val Asn Glu Glu Asn  
245 250 255

Glu Gly Phe Cys Gly Gly Thr Ile Leu Asn Glu Phe Tyr Val Leu Thr  
260 265 270

Ala Ala His Cys Leu His Gln Ala Lys Arg Phe Thr Val Arg Val Gly  
275 280 285

Asp Arg Asn Thr Glu Gln Glu Glu Gly Asn Glu Met Ala His Glu Val  
290 295 300

Glu Met Thr Val Lys His Ser Arg Phe Val Lys Glu Thr Tyr Asp Phe  
305 310 315 320

Asp Ile Ala Val Leu Arg Leu Lys Thr Pro Ile Arg Phe Arg Arg Asn  
325 330 335

Val Ala Pro Ala Cys Leu Pro Glu Lys Asp Trp Ala Glu Ala Thr Leu  
340 345 350

Met Thr Gln Lys Thr Gly Ile Val Ser Gly Phe Gly Arg Thr His Glu  
355 360 365

Lys Gly Arg Leu Ser Ser Thr Leu Lys Met Leu Glu Val Pro Tyr Val  
370 375 380

Asp Arg Ser Thr Cys Lys Leu Ser Ser Phe Thr Ile Thr Pro Asn  
385 390 395 400

Met Phe Cys Ala Gly Tyr Asp Thr Gln Pro Glu Asp Ala Cys Gln Gly  
405 410 415

Asp Ser Gly Gly Pro His Val Thr Arg Phe Lys Asp Thr Tyr Phe Val  
420 425 430

Thr Gly Ile Val Ser Trp Gly Glu Gly Cys Ala Arg Lys Gly Lys Phe  
435 440 445

148

Gly Val Tyr Thr Lys Val Ser Asn Phe Leu Lys Trp Ile Asp Lys Ile  
 450 455 460

Met Lys Ala Arg Ala Gly Ala Ala Gly Ser Arg Gly His Ser Glu Ala  
 465 470 475 480

Pro Ala Thr Trp Thr Val Pro  
 485

## (2) INFORMATION FOR SEQ ID NO: 54:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 790 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

Glu Pro Leu Asp Asp Tyr Val Asn Thr Gln Gly Ala Ser Leu Phe Ser  
 1 5 10 15

Val Thr Lys Lys Gln Leu Gly Ala Gly Ser Ile Glu Glu Cys Ala Ala  
 20 25 30

Lys Cys Glu Glu Asp Glu Glu Phe Thr Cys Arg Ala Phe Gln Tyr His  
 35 40 45

Ser Lys Glu Gln Gln Cys Val Ile Met Ala Glu Asn Arg Lys Ser Ser  
 50 55 60

Ile Ile Arg Met Arg Asp Val Val Leu Phe Glu Lys Lys Val Tyr Leu  
 65 70 75 80

Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser  
 85 90 95

Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro  
 100 105 110

His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu  
 115 120 125

Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys  
 130 135 140

Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu  
 145 150 155 160

Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys  
 165 170 175

Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln  
 180 185 190

Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn  
195 200 205

Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro Trp  
210 215 220

Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro  
225 230 235 240

Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys Leu  
245 250 255

Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val Ser  
260 265 270

Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr His Asn  
275 280 285

Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys  
290 295 300

Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn Ser  
305 310 315 320

Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser Ser Pro  
325 330 335

Val Ser Thr Glu Glu Leu Ala Pro Thr Ala Pro Pro Glu Leu Thr Pro  
340 345 350

Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln Ser Tyr Arg Gly Thr  
355 360 365

Ser Ser Thr Thr Thr Gly Lys Lys Cys Gln Ser Trp Ser Ser Met  
370 375 380

Thr Pro His Arg His Gln Lys Thr Pro Glu Asn Tyr Pro Asn Ala Gly  
385 390 395 400

Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp Lys Gly Pro Trp  
405 410 415

Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu Lys  
420 425 430

Lys Cys Ser Gly Thr Glu Ala Ser Val Val Ala Pro Pro Pro Val Val  
435 440 445

Leu Leu Pro Asn Val Glu Thr Pro Ser Glu Glu Asp Cys Met Phe Gly  
450 455 460

Asn Gly Lys Gly Tyr Arg Gly Lys Arg Ala Thr Thr Val Thr Gly Thr  
465 470 475 480

Pro Cys Gln Asp Trp Ala Ala Gln Glu Pro His Arg His Ser Ile Phe  
485 490 495

150

Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys Asn Tyr Cys Arg  
500 505 510

Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr Thr Thr Asn Pro  
515 520 525

Arg Lys Leu Tyr Asp Tyr Cys Asp Val Pro Gln Cys Ala Ala Pro Ser  
530 535 540

Phe Asp Cys Gly Lys Pro Gln Val Glu Pro Lys Lys Cys Pro Gly Arg  
545 550 555 560

Val Val Gly Gly Cys Val Ala His Pro His Ser Trp Pro Trp Gln Val  
565 570 575

Ser Leu Arg Thr Arg Phe Gly Met His Phe Cys Gly Gly Thr Leu Ile  
580 585 590

Ser Pro Glu Trp Val Leu Thr Ala Ala His Cys Leu Glu Lys Ser Pro  
595 600 605

Arg Pro Ser Ser Tyr Lys Val Ile Leu Gly Ala His Gln Glu Val Asn  
610 615 620

Leu Glu Pro His Val Gln Glu Ile Glu Val Ser Arg Leu Phe Leu Glu  
625 630 635 640

Pro Thr Arg Lys Asp Ile Ala Leu Leu Lys Leu Ser Ser Pro Ala Val  
645 650 655

Ile Thr Asp Lys Val Ile Pro Ala Cys Leu Pro Ser Pro Asn Tyr Val  
660 665 670

Val Ala Asp Arg Thr Glu Cys Phe Ile Thr Gly Trp Gly Glu Thr Gln  
675 680 685

Gly Thr Phe Gly Ala Gly Leu Leu Lys Glu Ala Gln Leu Pro Val Ile  
690 695 700

Glu Asn Lys Val Cys Asn Arg Tyr Glu Phe Leu Asn Gly Arg Val Gln  
705 710 715 720

Ser Thr Glu Leu Cys Ala Gly His Leu Ala Gly Gly Thr Asp Ser Cys  
725 730 735

Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu Lys Asp Lys Tyr  
740 745 750

Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys Ala Arg Pro Asn  
755 760 765

Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val Thr Trp Ile Glu  
770 775 780

Gly Val Met Arg Asn Asn  
785 790

## (2) INFORMATION FOR SEQ ID NO: 55:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 153 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

Val	Tyr	Leu	Gln	Thr	Ser	Leu	Lys	Tyr	Asn	Ile	Leu	Pro	Glu	Lys	Glu
1						5					10			15	

Glu	Phe	Pro	Phe	Ala	Leu	Gly	Val	Gln	Thr	Leu	Pro	Gln	Thr	Cys	Asp
					20				25				30		

Glu	Pro	Lys	Ala	His	Thr	Ser	Phe	Gln	Ile	Ser	Leu	Ser	Val	Ser	Tyr
					35			40				45			

Thr	Gly	Ser	Arg	Ser	Ala	Ser	Asn	Met	Ala	Ile	Val	Asp	Val	Lys	Met
					50			55			60				

Val	Ser	Gly	Phe	Ile	Pro	Leu	Lys	Pro	Thr	Val	Lys	Met	Leu	Glu	Arg
					65		70			75			80		

Ser	Asn	His	Val	Ser	Arg	Thr	Glu	Val	Ser	Ser	Asn	His	Val	Leu	Ile
					85			90				95			

Tyr	Leu	Asp	Lys	Val	Ser	Asn	Gln	Thr	Leu	Ser	Leu	Phe	Phe	Thr	Val
					100				105			110			

Leu	Gln	Asp	Val	Pro	Val	Arg	Asp	Leu	Lys	Pro	Ala	Ile	Val	Lys	Val
					115			120			125				

Tyr	Asp	Tyr	Tyr	Glu	Thr	Asp	Glu	Phe	Ala	Ile	Ala	Glu	Tyr	Asn	Ala
					130		135			140					

Pro	Cys	Ser	Lys	Asp	Leu	Gly	Asn	Ala							
					145		150								

## (2) INFORMATION FOR SEQ ID NO: 56:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 202 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

Met	Glu	Leu	Trp	Gly	Ala	Tyr	Leu	Leu	Cys	Leu	Phe	Ser	Leu	Leu	
1						5			10			15			

152

Thr Gln Val Thr Thr Glu Pro Pro Thr Gln Lys Pro Lys Lys Ile Val  
 20 25 30

Asn Ala Lys Lys Asp Val Val Asn Thr Lys Met Phe Glu Glu Leu Lys  
 35 40 45

Ser Arg Leu Asp Thr Leu Ala Gln Glu Val Ala Leu Leu Lys Glu Gln  
 50 55 60

Gln Ala Leu Gln Thr Val Cys Leu Lys Gly Thr Lys Val His Met Lys  
 65 70 75 80

Cys Phe Leu Ala Phe Thr Gln Thr Lys Thr Phe His Glu Ala Ser Glu  
 85 90 95

Asp Cys Ile Ser Arg Gly Gly Thr Leu Ser Thr Pro Gln Thr Gly Ser  
 100 105 110

Glu Asn Asp Ala Leu Tyr Glu Tyr Leu Arg Gln Ser Val Gly Asn Glu  
 115 120 125

Ala Glu Ile Trp Leu Gly Leu Asn Asp Met Ala Ala Glu Gly Thr Trp  
 130 135 140

Val Asp Met Thr Gly Ala Arg Ile Ala Tyr Lys Asn Trp Glu Thr Glu  
 145 150 155 160

Ile Thr Ala Gln Pro Asp Gly Gly Lys Thr Glu Asn Cys Ala Val Leu  
 165 170 175

Ser Gly Ala Ala Asn Gly Lys Trp Phe Asp Lys Arg Cys Arg Asp Gln  
 180 185 190

Leu Pro Tyr Ile Cys Gln Phe Gly Ile Val  
 195 200

## (2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 246 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala  
 1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Ser Tyr  
 20 25 30

Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile  
 35 40 45

153

Gly His Ile Tyr Pro Val Arg Ser Ile Thr Lys Tyr Asn Glu Lys Phe  
 50 55 60

Lys Ser Lys Ala Thr Leu Thr Leu Asp Thr Ser Ser Ser Thr Ala Tyr  
 65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Gln Asp Ser Ala Val Tyr Tyr Cys  
 85 90 95

Ser Arg Gly Asp Gly Ser Asp Tyr Tyr Ala Met Asp Tyr Trp Gly Gln  
 100 105 110

Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Ser Asp Ile Glu  
 115 120 125

Leu Thr Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly Gly Lys Val  
 130 135 140

Thr Met Thr Cys Arg Ala Ser Ser Val Ser Tyr Met His Trp Tyr  
 145 150 155 160

Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Ala Thr Ser  
 165 170 175

Asn Leu Ala Ser Gly Val Pro Thr Arg Phe Ser Gly Thr Gly Ser Gly  
 180 185 190

Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Ala Ala  
 195 200 205

Thr Tyr Tyr Cys Gln Gln Trp Ser Arg Asn Pro Phe Thr Phe Gly Ser  
 210 215 220

Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala Glu Gln Lys Leu Ile  
 225 230 235 240

Ser Glu Glu Asp Leu Asn  
 245

## (2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 101 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

Met Ser Asn Thr Gln Ala Glu Arg Ser Ile Ile Gly Met Ile Asp Met  
 1 5 10 15

Phe His Lys Tyr Thr Arg Arg Asp Asp Lys Ile Asp Lys Pro Ser Leu  
 20 25 30

154

Leu Thr Met Met Lys Glu Asn Phe Pro Asn Phe Leu Ser Ala Cys Asp  
35 40 45

Lys Lys Gly Thr Asn Tyr Leu Ala Asp Val Phe Glu Lys Lys Asp Lys  
50 55 60

Asn Glu Asp Lys Lys Ile Asp Phe Ser Glu Phe Leu Ser Leu Leu Gly  
65 70 75 80

Asp Ile Ala Thr Asp Tyr His Lys Gln Ser His Gly Ala Ala Pro Cys  
85 90 95

Ser Gly Gly Ser Gln  
100

## CLAIMS

1. A method for generating a processed ensemble of polypeptide molecules, in which processed ensemble the conformational states represented contain a substantial fraction of  
5 polypeptide molecules in one particular uniform conformation, from an initial ensemble of polypeptide molecules which have the same amino acid sequence as the processed ensemble of polypeptide molecules, comprising subjecting the initial ensemble of polypeptide molecules to a series of at least two  
10 successive cycles each of which comprises a sequence of
  - 1) at least one denaturing step involving conditions exerting a denaturing influence on the polypeptide molecules of the ensemble followed by
  - 2) at least one renaturing step involving conditions having a renaturing influence on the polypeptide molecules having conformations resulting from the preceding step.
2. A method according to claim 1, wherein the substantial fraction of polypeptide molecules in one conformational state  
20 in the processed ensemble constitutes at least 5% (w/w) of the initial ensemble of polypeptide molecules.
3. A method according to claim 1 or 2, wherein the polypeptide molecules of the processed ensemble comprise cysteine-containing molecules, and the processed ensemble  
25 comprises a substantial fraction of polypeptide molecules in one particular uniform conformation which, in addition have substantially identical disulphide bridging topology.
4. A method according to any of claims 1-3, wherein the polypeptide molecules are molecules which have an amino acid  
30 sequence identical to that of an authentic polypeptide, or are molecules which comprise an amino acid sequence corre-

sponding to that of an authentic polypeptide joined to one or two additional polypeptide segments.

5. A method according to claim 4, wherein the amino acid sequence corresponding to that of an authentic polypeptide is joined to the additional polypeptide segment or segments via a cleavable junction or similar or dissimilar cleavable junctions.

10 6. A method according to any of claims 1-5, wherein the series comprises at least 3 cycles, such as at least 5, at least 8, at least 10, and at least 25 cycles, and at most 2000 cycles, such as at most 1000, at most 500, at most 200 cycles, at most 100, and at most 50 cycles.

15 7. A method according to any of the preceding claims, wherein the duration of each denaturing step is at least 1 millisecond and at most 1 hour, and the duration of each renaturing step is at least 1 second and at most 12 hours.

20 8. A method according to claim 7, wherein the denaturing conditions of each individual denaturing step are kept substantially constant for a period of time, and the renaturing conditions of each individual renaturing step are kept substantially constant for a period of time, the periods of time during which conditions are kept substantially constant being separated by transition periods during which the conditions are changed.

25 9. A method according to claim 8, in which the transition period between steps for which conditions are kept substantially constant has a duration between 0.1 second and 12 hours.

30 10. A method according to claim 9, wherein the period of time for which the denaturing conditions of the denaturing step are kept substantially constant has a duration of between 1 and 10 minutes, and the period of time for which the renatu-

ring conditions of the renaturing step are kept substantially constant has a duration of between 1 and 45 minutes.

11. A method according to any of the preceding claims, wherein the polypeptide molecules are in contact with a liquid 5 phase during the denaturing and renaturing steps, the liquid phase being an aqueous phase or an organic phase.

12. A method according to claim 11, wherein the polypeptide molecules are substantially confined to an environment which allows changing or exchanging the liquid phase substantially 10 without entraining the polypeptide molecules.

13. A method according to claim 12, wherein the polypeptides are confined to a dialysis device or a liquid two-phase system.

14. A method according to claim 12, wherein the polypeptide 15 molecules are bound to a solid or semisolid carrier, such as a filter surface, a hollow fibre or a beaded chromatographic medium, e.g. an agarose or polyacrylamide gel, a fibrous cellulose matrix, an HPLC or FPLC matrix, a substance having molecules of such a size that the molecules with the polypeptide 20 molecules bound thereto, when dissolved or dispersed in a liquid phase, can be retained by means of a filter, a substance capable of forming micelles or participating in the formation of micelles allowing the liquid phase to be changed or exchanged substantially without entraining the micelles, 25 or a water-soluble polymer.

15. A method according to claim 14, wherein the polypeptide molecules are non-covalently adsorbed to the carrier through a moiety having affinity to a component of the carrier, such as a biotin group or an analogue thereof bound to an amino 30 acid moiety of the polypeptide, the carrier having avidin, streptavidin or analogues thereof attached thereto.

16. A method according to claim 15, wherein the moiety has an amino acid sequence identical to SEQ ID NO: 47, the carrier comprising a Nitrilotriacetic Acid derivative (NTA) charged with  $\text{Ni}^{++}$  ions.
- 5 17. A method according to any of the preceding claims, wherein the polypeptide molecules comprise a polypeptide segment which is capable of directing preferential cleavage by a cleaving agent at a specific peptide bond.
- 10 18. A method according to claim 17, wherein the cleavage-directing polypeptide segment is one which is capable of directing preferential cleavage at a specific peptide bond by a cleaving agent selected from the group consisting of cyanogen bromide, hydroxylamine, iodosobenzoic acid, N-bromo-succinimide, and enzymes such as bovine coagulation factor  $X_a$
- 15 or an analogue and/or homologue thereof and bovine enterokinase or an analogue and/or homologue thereof.
19. A method according to claim 17 or 18, wherein the polypeptide segment which directs preferential cleavage is a sequence which is substantially selectively recognized by the bovine coagulation factor  $X_a$  or an analogue and/or homologue thereof, such as a polypeptide segment which has an amino acid sequence selected from the group consisting of SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42.
- 20 20. A method according to any of the preceding claims, wherein the polypeptide molecules comprise a polypeptide segment which is *in vitro*-convertible into a derivatized polypeptide segment capable of directing preferential cleavage by a cleaving agent at a specific peptide bond.
- 25 21. A method according to claim 20, wherein the *in vitro*-convertible polypeptide segment is convertible into a derivatized polypeptide segment which is substantially selectively recognized by the bovine coagulation factor  $X_a$  or an analogue and/or homologue thereof.

22. A method according to claim 21, wherein the *in vitro*-convertible polypeptide segment has an amino acid sequence selected from the group consisting of SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46.

5 23. A method according to claim 22 wherein the polypeptide molecules comprise a polypeptide segment with either the amino acid sequence SEQ ID NO: 43 or SEQ ID NO: 44, which is converted into a derivatized polypeptide, which is substantially selectively recognized by bovine coagulation factor  $X_a$  or an analogue and/or homologue thereof, by reacting the cysteine residue with N-(2-mercaptopethyl)morpholyl-2-thiopyridyl disulphide or mercaptothioacetate-2-thiopyridyl disulphide, or

10 with the amino acid sequence SEQ ID NO: 45 or SEQ ID NO: 46, which is converted into a derivatized polypeptide, which is substantially selectively recognized by bovine coagulation factor  $X_a$ , by oxidation of the thioether moiety in the methionine side group to a sulphoxide or sulphone derivative.

15 24. A method according to any of claims 19, 22 or 23, wherein the polypeptide segment selected from the group consisting of SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42 or selected from the group consisting of SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46 is linked N-terminally to the authentic polypeptide.

20 25. A method according to any of claims 8-24, wherein the change of conditions during the transition period is accomplished by changing the chemical composition of the liquid phase with which the polypeptide molecules are in contact.

25 30 26. A method according to claim 25, wherein denaturing of the polypeptide molecules is accomplished by contacting the polypeptide molecules with a liquid phase in which at least

one denaturing compound is dissolved, and wherein renaturing of the polypeptide molecules is accomplished by contacting the polypeptide molecules with a liquid phase which either contains at least one dissolved denaturing compound in such a 5 concentration that the contact with the liquid phase will tend to renature rather than denature the ensemble of polypeptide molecules in their respective conformation states resulting from the preceding step, or contains no denaturing compound.

10 27. A method according to claim 26, wherein the denaturing of the polypeptide molecules is achieved or enhanced by decreasing or increasing pH of the liquid phase.

28. A method according to claim 26 or 27, wherein the denaturing compound is selected from urea, guanidine-HCl, and di- 15  $C_{1-6}$ alkylformamide such as dimethylformamide and di- $C_{1-6}$ -alkylsulphone.

29. A method according to any of claims 11-28, wherein the liquid phase used in at least one of the denaturing steps and/or in at least one of the renaturing steps contains at 20 least one disulphide-reshuffling system, X.

30. A method according to claim 29, wherein the at least one disulphide-reshuffling system X is one which is capable of reducing and/or reshuffling incorrectly formed disulphide bridges under conditions with respect to concentration of the 25 denaturing agent at which unfolded and/or misfolded proteins are denatured and at which there is substantially no reduction and/or reshuffling of correctly formed disulphide bridges.

31. A method according to claim 30, wherein the presence of 30 the disulphide reshuffling system X in at least one step results in a ratio between the relative amount of reduced/reshuffled initially incorrectly formed disulphide bridges and the relative amount of reduced/reshuffled

initially correctly formed disulphide bridges of at least 1.05.

32. A method according to any of claims 29-31 wherein the disulphide-reshuffling system contains glutathione, 2-mercaptoproethanol or thiocholine, each of which in admixture with its 5 corresponding symmetrical disulphide.

33. A method according to any of claims 11-32, wherein all cysteine residues in the polypeptide molecules have been converted to mixed disulphide products of either glutathione, 10 thiocholine, mercaptoethanol or mercaptoacetic acid, during at least one of the denaturing/renaturing cycles.

34. A method according to claim 33, wherein the conversion of the cysteine residues to mixed disulphide products is accomplished by reacting the fully denatured and fully reduced 15 ensemble of polypeptide molecules with an access of a reagent which is a high-energy mixed disulphide compound.

35. A method according to claim 34, wherein the mixed high energy disulphide compounds are aliphatic-aromatic.

36. A method according to claim 34 or 35, wherein the mixed 20 high energy disulphide compounds has the general formula:



wherein R<sub>1</sub> is 2-pyridyl, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are hydrogen or an optionally substituted lower aromatic or aliphatic hydrocarbon group.

37. A method according to any of claims 34-36, wherein the 30 high-energy mixed disulphide compounds are selected from the

group consisting of glutathionyl-2-thiopyridyl disulphide, 2-thiocholyl-2-thiopyridyl disulphide, 2-mercaptopropanol-2-thiopyridyl disulphide and mercaptoacetate-2-thiopyridyl disulphide.

- 5 38. A method according to any of claims 11-37, wherein the polarity of the liquid phase used in the renaturing of the polypeptide molecules has been modified by the addition of a salt, a polymer and/or a hydrofluoro compound, such as trifluoroethanol.
- 10 39. A method according to any of claims 1-24 or 29-38, wherein the denaturing and renaturing of the polypeptide molecules is accomplished by direct changes in physical parameters to which the polypeptide molecules are exposed, such as temperature or pressure.
- 15 40. A method according to claim 25, wherein the chemical changes in the liquid phase are accomplished by changing between a denaturing solution B and a renaturing solution A.
- 20 41. A method according to claim 40, wherein the concentration of one or more denaturing compounds in B is adjusted after each cycle.
42. A method according to claim 41, wherein the concentration of one or more denaturing compounds in B is decremented after each cycle.
- 25 43. A method according to claim 40, wherein the concentration of one or more denaturing compounds in medium B is kept constant in each cycle.
- 30 44. A method according to any of the preceding claims in which the polypeptide molecules of the ensemble have a length of at least 25 amino acid residues and at most 5000 amino acid residues.

45. A method according to any of the preceding claims, wherein the polypeptides of the initial ensemble are artificial polypeptides produced in prokaryotic cells by means of recombinant DNA-techniques.

5 46. A method according to claim 45, wherein the initial sample of polypeptide molecules are unfolded or misfolded diabody molecules (artificial bispecific and bivalent antibody fragments) or monomer fragments of diabody molecules.

10 47. A method for producing correctly folded diabody molecules, wherein an initial ensemble of polypeptide molecules comprising unfolded and/or misfolded polypeptides having amino acid sequences identical to monomer fragments of diabody molecules is subjected to a series of at least two successive cycles each of which comprises a sequence of

15 1) at least one denaturing step involving conditions exerting a denaturing influence on the polypeptide molecules of the ensemble followed by

20 2) at least one renaturing step involving conditions having a renaturing influence on the polypeptide molecules having conformations resulting from the preceding step,

25 the series of cycles being so adapted that a substantial fraction of the initial ensemble of polypeptide molecules is converted to a fraction of correctly folded diabody molecules.

48. A method according to claim 47, wherein the polypeptide molecules are in contact with a liquid phase containing at least one disulphide reshuffling system in at least one denaturing/renaturing cycle.

30 49. A polypeptide which is a proenzyme of a serine protease, which proenzyme has an amino acid sequence different from

that of bovine coagulation factor X (Protein Identification Ressource (PIR), National Biomedical Research Foundation, Georgetown University, Medical Center, U.S.A., entry: P1;EXBO) and which can be proteolytically activated to generate the active serine protease by incubation of a solution of the polypeptide in a non-denaturing buffer with a substance that cleaves the polypeptide to liberate a new N-terminal residue,

10 the substrate specificity of the serine protease being identical to or better than that of bovine blood coagulation factor  $X_a$ , as assessed by each of the ratios  $(k(I)/k(V)$  and  $k(III)/k(V)$  between cleavage rate,  $k$ , against each of the substrates I and III:

15 I: Benzoyl-Val-Gly-Arg-paranitroanilide,  
III: Tosyl-Gly-Pro-Arg-paranitroanilide,

versus that against the substrate

V: Benzoyl-Ile-Glu-Gly-Arg-paranitroanilide

20 at 20°C, pH=8 in a buffer consisting of 50 mM Tris, 100 mM NaCl, 1 mM CaCl<sub>2</sub>, being identical to or lower than the corresponding ratio determined for bovine coagulation factor  $X_a$  which is substantially free from contaminating proteases.

50. A polypeptide according to claim 49, wherein  $(k(I)/k(V)$  is at most 0.04 and  $k(III)/k(V)$  is at most 0.15.

25 51. A polypeptide according to claim 49, the substrate specificity of which is identical to or better than that of bovine blood coagulation factor  $X_a$ , as assessed by each of the ratios  $(k(I)/k(V)$ ,  $k(II)/k(V)$ ,  $k(III)/k(V)$  and  $k(IV)/k(V)$ ) between cleavage rate,  $k$ , against each of the substrates I-  
30 IV:

- I:      Benzoyl-Val-Gly-Arg-paranitroanilide,
- II:     Tosyl-Gly-Pro-Lys-paranitroanilide,
- III:    Tosyl-Gly-Pro-Arg-paranitroanilide,
- IV:     (d,1)Val-Leu-Arg-paranitroanilide

5      versus that against the substrate

- V:     Benzoyl-Ile-Glu-Gly-Arg-paranitroanilide

at 20°C, pH=8 in a buffer consisting of 50 mM Tris, 100 mM NaCl, 1 mM CaCl<sub>2</sub>, being identical to or lower than the corresponding ratio determined for bovine coagulation factor X<sub>a</sub>  
10 which is substantially free from contaminating proteases.

52. A polypeptide according to claim 51, wherein (k(I)/k(V) is at most 0.04, k(II)/k(V) is at most 0.015, k(III)/k(V) is at most 0.15, and k(IV)/k(V) is at most 0.005.

53. A polypeptide according to any of claims 49-52, which  
15 polypeptide has a molecular weight, M<sub>r</sub>, of at most 70,000 and of at least 15,000.

54. A polypeptide according to any of claims 49-53, which has an amino acid sequence which is a subsequence of SEQ ID NO: 2 or an analogue of such a subsequence.

20 55. A polypeptide according to claim 54 which has a sequence homology at the polypeptide level of at least 60% identity compared to a segment of SEQ ID NO: 2, allowing for deletions and/or insertions of at most 50 amino acid residues.

25 56. A polypeptide according to claim 54 which has an amino acid sequence consisting of residues 82-484 or residues 166-484 of SEQ ID NO: 2.

57. A nucleic acid fragment which is capable of encoding a polypeptide according to any of claims 54-56, such as a DNA fragment.

58. A nucleic acid fragment according to claim 57, in which at least 60% of the coding triplets encode the same amino acids as a nucleic acid fragment of the nucleic acid which encodes bovine coagulation factor X, allowing for insertions 5 and/or deletions of at most 150 nucleotides.

59. A nucleic acid fragment according to claim 57 which has a nucleotide sequence selected from the group consisting of, nucleotides 76-1527, nucleotides 319-1527, or nucleotides 571-1527 of SEQ ID NO: 1, or an analogue thereof.

10 60. An expression system comprising a nucleic acid fragment according to any of claims 57-59 encoding a polypeptide according to any of claims 54-56, the system comprising a 5'-flanking sequence capable of mediating expression of said nucleotide sequence.

15 61. A replicable expression vector carrying a nucleic acid fragment according to any of claims 57-59, which vector is capable of replicating in a host organism or a cell line, the vector being such as a plasmid, phage, cosmid, mini-chromosome or virus.

20 62. A vector according to claim 61 which, when introduced in a host cell, is integrated in the host cell genome.

63. An organism which carries and is capable of replicating the nucleic acid fragment according to any of claims 57-59.

25 64. An organism according to claim 63, which is a microorganism such as a bacterium, a yeast, a protozoan, or a cell derived from a multicellular organism such as a fungus, an insect cell, a plant cell, a mammalian cell or a cell line.

65. A method of producing a polypeptide as defined in any of claims 54-56, comprising the following steps of:

- a. inserting a nucleic acid fragment as defined in any of claims 57-59 in an expression vector,
- b. transforming a host organism according to claim 63 or 64 with the vector produced in step a,
- 5 c. culturing the host organism produced in step B. to express the polypeptide,
- d. harvesting the polypeptide,
- e. optionally subjecting the polypeptide to post-translational modification,
- 10 f. subjecting the polypeptide to a method according to any of claims 1-48, and
- g. optionally subjecting the polypeptide to further modification.

66. The use of a polypeptide according to any of claims 54-56  
15 for cleaving polypeptides at the cleavage site for bovine coagulation factor  $X_a$ , the cleavage site having the amino acid sequence selected from the group consisting of SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42.

67. The use of a polypeptide according to any of claims 54-56  
20 for cleaving polypeptides at the cleavage site for bovine coagulation factor  $X_a$ , the cleavage site having a modified version of the amino acid sequence selected from the group of SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46, which has been converted to a cleavable form according to  
25 the method in claim 23.

68. The use of a polypeptide according to any of claims 54-56 in a method according to claim 18, 19 or 24 for cleaving polypeptides at the specific  $FX_a$  recognition site, the cleaving site having the amino acid sequence SEQ ID NO: 38.

1/34




Fig. 1

2/34




Fig. 2

3/34

**A:**Human  $\beta_2$ -microglobulin:

-20	M S R S V A V A L L L S I S G L E A I Q R T P K I Q V Y	-1 1
-10		
20	S R H P A E N G K S N F L N C Y V S G F H P S D I E V D L L	30 40
50	K N G E R I E K V E H S D L S F S K D W S F Y L L Y Y T E F	60 70
80	T P T E K D E Y A C R V N H V T L S Q P K I V K W D R D M	90

**B:**Murine  $\beta_2$ -microglobulin:

-20	M A R S V T L V F L V I V S L T G L Y A I Q K T P Q I Q V Y	-1 1
-10		
20	S R H P P E N G K P N I L N C Y V T Q F H P P H I E I Q M L	30 40
50	K N G K K I P K V E M S D M S F S K D W S F Y I L A H T E F	60 70
80	T P T E T D T Y A C R V K H D S M A E P K T V Y W D R D M	90

**Fig. 3**

4/34




Fig. 4

5/34

## Human Growth Hormone (Somatotropin).

Human Growth Hormone (Somatotropin) sequence:

-26	M A T G S R T S L L L A F G L L C L P W L Q E G S A F F P T I	-1	1	4
10	P L S R L F D N A S S I R A H R I H Q L A F D T Y Q E F E E A	20	30	
40	Y I P K E Q K Y S F L Q N P Q T S L C F S E S I P T P S N R	50	60	
70	E E T Q Q K S N L E L L R I S S L L L I Q S W L E P V Q F L R	80	90	
100	S V F A N S L V Y G A S D S N V Y D L L K D L E E G I Q T L	110	120	
130	M G R L E D G S P R T G Q I F K Q T Y S K F D T N S H N D D	140	150	
160	A L L K N Y G L L Y C F R K D M D K V E T F L R I V Q C R S	170	180	
190	V E G S C G F			

Fig. 5

6/34

 $\alpha_2$  MR:

#1                    G S I E G R A I                    C R \*  
 GATCCATCGAGGGTAGGGCTATC ----- TGCCGATA

#2                    G S I E G R A I                    K A \*  
 GATCCATCGAGGGTAGGGCTATC ----- AAGGCATA

#3                    G S I E G R A I                    K K \*  
 GATCCATCGAGGGTAGGGCTATC ----- AAGAAGTA

M G S H H H H H H  
 CATATGGGATCGCATCACCATCACCATCACG ----- AGCTTGAATTTC  
 Bam HI   Hind III




Fig. 6

7/34

 $\alpha_2$  MR:

# 4

G S I E G R G T L D \*  
 GATCCATCGAGGGTAGGGCACC ----- CTGGACTA

# 5

G S I E G R V P D Q \*  
 GATCCATCGAGGGTAGGGTGCCT ----- GACCAGTA

# 6

G S I E G R G G Q C F K \*  
 GATCAATCGAGGGTAGGGTGGTCAGTGC ----- TTTAAGTA

G K G S H H H H H H  
 GGGAGGGATCGCATACCCATCACCATCACG ----- AGCTTGGCGTA

Bam HI Hind III




Fig. 7

8/34

$\alpha_2$  MR:

# 7 G S I E G R G T F K \*  
GATCCATCGAGGGTAGGGGCACC ----- TTTAAGTA

# 8 G S I E G R A V H I \*  
GATCCATCGAGGGTAGGGCGGTG ----- CACATCTA

#9 G S I E G R V S S I \*  
GATCCATCGAGGGTAGGGTGTCC ----- AGCATCTA




Fig. 8

9/34

 $\alpha_2$ -Macroglobulin Receptor.

20

1 MLTPPLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA  
 109  
 61 PEICPQSKAQRCQPNEHNCLGTELCPMSRLCNGVQDCMDGSDEGPHCRELQGNCSR LGC  
 121 QHHCVPTLDGPTCYCNSSFQLQADGKTCDFDEC SVYGTCSQLCTNDGSFICGCVEGYL  
 190  
 181 LQPDNRSCAKNEPVDRPVILLIANSQNLATYLSGAQVSTITPTSTRQTTAMDFSYANE  
 241 TVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLGNFYFVDDI  
 301 DDRIFVCNRNGDTCVTLLDELYNPKGIALDPAMGVFTDYQIPKVERCDMDGQNRTK  
 361 LVDSKIVFPHGITLDLVSRLVYADLTYIEVVDYEGKGRQTI IQGILIEHLYGLTVFE  
 421 NYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGALHIHQRRQPRVRSHACEN  
 521  
 481 DQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSKCKPEHEFLYVGKGRPGIIRG  
 541 MDMGAKVPDEHMIP IENLMNPRALDFHAETGFIFYADTTSYLIGRQKIDGTERETILKDG  
 601 IHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG  
 661 WMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSDLIPAGRILYWDAY  
 721 DRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTV  
 803  
 781 LLRSERPPIFEIRMYDAQQQQVGTNKC RVNNNGCSSICLATPGSRQCACAEDQVLDADGV  
 841 TCLANPSYVPPPQCPGEFACANSRCI QERWKCDGNDCLDSDEAPALCHQHTCPSDRF  
 901 KCENNRCIPNRWLCDGNDNGNSEDES NATCSARTCPNQFSCASGRCPISWTCDLDD  
 961 CGDRSDESASCAYPTCFPLTQFTCNGR CININWRCDNDNDCGDNNSDEAGCSHSCSSTQF  
 1021 KCNSGR C IPEHWTCDGNDNGDYSDETHANCTNQATRPPGCHTDEFQCR LDGLCIPLRW  
 1081 RCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKA WVDGND CEDNSDEENC  
 1184  
 1141 ESLACRPPSHPCANNTS VCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCVAP  
 1201 GEGIVCSCP LGMELGPDNHTCQIQSYCAHKLKSQKCDQNKFSVKCSCYEGWVLEPDGES  
 1265  
 1261 CRSLDPFKPFIIFSNRHEIRRIDLHKGDYSLVPLVPLRNTIALDFHLSQSALYWTDVVEDK  
 1321 IYRGKLLDNGALTSFEVVIQYGLATPEGLAVD WIAGNIYWVESNLDQIEVAKLDGLRTT  
 1381 LLAGDIEHPRAIALDPRD GILFWTDWDASLPRIEAASMSGAGRRTVHRETGS GGWPNGLT  
 1441 VDYLEKRILWIDARS DAIYSARYDGS GHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT  
 1501 LAKANKWTGHNVTVVQRTNTQFDLQVYHPSRQPMAPNPCEANGQGPCSHLCLINYRNT  
 1582  
 1561 VSCACP HLMKLHKDNTTCYEFKKFLYARQMEIRGVLDAPYYNIISFTVPDIDNVTVL  
 1621 DYDAREQRVY WSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWSRNLFWTSYDTN  
 1681 KKQINVARLDGSFKNAV VQGLEQPHGLVHPLRGKLYWTGDNISMANMDGSNRTLLFSG  
 1741 QKGPVGLAIDFPESKLYWISSGNHTINRCNLDSG SLEVIDAMRSQ LGKATALAIMGDKLW  
 1801 WADQVSEKMGTC SKADGSGSVL RNSTTLMHMKVYDESIQLDHKG TNPCSVNNNGDCSQL  
 1861 CLPTSETTRSCMCTAGYSLRSGQOACEGVGSFLLYSVHEGIRGIPPLDPNDKSDALPVSG  
 1921 TSLAVGIDFHAENDTIYWDMGLSTISRAKRDQTWREDVVTNGI GRVEGIAVDWIAGNIY  
 1981 WTDQGF D VIEVARLNGSFRYVVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG  
 2041 TERRV L VNVSI SWPNG ISVSDYQDGKLYWCDARTDKIERIDLETGENREVV LSSNNMDMFS  
 2101 VSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVOLKD IKVFNDRDQKGTNVCA  
 2161 VANGGCQQLCILYRGRGQACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL  
 2221 NAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE  
 2281 NVGSVEGLAYHRGWDTLYWTSYTTSITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD  
 2341 ECQNLMFWTNWNEQHPSIMRAALSGANVLT LIEKD IRTPNGLAIDHRAEKLYFS DATLDK  
 2401 IERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRAVQRANKHVGNSNMKLLRVDI  
 2520  
 2461 PQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSRGGRI LQDDLT CRAV  
 2521 NSSCRAQDEFECANGECINFSLTCGVPHCKDKSDEKPSYCNSRRCKTFRQCSNGRCVS  
 2581 NMLWCNGADD CGDGSDEIPCNKTACGVGEFRCRDGT CIGNSSSRCNQFVDCEDASDEMNC  
 2641 ATDCSSYFRLGVKGVLFQP CERTSLCYAPS WCDGANDCGDYS DERDCPGVKRPRCPLNY  
 2701 FACPSGR CIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG

Fig. 9a

10/34

2761 DGSDEAAHCEGKTCGSSFSSCP GT HVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD  
 2821 REFM CQNRQCIPKH FVCDH D RDCADGSDE SPECEYPTCGPSEFRCANGRCLSSRQWECDG  
 2881 ENDCHDQSDEAPKNPHCTSPEHKCNASSQFLCSSGRVAEALLCNGQDDCGDSSDERGCH  
 2941

2941 INECLSRKLSSGCSQDCEDLKIGFKKCRCPGFRLLKDDGRTCA DVDEC CTTFPCSORCINTH  
 3001 GSYKCLCVEGYAPRGDDPHSCKAVTDEEPFLIFANRYYL RKLNL DGSNYTLLKGQGLNNAV  
 3061 ALDFDYREQMIYWTDTQGSMIRRMHLLNGSNVQVLHRTGLSNBPDGLA DWDWGGNLYWCD  
 3121 KGRDTIEVSKLNGAYRTVLYSSGIREPRALVV DQNGLYWTDWGHDHSLLIGRIMDGSSR  
 3181 SVIVDTKITWPNGLTL DXYTERIYADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF  
 3241 EDYVYWTDWETKSINRAHKTGTNKTLLISTLH R P M D L H V F H A L R Q P D V P N H P C K V N N G G  
 3301 CSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDK CIPFWWKCDT EDDCG  
 3361 DHSDEPPDCPEFKCRPGQFQCSTGICCTNPAFICDGDNDCQDN SDEANCDIHVCLPSQFKC  
 3421 TNTNRCIPG1FRCNGQDNCGDGEDERDCPEVTCA P QFC SITKRCIPR W V C D R D N D C V  
 3481 DGSDEPANCTQMTCGVDEFRCKDSGR CIPARWKCDGE DDCGDSDEPEKECDERTCEPYQ  
 3541 FRCKNNRRCVPGRWQCDYDNDGDNNSDEECSCTPRPCSESEFSCANGR C I A G R W K C D G H D C  
 3601 ADGSDEKDCTPRCDMDQFQCKSGH C I P L R W R C D A D A D C M D S D E E A C G T G V R T C P L D E F Q  
 3661 CNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCVLWIGRQCDGTD  
 3721 NCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDCCGDSDEEDCSIDP  
 3781 KLTSCATNASIGDEARCVRTEKAYACRSGFHTVPGQPGCQDINECLRFGTCSOLCNN  
 3841 TKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIIRSLEPGPHPSAYEQAFQGDESV  
 3901 RIDAMDVHVKA GRVYWTNWHGTISYRS L P A A P P T S N R H R Q I D R G V T H L N I S G L K M P  
 3961 RGIAIDWVAGNVYWTSGRDVIEVAQMKGENRKTLSIGMIDEPHAIIVVDELRGTMWSDW  
 4021 GNHPKIETAMDGTLRETLVQDN1QWPTGLAVDYNERLYWADAKL S V I G S I R L N G T D P I  
 4081 VAADSKRGLSHPFSIDFEDYIYGVTYINNRVFKIHKFGHSPLYVNLTGGLISHASDVVLYH  
 4141 OHKOPEVTNP CDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPPVPSPTPPPDA P R P G T C  
 4201 NLQCFNGGSCFLNARROPKCRCPQRTGDKCELDQCWIEHCRNGGTCAASPSGMPTCRCP  
 4261 GFTGPKCTQQVCAGYCANNSTCTVNGNQ P Q C R C L P G F LGDRCQYRQCSGYCENFGTCQM  
 4321 AADGSRQRCRTAYFEGSRCEVNKCSCRCLEGACVUNKQSGDVT C N C T D G R V A P S C L T C V G H  
 4381 CSNGGSCTMNSKMMPECQCPPHMTGP R C E E H V F S Q Q Q P G H I A S I L I P L I L L I L L I V A G V  
 4441 VFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGE P D D V G G L L D A D F A L D P D K P T  
 4501 NFTNPVYATLYMGGGHGSRSLASTDERRELLGRGPEDIEG DPLA

3331  
 3728

Fig. 9b

11/34




Fig. 10


12/34

Bovine FX.

1 MAGLLHLVLLSTALGGLLRPAGSVFLP RDQ  
31 AHRVLQARRANSFILEEVKGNLERECL  
61 ACSSLEAREVFEDEDAEQTDDEFWSSKYKDG  
91 EGHPCLNOGHCKDGIGDYTCCTCAEGFEGKN  
121 CEFSTREICSSLDDNGGCDQFCREERS  
151 CAHGYVLDSSKSCVSTERFPCKFTQGRS  
181 RRWAITHTSEDALDASSELEHYDPADLSPTES  
211 SLDDLGLNRTEPSAGEDGSSQVVRIVGG  
241 AGECECPWQALLVNEENEGFCGG  
271 LTAAHCLHQAKRFTVRVGDRNTEQEE  
301 AH E V E M T V K H S R F V K E T Y D F D  
331 I R F R R N V A P A C L P E K D W A E A T  
361 S G F G R T H E K G R L S S T L K M  
391 L S S S F T I T P N M F C A G Y D T Q P E D  
421 P H V T R F K D T Y F V T G I V S W  
451 Y T K V S N F L K W I D K I M K A R A  
481 P A T W T V P  
484

Fig. 11

13/34



14/34




Fig. 13

## Glu - Plasminogen.

Fig. 14

16/34




Fig. 15




Fig. 16

17/34




Fig. 17

18/34




Fig. 18

19/34

Human  $\alpha_2$ MRBDv.

(1299)V Y L Q T S L K Y N I L P E K E E F P F A L G V Q T L P Q T  
40 C D E P K A H T S F Q I S L S V S Y T G S R S A S N M A I V  
70 D V K M V S G F I P L K P T V K M L E R S N H V S R T E V S  
100 S N H V L I Y L D K V S N Q T L S L F F T V L Q D V P V R D  
130 L K P A I V K V Y D Y Y E T D E F A I A E Y N A P C S K D L  
153 G N A (1451)

Fig. 19

20/34




Fig. 20

21/34

## Human Ttranectin.

Human Ttranectin.

1 -21 M E L W G A Y L L C L I F S L L T Q V T T E P P T Q K P K K 9  
10 I V N A K K D V V V N T K M F E E L K S R L D T L A Q E V A L 30  
40 L K E Q Q A L Q T V C L K G T K V H M K C F L A F T Q T K T 60  
70 F H E A S E D C I S R G G T L S T P Q T G S E N D A L Y E Y 90  
100 L R Q S V G N E A E I W L G L N D M A A E G T W V D M T G A 120  
130 R I A Y K N W E T E I T A Q P D G G K T E N C A V L S G A A 150  
160 N G K W F D K R C R D Q L P Y I C Q F G I V 180

Fig. 21

22/34




Fig. 22

23/34

DB32.

1 Q V K L Q Q S G A E L V K P G A S V K M S C K A S G Y T F A  
31 S Y W I N W V K Q R P G Q G L E W I G H I Y P V R S I T K Y  
61 N E K F K S K A T L T L D T S S S T A Y M Q L S S L T S E D  
91 S A V Y Y C S R G D G S D Y Y A M D Y W G Q G T T V T V S S  
121 G G G S D I E L T Q S P A I L S A S P G G K V T M T C R A  
151 S S S V S Y M H W Y Q Q K P G S S P K P W I Y A T S N L A S  
181 G V P T R F S G T G S G T S Y S L T I S R V E A E D A T Y  
211 Y C Q Q W S, R N P F T F G S G T K L E I K R A A E Q K L I  
241 S E E D L N

Fig. 23

24/34




Fig. 24


25/34

## Human Psoriasin.


1 M S N T Q A E R S I I G M I D M F H K Y T R R D D K I D K P  
10 S L L T M M K E N F P N F L S A C C D K K G T N Y L A D V F E  
20  
30  
40  
50  
60  
70  
80  
90  
100 H G A A P C S S G G S Q

Fig. 25

**26/34**



**Fig. 26a**



**Fig. 26b**

27/34

1 2 3 4 5 6 7 8 9 10 11 12






Fig. 27

**28/34**




**Fig. 28**

**29/34**



**Fig. 29**

**30/34**




**Fig. 30**

31/34



**Fig. 31**

**32/34**



**Fig. 32**

33/34




Fig. 33

34/34




Fig. 34

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**